Carrel name: keyword-liver-cord Creating study carrel named keyword-liver-cord Initializing database file: cache/cord-005949-8po9xe5g.json key: cord-005949-8po9xe5g authors: Streetz, K.L.; Tacke, F.; Koch, A.; Trautwein, C. title: Akutes Leberversagen: Übersicht zur aktuellen Diagnostik und Therapie date: 2013-11-06 journal: Med Klin Intensivmed Notfmed DOI: 10.1007/s00063-013-0285-4 sha: doc_id: 5949 cord_uid: 8po9xe5g file: cache/cord-014770-cgtzlra1.json key: cord-014770-cgtzlra1 authors: Brandt, Lawrence J.; Farmer, Richard D.; Achord, James L.; Friedman, Lawrence S.; Powers, Cynthia I.; Dorman, Nancy J.; Sullivan, Donna C.; El-Newihi, Hussein M.; Bank, Simmy; Ahn, John; DeVault, Kenneth; Thomas, Eapen title: Book reviews date: 1995 journal: Dig Dis Sci DOI: 10.1007/bf02065002 sha: doc_id: 14770 cord_uid: cgtzlra1 file: cache/cord-016130-5q9ufu28.json key: cord-016130-5q9ufu28 authors: Linday, Linda A. title: Nutritional Supplements and Upper Respiratory Tract Illnesses in Young Children in the United States date: 2010-12-17 journal: Preventive Nutrition DOI: 10.1007/978-1-59259-880-9_21 sha: doc_id: 16130 cord_uid: 5q9ufu28 file: cache/cord-018801-amet0wx4.json key: cord-018801-amet0wx4 authors: Park, Caroline; Clark, Damon title: Care of the Patient with Liver Failure Requiring Transplantation date: 2018-05-04 journal: Surgical Critical Care Therapy DOI: 10.1007/978-3-319-71712-8_55 sha: doc_id: 18801 cord_uid: amet0wx4 file: cache/cord-018414-6ffhm895.json key: cord-018414-6ffhm895 authors: Kang, Yoogoo; Elia, Elia title: Anesthesia Management of Liver Transplantation date: 2016-07-22 journal: Contemporary Liver Transplantation DOI: 10.1007/978-3-319-07209-8_9 sha: doc_id: 18414 cord_uid: 6ffhm895 file: cache/cord-017603-wq4cgqs2.json key: cord-017603-wq4cgqs2 authors: Shanmugam, Naresh; Dhawan, Anil title: Acute Liver Failure in Children date: 2018-10-16 journal: Pediatric Hepatology and Liver Transplantation DOI: 10.1007/978-3-319-96400-3_8 sha: doc_id: 17603 cord_uid: wq4cgqs2 file: cache/cord-018318-vzzrsqsn.json key: cord-018318-vzzrsqsn authors: Naidu, C. Sudeep; Sarin, Arti title: Postoperative Liver Failure date: 2017-02-08 journal: GI Surgery Annual DOI: 10.1007/978-981-10-2678-2_3 sha: doc_id: 18318 cord_uid: vzzrsqsn file: cache/cord-029138-avfvpqs5.json key: cord-029138-avfvpqs5 authors: Croome, Kristopher P.; Taner, C. Burcin title: The Changing Landscapes in DCD Liver Transplantation date: 2020-07-13 journal: Curr Transplant Rep DOI: 10.1007/s40472-020-00283-1 sha: doc_id: 29138 cord_uid: avfvpqs5 file: cache/cord-002272-c7f1l13s.json key: cord-002272-c7f1l13s authors: Sauter, Kristin A.; Waddell, Lindsey A.; Lisowski, Zofia M.; Young, Rachel; Lefevre, Lucas; Davis, Gemma M.; Clohisey, Sara M.; McCulloch, Mary; Magowan, Elizabeth; Mabbott, Neil A.; Summers, Kim M.; Hume, David A. title: Macrophage colony-stimulating factor (CSF1) controls monocyte production and maturation and the steady-state size of the liver in pigs date: 2016-07-21 journal: Am J Physiol Gastrointest Liver Physiol DOI: 10.1152/ajpgi.00116.2016 sha: doc_id: 2272 cord_uid: c7f1l13s file: cache/cord-016880-q44623s8.json key: cord-016880-q44623s8 authors: van Hoek, B.; Verkade, H.J.; Porte, R.J. title: 22 Levertransplantatie date: 2015-01-02 journal: Leverziekten DOI: 10.1007/978-90-313-7437-3_22 sha: doc_id: 16880 cord_uid: q44623s8 file: cache/cord-032131-ghgciqfk.json key: cord-032131-ghgciqfk authors: Ganschow, Rainer; Melter, Michael; Deutsch, Johann title: Lebertransplantation und Leberversagen date: 2013 journal: Pädiatrische Gastroenterologie, Hepatologie und Ernährung DOI: 10.1007/978-3-642-24710-1_19 sha: doc_id: 32131 cord_uid: ghgciqfk file: cache/cord-001567-3bw7jbzq.json key: cord-001567-3bw7jbzq authors: Borlak, Jürgen; Singh, Prashant; Gazzana, Giuseppe title: Proteome mapping of epidermal growth factor induced hepatocellular carcinomas identifies novel cell metabolism targets and mitogen activated protein kinase signalling events date: 2015-02-25 journal: BMC Genomics DOI: 10.1186/s12864-015-1312-z sha: doc_id: 1567 cord_uid: 3bw7jbzq file: cache/cord-006391-esnsa4u5.json key: cord-006391-esnsa4u5 authors: nan title: Abstracts 5(th) Tripartite Meeting Salzburg/Austria, September 9–11,1982 date: 1982 journal: Langenbecks Arch Chir DOI: 10.1007/bf01279099 sha: doc_id: 6391 cord_uid: esnsa4u5 file: cache/cord-003921-8r8z0otz.json key: cord-003921-8r8z0otz authors: Nakamura, Kojiro; Kageyama, Shoichi; Kupiec-Weglinski, Jerzy W. title: The Evolving Role of Neutrophils in Liver Transplant Ischemia-Reperfusion Injury date: 2019-01-29 journal: Curr Transplant Rep DOI: 10.1007/s40472-019-0230-4 sha: doc_id: 3921 cord_uid: 8r8z0otz file: cache/cord-023033-tgt69ir6.json key: cord-023033-tgt69ir6 authors: nan title: Poster Session (pp. 78A–178A) date: 2006-02-10 journal: Hepatology DOI: 10.1002/hep.1840380503 sha: doc_id: 23033 cord_uid: tgt69ir6 file: cache/cord-033914-a9e3rncp.json key: cord-033914-a9e3rncp authors: Kauffman-Ortega, E.; Valdovinos-Díaz, M.A. title: In memoriam Ludwig van Beethoven. Clinical history and possible diagnoses of the genius of musical composition in silence() date: 2020-10-17 journal: nan DOI: 10.1016/j.rgmxen.2020.10.006 sha: doc_id: 33914 cord_uid: a9e3rncp file: cache/cord-262152-gdnc51m5.json key: cord-262152-gdnc51m5 authors: Chaibi, Sayma; Boussier, Jeremy; Hajj, Weam El; Abitbol, Yael; Taieb, Sarah; Horaist, Clemence; Jouannaud, Vincent; Wang, Pascal; Piquet, Jacques; Maurer, Cyril; Lahmek, Pierre; Nahon, Stéphane title: Liver Function Test Abnormalities Are Associated With A Poorer Prognosis In Covid-19 Patients: Results Of A French Cohort date: 2020-10-19 journal: Clin Res Hepatol Gastroenterol DOI: 10.1016/j.clinre.2020.10.002 sha: doc_id: 262152 cord_uid: gdnc51m5 file: cache/cord-033821-i14dmmps.json key: cord-033821-i14dmmps authors: Guo, Yue-Cheng; Lu, Lun-Gen title: Antihepatic Fibrosis Drugs in Clinical Trials date: 2020-08-24 journal: J Clin Transl Hepatol DOI: 10.14218/jcth.2020.00023 sha: doc_id: 33821 cord_uid: i14dmmps file: cache/cord-005892-3yuznrdv.json key: cord-005892-3yuznrdv authors: Hübener, P.; Braun, G.; Fuhrmann, V. title: Das akut-auf-chronische Leberversagen als diagnostische und therapeutische Herausforderung der Intensivmedizin date: 2017-02-16 journal: Med Klin Intensivmed Notfmed DOI: 10.1007/s00063-017-0263-3 sha: doc_id: 5892 cord_uid: 3yuznrdv file: cache/cord-280234-anlytu3q.json key: cord-280234-anlytu3q authors: Memar, Elmira Haji Esmaeil; Mamishi, Setareh; Ekbatani, Meisam Sharifzadeh; Alimadadi, Hosein; Yaghmaei, Bahareh; Chegini, Victoria; Janani, Somayeh; Mahmoudi, Shima title: Fulminant hepatic failure: a rare and devastating manifestation of Coronavirus disease 2019 in an 11-year-old boy date: 2020-09-29 journal: Arch Pediatr DOI: 10.1016/j.arcped.2020.09.009 sha: doc_id: 280234 cord_uid: anlytu3q file: cache/cord-016757-3d320c0a.json key: cord-016757-3d320c0a authors: nan title: Acute and chronic liver insufficiency date: 2008 journal: Hepatology Textbook and Atlas DOI: 10.1007/978-3-540-76839-5_20 sha: doc_id: 16757 cord_uid: 3d320c0a file: cache/cord-018225-dozmy3lb.json key: cord-018225-dozmy3lb authors: Hawker, Felicity H. title: The liver in critical illness date: 2008 journal: Classic Papers in Critical Care DOI: 10.1007/978-1-84800-145-9_7 sha: doc_id: 18225 cord_uid: dozmy3lb file: cache/cord-018620-3kqx8arn.json key: cord-018620-3kqx8arn authors: Rueda, Mario; Lipsett, Pamela A. title: Hepatic Failure date: 2016-10-09 journal: Principles of Adult Surgical Critical Care DOI: 10.1007/978-3-319-33341-0_18 sha: doc_id: 18620 cord_uid: 3kqx8arn file: cache/cord-323736-zup9cp6s.json key: cord-323736-zup9cp6s authors: Ko, Sheung‐Fat; Chen, Yi‐Ling; Sung, Pei‐Hsun; Chiang, John Y.; Chu, Yi‐Ching; Huang, Chung‐Cheng; Huang, Chi‐Ruei; Yip, Hon‐Kan title: Hepatic (31)P‐magnetic resonance spectroscopy identified the impact of melatonin‐pretreated mitochondria in acute liver ischaemia‐reperfusion injury date: 2020-07-21 journal: J Cell Mol Med DOI: 10.1111/jcmm.15617 sha: doc_id: 323736 cord_uid: zup9cp6s file: cache/cord-022300-9w0lehal.json key: cord-022300-9w0lehal authors: Hoskins, Johnny D. title: The Liver and Pancreas date: 2009-05-15 journal: Veterinary Pediatrics DOI: 10.1016/b978-0-7216-7665-4.50015-2 sha: doc_id: 22300 cord_uid: 9w0lehal file: cache/cord-261608-4sjlg0p0.json key: cord-261608-4sjlg0p0 authors: Trejo-Paredes, Camila; Mohammed, Turab Jawaid; Salmon, Adrian title: COVID-19-INDUCED LIVER INJURY: A CLINICAL DISTRACTION? date: 2020-10-31 journal: Chest DOI: 10.1016/j.chest.2020.08.901 sha: doc_id: 261608 cord_uid: 4sjlg0p0 file: cache/cord-277535-u283k70i.json key: cord-277535-u283k70i authors: Vaja, Rakesh; Rana, Meenal title: Drugs and the liver date: 2020-09-22 journal: nan DOI: 10.1016/j.mpaic.2020.07.001 sha: doc_id: 277535 cord_uid: u283k70i file: cache/cord-291851-xesef17i.json key: cord-291851-xesef17i authors: Wong, Yu-Jun; Tan, Malcolm; Zheng, Qishi; Li, Weiquan; Kumar, Rahul; Fock, Kwong-Ming; Teo, Eng-Kiong; Ang, Tiing-Leong title: A systematic review and meta-analysis of the COVID-19 associated liver injury date: 2020-08-31 journal: Ann Hepatol DOI: 10.1016/j.aohep.2020.08.064 sha: doc_id: 291851 cord_uid: xesef17i file: cache/cord-292501-2jv7xkfn.json key: cord-292501-2jv7xkfn authors: Jiang, Saiping; Wang, Rongrong; Li, Lu; Hong, Dongsheng; Ru, Renping; Rao, Yuefeng; Miao, Jing; Chen, Na; Wu, Xiuhua; Ye, Ziqi; Hu, Yunzhen; Xie, Minghua; Zuo, Minjuan; Lu, Xiaoyang; Qiu, Yunqing; Liang, Tingbo title: Liver Injury in Critically Ill and Non-critically Ill COVID-19 Patients: A Multicenter, Retrospective, Observational Study date: 2020-06-23 journal: Front Med (Lausanne) DOI: 10.3389/fmed.2020.00347 sha: doc_id: 292501 cord_uid: 2jv7xkfn file: cache/cord-025168-be7zube4.json key: cord-025168-be7zube4 authors: Saleh, Mahshid; Taher, Mohammad; Sohrabpour, Amir Ali; Vaezi, Amir Abbas; Nasiri Toosi, Mohsen; Kavianpour, Maria; Ghazvinian, Zeinab; Abdolahi, Shahrokh; Verdi, Javad title: Perspective of placenta derived mesenchymal stem cells in acute liver failure date: 2020-05-24 journal: Cell Biosci DOI: 10.1186/s13578-020-00433-z sha: doc_id: 25168 cord_uid: be7zube4 file: cache/cord-275637-ea6w2kqv.json key: cord-275637-ea6w2kqv authors: Roca-Fernandez, A.; Dennis, A.; Nicolls, R.; McGonigle, J.; Kelly, M.; Banerjee, R. title: HIGH LIVER FAT ASSOCIATES WITH HIGHER RISK OF DEVELOPING SYMPTOMATIC COVID-19 INFECTION - INITIAL UK BIOBANK OBSERVATIONS date: 2020-06-05 journal: nan DOI: 10.1101/2020.06.04.20122457 sha: doc_id: 275637 cord_uid: ea6w2kqv file: cache/cord-328147-61gtx2h2.json key: cord-328147-61gtx2h2 authors: Lopez-Mendez, Ivan; Aquino-Matus, Jorge; Gall, Sofia Murua-Beltrán; Prieto-Nava, Jose D.; Juarez-Hernandez, Eva; Uribe, Misael; Castro-Narro, Graciela title: Association of liver steatosis and fibrosis with clinical outcomes in patients with SARS-CoV-2 infection (COVID-19) date: 2020-10-21 journal: Ann Hepatol DOI: 10.1016/j.aohep.2020.09.015 sha: doc_id: 328147 cord_uid: 61gtx2h2 file: cache/cord-309795-2kozsv4z.json key: cord-309795-2kozsv4z authors: Dewidar, Bedair; Kahl, Sabine; Pafili, Kalliopi; Roden, Michael title: Metabolic liver disease in diabetes – from mechanisms to clinical trials date: 2020-06-20 journal: Metabolism DOI: 10.1016/j.metabol.2020.154299 sha: doc_id: 309795 cord_uid: 2kozsv4z file: cache/cord-305956-l02xdq87.json key: cord-305956-l02xdq87 authors: Alqahtani, Saleh A; Schattenberg, Jörn M title: Liver injury in COVID-19: The current evidence date: 2020-05-26 journal: United European Gastroenterol J DOI: 10.1177/2050640620924157 sha: doc_id: 305956 cord_uid: l02xdq87 file: cache/cord-022555-a7ie82fs.json key: cord-022555-a7ie82fs authors: nan title: Digestive System, Liver, and Abdominal Cavity date: 2011-12-05 journal: The Cat DOI: 10.1016/b978-1-4377-0660-4.00023-5 sha: doc_id: 22555 cord_uid: a7ie82fs file: cache/cord-324509-5c6fzdjm.json key: cord-324509-5c6fzdjm authors: Huang, Haijun; Chen, Shanshan; Li, Hong; Zhou, Xian‐Long; Dai, Yining; Jia, Wu; Zhang, Jun; Shao, Lina; Yan, Rong; Wang, Mingshan; Wang, Jiafeng; Tu, Yuexing; Ge, Minghua title: The association between markers of liver injury and clinical outcomes in patients with COVID‐19 in Wuhan date: 2020-07-22 journal: Aliment Pharmacol Ther DOI: 10.1111/apt.15962 sha: doc_id: 324509 cord_uid: 5c6fzdjm file: cache/cord-271635-tydlyc1q.json key: cord-271635-tydlyc1q authors: Abdel-Hamid, Nabil M.; Abass, Shimaa A.; Mohamed, Ahmed A.; Muneam Hamid, Daniah title: Herbal management of hepatocellular carcinoma through cutting the pathways of the common risk factors date: 2018-11-30 journal: Biomedicine & Pharmacotherapy DOI: 10.1016/j.biopha.2018.08.104 sha: doc_id: 271635 cord_uid: tydlyc1q file: cache/cord-318755-fip8wj6y.json key: cord-318755-fip8wj6y authors: El Kassas, Mohamed; Alboraie, Mohamed; Al Balakosy, Amira; Abdeen, Nermeen; Afify, Shimaa; Abdalgaber, Mohammad; Sherief, Ahmed F; Madkour, Ahmad; Abdellah Ahmed, Mohamed; Eltabbakh, Mohamed; Salaheldin, Mohamed; Wifi, Mohamed-Naguib title: Liver transplantation in the era of COVID-19 date: 2020-05-12 journal: Arab J Gastroenterol DOI: 10.1016/j.ajg.2020.04.019 sha: doc_id: 318755 cord_uid: fip8wj6y file: cache/cord-284693-mgpxnnk0.json key: cord-284693-mgpxnnk0 authors: Jothimani, Dinesh; Venugopal, Radhika; Vij, Mukul; Rela, Mohamed title: Post Liver transplant recurrent and de novo viral infections date: 2020-09-26 journal: Best Pract Res Clin Gastroenterol DOI: 10.1016/j.bpg.2020.101689 sha: doc_id: 284693 cord_uid: mgpxnnk0 file: cache/cord-279667-ikfduu2k.json key: cord-279667-ikfduu2k authors: Ronnje, Louise; Länsberg, John-Kalle; Vikhareva, Olga; Hansson, Stefan R.; Herbst, Andreas; Zaigham, Mehreen title: Complicated COVID-19 in pregnancy: a case report with severe liver and coagulation dysfunction promptly improved by delivery date: 2020-09-04 journal: BMC Pregnancy Childbirth DOI: 10.1186/s12884-020-03172-8 sha: doc_id: 279667 cord_uid: ikfduu2k file: cache/cord-022483-hdmwv540.json key: cord-022483-hdmwv540 authors: nan title: Gastrointestinal Disease date: 2009-06-05 journal: Equine Neonatal Medicine DOI: 10.1016/b978-1-4160-2353-1.50016-8 sha: doc_id: 22483 cord_uid: hdmwv540 file: cache/cord-030369-4dn02a35.json key: cord-030369-4dn02a35 authors: Peng, Liang; Gao, Zhi-Liang; Wang, Yu-Ming; He, Deng-Ming; Zhao, Jing-Ming; Bai, Xue-Fan; Wang, Xiao-Jing title: Clinical Manifestations and Laboratory Tests of AECHB and Severe Hepatitis (Liver Failure) date: 2019-05-21 journal: Acute Exacerbation of Chronic Hepatitis B DOI: 10.1007/978-94-024-1603-9_1 sha: doc_id: 30369 cord_uid: 4dn02a35 file: cache/cord-290412-m6fesoyb.json key: cord-290412-m6fesoyb authors: Zhao, Chang-qing; Zhou, Yang; Ping, Jian; Xu, Lie-ming title: Traditional Chinese medicine for treatment of liver diseases: progress, challenges and opportunities date: 2014-09-30 journal: Journal of Integrative Medicine DOI: 10.1016/s2095-4964(14)60039-x sha: doc_id: 290412 cord_uid: m6fesoyb file: cache/cord-324529-xbrdtxnz.json key: cord-324529-xbrdtxnz authors: Wang, Ming; Yan, Weiming; Qi, Weipeng; Wu, Di; Zhu, Lin; Li, Weina; Wang, Xiaojing; Ma, Ke; Ni, Ming; Xu, Dong; Wang, Hongwu; Chen, Guang; Yu, Haijing; Ding, Hongfang; Xing, Mingyou; Han, Meifang; Luo, Xiaoping; Chen, Tao; Guo, Wei; Xi, Dong; Ning, Qin title: Clinical characteristics and risk factors of liver injury in COVID-19: a retrospective cohort study from Wuhan, China date: 2020-10-07 journal: Hepatol Int DOI: 10.1007/s12072-020-10075-5 sha: doc_id: 324529 cord_uid: xbrdtxnz file: cache/cord-327601-4uqgwlnx.json key: cord-327601-4uqgwlnx authors: Bangash, Mansoor N.; Patel, Jaimin M.; Parekh, Dhruv; Murphy, Nicholas; Brown, Rachel M.; Elsharkawy, Ahmed M.; Mehta, Gautam; Armstrong, Matthew J.; Neil, Desley title: SARS-CoV-2: is the liver merely a bystander to severe disease? date: 2020-06-02 journal: J Hepatol DOI: 10.1016/j.jhep.2020.05.035 sha: doc_id: 327601 cord_uid: 4uqgwlnx file: cache/cord-288721-3bv3aak6.json key: cord-288721-3bv3aak6 authors: Schneider, Annika; Kurz, Sandra; Manske, Katrin; Janas, Marianne; Heikenwälder, Mathias; Misgeld, Thomas; Aichler, Michaela; Weissmann, Sebastian Felix; Zischka, Hans; Knolle, Percy; Wohlleber, Dirk title: Single organelle analysis to characterize mitochondrial function and crosstalk during viral infection date: 2019-06-11 journal: Sci Rep DOI: 10.1038/s41598-019-44922-9 sha: doc_id: 288721 cord_uid: 3bv3aak6 file: cache/cord-340576-dabcs3w5.json key: cord-340576-dabcs3w5 authors: Nishikawa, Hiroki; Enomoto, Hirayuki; Nishiguchi, Shuhei; Iijima, Hiroko title: Liver Cirrhosis and Sarcopenia from the Viewpoint of Dysbiosis date: 2020-07-24 journal: Int J Mol Sci DOI: 10.3390/ijms21155254 sha: doc_id: 340576 cord_uid: dabcs3w5 file: cache/cord-332827-gll4nqdd.json key: cord-332827-gll4nqdd authors: Peixe, Paula; Calinas, Filipe; Tato Marinho, Rui title: Hepatology in the COVID Era: Another C Virus, again Challenging the Liver date: 2020-04-30 journal: GE Port J Gastroenterol DOI: 10.1159/000508116 sha: doc_id: 332827 cord_uid: gll4nqdd file: cache/cord-283120-hyzk59qv.json key: cord-283120-hyzk59qv authors: Sharma, Ashish; Jaiswal, Pragya; Kerakhan, Yasameen; Saravanan, Lakshmi; Murtaza, Zeba; Zergham, Azka; Honganur, Nagaraj-Sanchitha; Akbar, Aelia; Deol, Aran; Francis, Benedict; Patel, Shakumar; Mehta, Deep; Jaiswal, Richa; Singh, Jagmeet; Patel, Urvish; Malik, Preeti title: Liver disease and outcomes among COVID-19 hospitalized patients- a systematic review and meta-analysis date: 2020-10-16 journal: Ann Hepatol DOI: 10.1016/j.aohep.2020.10.001 sha: doc_id: 283120 cord_uid: hyzk59qv file: cache/cord-340710-dmow5p7k.json key: cord-340710-dmow5p7k authors: Lagana, Stephen M.; Kudose, Satoru; Iuga, Alina C.; Lee, Michael J.; Fazlollahi, Ladan; Remotti, Helen E.; Del Portillo, Armando; De Michele, Simona; de Gonzalez, Anne Koehne; Saqi, Anjali; Khairallah, Pascale; Chong, Alexander M.; Park, Heekuk; Uhlemann, Anne-Catrin; Lefkowitch, Jay H.; Verna, Elizabeth C. title: Hepatic pathology in patients dying of COVID-19: a series of 40 cases including clinical, histologic, and virologic data date: 2020-08-13 journal: Mod Pathol DOI: 10.1038/s41379-020-00649-x sha: doc_id: 340710 cord_uid: dmow5p7k file: cache/cord-009987-biop7gyd.json key: cord-009987-biop7gyd authors: Ali, Muhammad; Khan, Tariq; Fatima, Kaneez; Ali, Qurat ul Ain; Ovais, Muhammad; Khalil, Ali Talha; Ullah, Ikram; Raza, Abida; Shinwari, Zabta Khan; Idrees, Muhammad title: Selected hepatoprotective herbal medicines: Evidence from ethnomedicinal applications, animal models, and possible mechanism of actions date: 2017-10-19 journal: Phytother Res DOI: 10.1002/ptr.5957 sha: doc_id: 9987 cord_uid: biop7gyd file: cache/cord-342930-f7cw2ca6.json key: cord-342930-f7cw2ca6 authors: Portincasa, Piero; Krawczyk, Marcin; Machill, Antonia; Lammert, Frank; Ciaula, Agostino Di title: Hepatic consequences of COVID-19 infection. Lapping or biting? date: 2020-06-01 journal: Eur J Intern Med DOI: 10.1016/j.ejim.2020.05.035 sha: doc_id: 342930 cord_uid: f7cw2ca6 file: cache/cord-303046-unksl7p4.json key: cord-303046-unksl7p4 authors: Pawlotsky, Jean-Michel title: COVID-19 and the liver-related deaths to come date: 2020-06-11 journal: Nat Rev Gastroenterol Hepatol DOI: 10.1038/s41575-020-0328-2 sha: doc_id: 303046 cord_uid: unksl7p4 file: cache/cord-300187-fr6tme32.json key: cord-300187-fr6tme32 authors: Kearns, Shawn title: Infectious Hepatopathies in Dogs and Cats date: 2009-11-26 journal: Top Companion Anim Med DOI: 10.1053/j.tcam.2009.06.004 sha: doc_id: 300187 cord_uid: fr6tme32 file: cache/cord-023017-k6edtg58.json key: cord-023017-k6edtg58 authors: nan title: AASLD Abstracts (pp. 282A–382A) date: 2006-02-10 journal: Hepatology DOI: 10.1002/hep.1840380505 sha: doc_id: 23017 cord_uid: k6edtg58 file: cache/cord-022754-ehq9qnoo.json key: cord-022754-ehq9qnoo authors: nan title: Liver date: 2012-07-25 journal: Canine and Feline Gastroenterology DOI: 10.1016/b978-1-4160-3661-6.00061-4 sha: doc_id: 22754 cord_uid: ehq9qnoo file: cache/cord-355395-rckzi8vz.json key: cord-355395-rckzi8vz authors: Tian, Dandan; Ye, Qing title: Hepatic complications of COVID‐19 and its treatment date: 2020-05-21 journal: J Med Virol DOI: 10.1002/jmv.26036 sha: doc_id: 355395 cord_uid: rckzi8vz file: cache/cord-348024-n8wn4och.json key: cord-348024-n8wn4och authors: Lei, Fang; Liu, Ye‐Mao; Zhou, Feng; Qin, Juan‐Juan; Zhang, Peng; Zhu, Lihua; Zhang, Xiao‐Jing; Cai, Jingjing; Lin, Lijin; Ouyang, Shan; Wang, Xiaoming; Yang, Chengzhang; Cheng, Xu; Liu, Weifang; Li, Haomiao; Xie, Jing; Wu, Bin; Luo, Huiming; Xiao, Fei; Chen, Jing; Tao, Liang; Cheng, Gang; She, Zhi‐Gang; Zhou, Jianghua; Wang, Haitao; Lin, Jun; Luo, Pengcheng; Fu, Shouzhi; Zhou, Jihui; Ye, Ping; Xiao, Bing; Mao, Weiming; Liu, Liming; Yan, Youqin; Liu, Ling; Chen, Guohua; Li, Hongliang; Huang, Xiaodong; Zhang, Bing‐Hong; Yuan, Yufeng title: Longitudinal association between markers of liver injury and mortality in COVID‐19 in China date: 2020-05-02 journal: Hepatology DOI: 10.1002/hep.31301 sha: doc_id: 348024 cord_uid: n8wn4och file: cache/cord-339786-elrzlbsg.json key: cord-339786-elrzlbsg authors: Gurala, Dhineshreddy; Al Moussawi, Hassan; Philipose, Jobin; Abergel, Jeffrey R title: Acute Liver Failure in a COVID-19 Patient Without any Preexisting Liver Disease date: 2020-08-26 journal: Cureus DOI: 10.7759/cureus.10045 sha: doc_id: 339786 cord_uid: elrzlbsg file: cache/cord-032181-gmcugd8h.json key: cord-032181-gmcugd8h authors: Song, Jian-Xin; Zhu, Lin; Zhu, Chuan-Long; Hu, Jin-Hua; Sun, Zi-Jian; Xu, Xiang; Xin, Min-You; Zhang, Qiong-Fang; Zhang, Da-Zhi; Shang, Jia; Huang, Jia-Quan; Xu, Dong title: Main Complications of AECHB and Severe Hepatitis B (Liver Failure) date: 2019-05-21 journal: Acute Exacerbation of Chronic Hepatitis B DOI: 10.1007/978-94-024-1603-9_2 sha: doc_id: 32181 cord_uid: gmcugd8h file: cache/cord-342808-yonbowkb.json key: cord-342808-yonbowkb authors: Francque, Sven title: Innovative liver research continues during the current pandemic date: 2020-05-24 journal: JHEP Rep DOI: 10.1016/j.jhepr.2020.100121 sha: doc_id: 342808 cord_uid: yonbowkb file: cache/cord-340325-0oh40b6r.json key: cord-340325-0oh40b6r authors: Witzigmann, Dominik; Kulkarni, Jayesh A.; Leung, Jerry; Chen, Sam; Cullis, Pieter R.; van der Meel, Roy title: Lipid nanoparticle technology for therapeutic gene regulation in the liver date: 2020-07-02 journal: Adv Drug Deliv Rev DOI: 10.1016/j.addr.2020.06.026 sha: doc_id: 340325 cord_uid: 0oh40b6r file: cache/cord-353633-a4pu6rlu.json key: cord-353633-a4pu6rlu authors: Perakakis, Nikolaos; Stefanakis, Konstantinos; Mantzoros, Christos S. title: The role of omics in the pathophysiology, diagnosis and treatment of non-alcoholic fatty liver disease date: 2020-07-23 journal: Metabolism DOI: 10.1016/j.metabol.2020.154320 sha: doc_id: 353633 cord_uid: a4pu6rlu file: cache/cord-000083-3p81yr4n.json key: cord-000083-3p81yr4n authors: nan title: Poster Exhibition date: 2009-01-31 journal: Hepatol Int DOI: 10.1007/s12072-009-9123-4 sha: doc_id: 83 cord_uid: 3p81yr4n Reading metadata file and updating bibliogrpahics === updating bibliographic database Building study carrel named keyword-liver-cord === file2bib.sh === id: cord-261608-4sjlg0p0 author: Trejo-Paredes, Camila title: COVID-19-INDUCED LIVER INJURY: A CLINICAL DISTRACTION? date: 2020-10-31 pages: extension: .txt txt: ./txt/cord-261608-4sjlg0p0.txt cache: ./cache/cord-261608-4sjlg0p0.txt Content-Encoding UTF-8 Content-Type text/plain; charset=UTF-8 X-Parsed-By ['org.apache.tika.parser.DefaultParser', 'org.apache.tika.parser.csv.TextAndCSVParser'] X-TIKA:content_handler ToTextContentHandler X-TIKA:embedded_depth 0 X-TIKA:parse_time_millis 2 resourceName b'cord-261608-4sjlg0p0.txt' === file2bib.sh === OMP: Error #34: System unable to allocate necessary resources for OMP thread: OMP: System error #11: Resource temporarily unavailable OMP: Hint Try decreasing the value of OMP_NUM_THREADS. /data-disk/reader-compute/reader-cord/bin/file2bib.sh: line 39: 95791 Aborted $FILE2BIB "$FILE" > "$OUTPUT" === file2bib.sh === OMP: Error #34: System unable to allocate necessary resources for OMP thread: OMP: System error #11: Resource temporarily unavailable OMP: Hint Try decreasing the value of OMP_NUM_THREADS. /data-disk/reader-compute/reader-cord/bin/file2bib.sh: line 39: 92841 Aborted $FILE2BIB "$FILE" > "$OUTPUT" === file2bib.sh === OMP: Error #34: System unable to allocate necessary resources for OMP thread: OMP: System error #11: Resource temporarily unavailable OMP: Hint Try decreasing the value of OMP_NUM_THREADS. /data-disk/reader-compute/reader-cord/bin/file2bib.sh: line 39: 97047 Aborted $FILE2BIB "$FILE" > "$OUTPUT" === file2bib.sh === OMP: Error #34: System unable to allocate necessary resources for OMP thread: OMP: System error #11: Resource temporarily unavailable OMP: Hint Try decreasing the value of OMP_NUM_THREADS. /data-disk/reader-compute/reader-cord/bin/file2bib.sh: line 39: 96227 Aborted $FILE2BIB "$FILE" > "$OUTPUT" === file2bib.sh === id: cord-005949-8po9xe5g author: Streetz, K.L. title: Akutes Leberversagen: Übersicht zur aktuellen Diagnostik und Therapie date: 2013-11-06 pages: extension: .txt txt: ./txt/cord-005949-8po9xe5g.txt cache: ./cache/cord-005949-8po9xe5g.txt Content-Encoding UTF-8 Content-Type text/plain; charset=UTF-8 X-Parsed-By ['org.apache.tika.parser.DefaultParser', 'org.apache.tika.parser.csv.TextAndCSVParser'] X-TIKA:content_handler ToTextContentHandler X-TIKA:embedded_depth 0 X-TIKA:parse_time_millis 2 resourceName b'cord-005949-8po9xe5g.txt' === file2bib.sh === id: cord-280234-anlytu3q author: Memar, Elmira Haji Esmaeil title: Fulminant hepatic failure: a rare and devastating manifestation of Coronavirus disease 2019 in an 11-year-old boy date: 2020-09-29 pages: extension: .txt txt: ./txt/cord-280234-anlytu3q.txt cache: ./cache/cord-280234-anlytu3q.txt Content-Encoding ISO-8859-1 Content-Type text/plain; charset=ISO-8859-1 X-Parsed-By ['org.apache.tika.parser.DefaultParser', 'org.apache.tika.parser.csv.TextAndCSVParser'] X-TIKA:content_handler ToTextContentHandler X-TIKA:embedded_depth 0 X-TIKA:parse_time_millis 3 resourceName b'cord-280234-anlytu3q.txt' === file2bib.sh === OMP: Error #34: System unable to allocate necessary resources for OMP thread: OMP: System error #11: Resource temporarily unavailable OMP: Hint Try decreasing the value of OMP_NUM_THREADS. /data-disk/reader-compute/reader-cord/bin/file2bib.sh: line 39: 95708 Aborted $FILE2BIB "$FILE" > "$OUTPUT" === file2bib.sh === id: cord-005892-3yuznrdv author: Hübener, P. title: Das akut-auf-chronische Leberversagen als diagnostische und therapeutische Herausforderung der Intensivmedizin date: 2017-02-16 pages: extension: .txt txt: ./txt/cord-005892-3yuznrdv.txt cache: ./cache/cord-005892-3yuznrdv.txt Content-Encoding UTF-8 Content-Type text/plain; charset=UTF-8 X-Parsed-By ['org.apache.tika.parser.DefaultParser', 'org.apache.tika.parser.csv.TextAndCSVParser'] X-TIKA:content_handler ToTextContentHandler X-TIKA:embedded_depth 0 X-TIKA:parse_time_millis 3 resourceName b'cord-005892-3yuznrdv.txt' === file2bib.sh === id: cord-305956-l02xdq87 author: Alqahtani, Saleh A title: Liver injury in COVID-19: The current evidence date: 2020-05-26 pages: extension: .txt txt: ./txt/cord-305956-l02xdq87.txt cache: ./cache/cord-305956-l02xdq87.txt Content-Encoding UTF-8 Content-Type text/plain; charset=UTF-8 X-Parsed-By ['org.apache.tika.parser.DefaultParser', 'org.apache.tika.parser.csv.TextAndCSVParser'] X-TIKA:content_handler ToTextContentHandler X-TIKA:embedded_depth 0 X-TIKA:parse_time_millis 3 resourceName b'cord-305956-l02xdq87.txt' === file2bib.sh === id: cord-262152-gdnc51m5 author: Chaibi, Sayma title: Liver Function Test Abnormalities Are Associated With A Poorer Prognosis In Covid-19 Patients: Results Of A French Cohort date: 2020-10-19 pages: extension: .txt txt: ./txt/cord-262152-gdnc51m5.txt cache: ./cache/cord-262152-gdnc51m5.txt Content-Encoding UTF-8 Content-Type text/plain; charset=UTF-8 X-Parsed-By ['org.apache.tika.parser.DefaultParser', 'org.apache.tika.parser.csv.TextAndCSVParser'] X-TIKA:content_handler ToTextContentHandler X-TIKA:embedded_depth 0 X-TIKA:parse_time_millis 3 resourceName b'cord-262152-gdnc51m5.txt' === file2bib.sh === id: cord-328147-61gtx2h2 author: Lopez-Mendez, Ivan title: Association of liver steatosis and fibrosis with clinical outcomes in patients with SARS-CoV-2 infection (COVID-19) date: 2020-10-21 pages: extension: .txt txt: ./txt/cord-328147-61gtx2h2.txt cache: ./cache/cord-328147-61gtx2h2.txt Content-Encoding UTF-8 Content-Type text/plain; charset=UTF-8 X-Parsed-By ['org.apache.tika.parser.DefaultParser', 'org.apache.tika.parser.csv.TextAndCSVParser'] X-TIKA:content_handler ToTextContentHandler X-TIKA:embedded_depth 0 X-TIKA:parse_time_millis 4 resourceName b'cord-328147-61gtx2h2.txt' === file2bib.sh === id: cord-033914-a9e3rncp author: Kauffman-Ortega, E. title: In memoriam Ludwig van Beethoven. Clinical history and possible diagnoses of the genius of musical composition in silence() date: 2020-10-17 pages: extension: .txt txt: ./txt/cord-033914-a9e3rncp.txt cache: ./cache/cord-033914-a9e3rncp.txt Content-Encoding UTF-8 Content-Type text/plain; charset=UTF-8 X-Parsed-By ['org.apache.tika.parser.DefaultParser', 'org.apache.tika.parser.csv.TextAndCSVParser'] X-TIKA:content_handler ToTextContentHandler X-TIKA:embedded_depth 0 X-TIKA:parse_time_millis 3 resourceName b'cord-033914-a9e3rncp.txt' === file2bib.sh === OMP: Error #34: System unable to allocate necessary resources for OMP thread: OMP: System error #11: Resource temporarily unavailable OMP: Hint Try decreasing the value of OMP_NUM_THREADS. /data-disk/reader-compute/reader-cord/bin/file2bib.sh: line 39: 92136 Aborted $FILE2BIB "$FILE" > "$OUTPUT" === file2bib.sh === id: cord-275637-ea6w2kqv author: Roca-Fernandez, A. title: HIGH LIVER FAT ASSOCIATES WITH HIGHER RISK OF DEVELOPING SYMPTOMATIC COVID-19 INFECTION - INITIAL UK BIOBANK OBSERVATIONS date: 2020-06-05 pages: extension: .txt txt: ./txt/cord-275637-ea6w2kqv.txt cache: ./cache/cord-275637-ea6w2kqv.txt Content-Encoding UTF-8 Content-Type text/plain; charset=UTF-8 X-Parsed-By ['org.apache.tika.parser.DefaultParser', 'org.apache.tika.parser.csv.TextAndCSVParser'] X-TIKA:content_handler ToTextContentHandler X-TIKA:embedded_depth 0 X-TIKA:parse_time_millis 4 resourceName b'cord-275637-ea6w2kqv.txt' === file2bib.sh === id: cord-017603-wq4cgqs2 author: Shanmugam, Naresh title: Acute Liver Failure in Children date: 2018-10-16 pages: extension: .txt txt: ./txt/cord-017603-wq4cgqs2.txt cache: ./cache/cord-017603-wq4cgqs2.txt Content-Encoding UTF-8 Content-Type text/plain; charset=UTF-8 X-Parsed-By ['org.apache.tika.parser.DefaultParser', 'org.apache.tika.parser.csv.TextAndCSVParser'] X-TIKA:content_handler ToTextContentHandler X-TIKA:embedded_depth 0 X-TIKA:parse_time_millis 2 resourceName b'cord-017603-wq4cgqs2.txt' === file2bib.sh === OMP: Error #34: System unable to allocate necessary resources for OMP thread: OMP: System error #11: Resource temporarily unavailable OMP: Hint Try decreasing the value of OMP_NUM_THREADS. /data-disk/reader-compute/reader-cord/bin/file2bib.sh: line 39: 97015 Aborted $FILE2BIB "$FILE" > "$OUTPUT" === file2bib.sh === id: cord-327601-4uqgwlnx author: Bangash, Mansoor N. title: SARS-CoV-2: is the liver merely a bystander to severe disease? date: 2020-06-02 pages: extension: .txt txt: ./txt/cord-327601-4uqgwlnx.txt cache: ./cache/cord-327601-4uqgwlnx.txt Content-Encoding UTF-8 Content-Type text/plain; charset=UTF-8 X-Parsed-By ['org.apache.tika.parser.DefaultParser', 'org.apache.tika.parser.csv.TextAndCSVParser'] X-TIKA:content_handler ToTextContentHandler X-TIKA:embedded_depth 0 X-TIKA:parse_time_millis 2 resourceName b'cord-327601-4uqgwlnx.txt' === file2bib.sh === id: cord-324509-5c6fzdjm author: Huang, Haijun title: The association between markers of liver injury and clinical outcomes in patients with COVID‐19 in Wuhan date: 2020-07-22 pages: extension: .txt txt: ./txt/cord-324509-5c6fzdjm.txt cache: ./cache/cord-324509-5c6fzdjm.txt Content-Encoding UTF-8 Content-Type text/plain; charset=UTF-8 X-Parsed-By ['org.apache.tika.parser.DefaultParser', 'org.apache.tika.parser.csv.TextAndCSVParser'] X-TIKA:content_handler ToTextContentHandler X-TIKA:embedded_depth 0 X-TIKA:parse_time_millis 3 resourceName b'cord-324509-5c6fzdjm.txt' === file2bib.sh === id: cord-283120-hyzk59qv author: Sharma, Ashish title: Liver disease and outcomes among COVID-19 hospitalized patients- a systematic review and meta-analysis date: 2020-10-16 pages: extension: .txt txt: ./txt/cord-283120-hyzk59qv.txt cache: ./cache/cord-283120-hyzk59qv.txt Content-Encoding UTF-8 Content-Type text/plain; charset=UTF-8 X-Parsed-By ['org.apache.tika.parser.DefaultParser', 'org.apache.tika.parser.csv.TextAndCSVParser'] X-TIKA:content_handler ToTextContentHandler X-TIKA:embedded_depth 0 X-TIKA:parse_time_millis 4 resourceName b'cord-283120-hyzk59qv.txt' === file2bib.sh === id: cord-277535-u283k70i author: Vaja, Rakesh title: Drugs and the liver date: 2020-09-22 pages: extension: .txt txt: ./txt/cord-277535-u283k70i.txt cache: ./cache/cord-277535-u283k70i.txt Content-Encoding ISO-8859-1 Content-Type text/plain; charset=ISO-8859-1 X-Parsed-By ['org.apache.tika.parser.DefaultParser', 'org.apache.tika.parser.csv.TextAndCSVParser'] X-TIKA:content_handler ToTextContentHandler X-TIKA:embedded_depth 0 X-TIKA:parse_time_millis 3 resourceName b'cord-277535-u283k70i.txt' === file2bib.sh === id: cord-014770-cgtzlra1 author: Brandt, Lawrence J. title: Book reviews date: 1995 pages: extension: .txt txt: ./txt/cord-014770-cgtzlra1.txt cache: ./cache/cord-014770-cgtzlra1.txt Content-Encoding ISO-8859-1 Content-Type text/plain; charset=ISO-8859-1 X-Parsed-By ['org.apache.tika.parser.DefaultParser', 'org.apache.tika.parser.csv.TextAndCSVParser'] X-TIKA:content_handler ToTextContentHandler X-TIKA:embedded_depth 0 X-TIKA:parse_time_millis 3 resourceName b'cord-014770-cgtzlra1.txt' === file2bib.sh === id: cord-342930-f7cw2ca6 author: Portincasa, Piero title: Hepatic consequences of COVID-19 infection. Lapping or biting? date: 2020-06-01 pages: extension: .txt txt: ./txt/cord-342930-f7cw2ca6.txt cache: ./cache/cord-342930-f7cw2ca6.txt Content-Encoding UTF-8 Content-Type text/plain; charset=UTF-8 X-Parsed-By ['org.apache.tika.parser.DefaultParser', 'org.apache.tika.parser.csv.TextAndCSVParser'] X-TIKA:content_handler ToTextContentHandler X-TIKA:embedded_depth 0 X-TIKA:parse_time_millis 3 resourceName b'cord-342930-f7cw2ca6.txt' === file2bib.sh === id: cord-290412-m6fesoyb author: Zhao, Chang-qing title: Traditional Chinese medicine for treatment of liver diseases: progress, challenges and opportunities date: 2014-09-30 pages: extension: .txt txt: ./txt/cord-290412-m6fesoyb.txt cache: ./cache/cord-290412-m6fesoyb.txt Content-Encoding UTF-8 Content-Type text/plain; charset=UTF-8 X-Parsed-By ['org.apache.tika.parser.DefaultParser', 'org.apache.tika.parser.csv.TextAndCSVParser'] X-TIKA:content_handler ToTextContentHandler X-TIKA:embedded_depth 0 X-TIKA:parse_time_millis 3 resourceName b'cord-290412-m6fesoyb.txt' === file2bib.sh === id: cord-291851-xesef17i author: Wong, Yu-Jun title: A systematic review and meta-analysis of the COVID-19 associated liver injury date: 2020-08-31 pages: extension: .txt txt: ./txt/cord-291851-xesef17i.txt cache: ./cache/cord-291851-xesef17i.txt Content-Encoding UTF-8 Content-Type text/plain; charset=UTF-8 X-Parsed-By ['org.apache.tika.parser.DefaultParser', 'org.apache.tika.parser.csv.TextAndCSVParser'] X-TIKA:content_handler ToTextContentHandler X-TIKA:embedded_depth 0 X-TIKA:parse_time_millis 3 resourceName b'cord-291851-xesef17i.txt' === file2bib.sh === id: cord-323736-zup9cp6s author: Ko, Sheung‐Fat title: Hepatic (31)P‐magnetic resonance spectroscopy identified the impact of melatonin‐pretreated mitochondria in acute liver ischaemia‐reperfusion injury date: 2020-07-21 pages: extension: .txt txt: ./txt/cord-323736-zup9cp6s.txt cache: ./cache/cord-323736-zup9cp6s.txt Content-Encoding UTF-8 Content-Type text/plain; charset=UTF-8 X-Parsed-By ['org.apache.tika.parser.DefaultParser', 'org.apache.tika.parser.csv.TextAndCSVParser'] X-TIKA:content_handler ToTextContentHandler X-TIKA:embedded_depth 0 X-TIKA:parse_time_millis 4 resourceName b'cord-323736-zup9cp6s.txt' === file2bib.sh === id: cord-018801-amet0wx4 author: Park, Caroline title: Care of the Patient with Liver Failure Requiring Transplantation date: 2018-05-04 pages: extension: .txt txt: ./txt/cord-018801-amet0wx4.txt cache: ./cache/cord-018801-amet0wx4.txt Content-Encoding UTF-8 Content-Type text/plain; charset=UTF-8 X-Parsed-By ['org.apache.tika.parser.DefaultParser', 'org.apache.tika.parser.csv.TextAndCSVParser'] X-TIKA:content_handler ToTextContentHandler X-TIKA:embedded_depth 0 X-TIKA:parse_time_millis 3 resourceName b'cord-018801-amet0wx4.txt' === file2bib.sh === id: cord-318755-fip8wj6y author: El Kassas, Mohamed title: Liver transplantation in the era of COVID-19 date: 2020-05-12 pages: extension: .txt txt: ./txt/cord-318755-fip8wj6y.txt cache: ./cache/cord-318755-fip8wj6y.txt Content-Encoding ISO-8859-1 Content-Type text/plain; charset=ISO-8859-1 X-Parsed-By ['org.apache.tika.parser.DefaultParser', 'org.apache.tika.parser.csv.TextAndCSVParser'] X-TIKA:content_handler ToTextContentHandler X-TIKA:embedded_depth 0 X-TIKA:parse_time_millis 3 resourceName b'cord-318755-fip8wj6y.txt' === file2bib.sh === id: cord-033821-i14dmmps author: Guo, Yue-Cheng title: Antihepatic Fibrosis Drugs in Clinical Trials date: 2020-08-24 pages: extension: .txt txt: ./txt/cord-033821-i14dmmps.txt cache: ./cache/cord-033821-i14dmmps.txt Content-Encoding UTF-8 Content-Type text/plain; charset=UTF-8 X-Parsed-By ['org.apache.tika.parser.DefaultParser', 'org.apache.tika.parser.csv.TextAndCSVParser'] X-TIKA:content_handler ToTextContentHandler X-TIKA:embedded_depth 0 X-TIKA:parse_time_millis 4 resourceName b'cord-033821-i14dmmps.txt' === file2bib.sh === id: cord-303046-unksl7p4 author: Pawlotsky, Jean-Michel title: COVID-19 and the liver-related deaths to come date: 2020-06-11 pages: extension: .txt txt: ./txt/cord-303046-unksl7p4.txt cache: ./cache/cord-303046-unksl7p4.txt Content-Encoding UTF-8 Content-Type text/plain; charset=UTF-8 X-Parsed-By ['org.apache.tika.parser.DefaultParser', 'org.apache.tika.parser.csv.TextAndCSVParser'] X-TIKA:content_handler ToTextContentHandler X-TIKA:embedded_depth 0 X-TIKA:parse_time_millis 2 resourceName b'cord-303046-unksl7p4.txt' === file2bib.sh === id: cord-292501-2jv7xkfn author: Jiang, Saiping title: Liver Injury in Critically Ill and Non-critically Ill COVID-19 Patients: A Multicenter, Retrospective, Observational Study date: 2020-06-23 pages: extension: .txt txt: ./txt/cord-292501-2jv7xkfn.txt cache: ./cache/cord-292501-2jv7xkfn.txt Content-Encoding UTF-8 Content-Type text/plain; charset=UTF-8 X-Parsed-By ['org.apache.tika.parser.DefaultParser', 'org.apache.tika.parser.csv.TextAndCSVParser'] X-TIKA:content_handler ToTextContentHandler X-TIKA:embedded_depth 0 X-TIKA:parse_time_millis 3 resourceName b'cord-292501-2jv7xkfn.txt' === file2bib.sh === id: cord-279667-ikfduu2k author: Ronnje, Louise title: Complicated COVID-19 in pregnancy: a case report with severe liver and coagulation dysfunction promptly improved by delivery date: 2020-09-04 pages: extension: .txt txt: ./txt/cord-279667-ikfduu2k.txt cache: ./cache/cord-279667-ikfduu2k.txt Content-Encoding UTF-8 Content-Type text/plain; charset=UTF-8 X-Parsed-By ['org.apache.tika.parser.DefaultParser', 'org.apache.tika.parser.csv.TextAndCSVParser'] X-TIKA:content_handler ToTextContentHandler X-TIKA:embedded_depth 0 X-TIKA:parse_time_millis 2 resourceName b'cord-279667-ikfduu2k.txt' === file2bib.sh === id: cord-018225-dozmy3lb author: Hawker, Felicity H. title: The liver in critical illness date: 2008 pages: extension: .txt txt: ./txt/cord-018225-dozmy3lb.txt cache: ./cache/cord-018225-dozmy3lb.txt Content-Encoding UTF-8 Content-Type text/plain; charset=UTF-8 X-Parsed-By ['org.apache.tika.parser.DefaultParser', 'org.apache.tika.parser.csv.TextAndCSVParser'] X-TIKA:content_handler ToTextContentHandler X-TIKA:embedded_depth 0 X-TIKA:parse_time_millis 4 resourceName b'cord-018225-dozmy3lb.txt' === file2bib.sh === id: cord-003921-8r8z0otz author: Nakamura, Kojiro title: The Evolving Role of Neutrophils in Liver Transplant Ischemia-Reperfusion Injury date: 2019-01-29 pages: extension: .txt txt: ./txt/cord-003921-8r8z0otz.txt cache: ./cache/cord-003921-8r8z0otz.txt Content-Encoding UTF-8 Content-Type text/plain; charset=UTF-8 X-Parsed-By ['org.apache.tika.parser.DefaultParser', 'org.apache.tika.parser.csv.TextAndCSVParser'] X-TIKA:content_handler ToTextContentHandler X-TIKA:embedded_depth 0 X-TIKA:parse_time_millis 3 resourceName b'cord-003921-8r8z0otz.txt' === file2bib.sh === id: cord-332827-gll4nqdd author: Peixe, Paula title: Hepatology in the COVID Era: Another C Virus, again Challenging the Liver date: 2020-04-30 pages: extension: .txt txt: ./txt/cord-332827-gll4nqdd.txt cache: ./cache/cord-332827-gll4nqdd.txt Content-Encoding UTF-8 Content-Type text/plain; charset=UTF-8 X-Parsed-By ['org.apache.tika.parser.DefaultParser', 'org.apache.tika.parser.csv.TextAndCSVParser'] X-TIKA:content_handler ToTextContentHandler X-TIKA:embedded_depth 0 X-TIKA:parse_time_millis 2 resourceName b'cord-332827-gll4nqdd.txt' === file2bib.sh === id: cord-324529-xbrdtxnz author: Wang, Ming title: Clinical characteristics and risk factors of liver injury in COVID-19: a retrospective cohort study from Wuhan, China date: 2020-10-07 pages: extension: .txt txt: ./txt/cord-324529-xbrdtxnz.txt cache: ./cache/cord-324529-xbrdtxnz.txt Content-Encoding UTF-8 Content-Type text/plain; charset=UTF-8 X-Parsed-By ['org.apache.tika.parser.DefaultParser', 'org.apache.tika.parser.csv.TextAndCSVParser'] X-TIKA:content_handler ToTextContentHandler X-TIKA:embedded_depth 0 X-TIKA:parse_time_millis 3 resourceName b'cord-324529-xbrdtxnz.txt' === file2bib.sh === id: cord-025168-be7zube4 author: Saleh, Mahshid title: Perspective of placenta derived mesenchymal stem cells in acute liver failure date: 2020-05-24 pages: extension: .txt txt: ./txt/cord-025168-be7zube4.txt cache: ./cache/cord-025168-be7zube4.txt Content-Encoding UTF-8 Content-Type text/plain; charset=UTF-8 X-Parsed-By ['org.apache.tika.parser.DefaultParser', 'org.apache.tika.parser.csv.TextAndCSVParser'] X-TIKA:content_handler ToTextContentHandler X-TIKA:embedded_depth 0 X-TIKA:parse_time_millis 5 resourceName b'cord-025168-be7zube4.txt' === file2bib.sh === id: cord-002272-c7f1l13s author: Sauter, Kristin A. title: Macrophage colony-stimulating factor (CSF1) controls monocyte production and maturation and the steady-state size of the liver in pigs date: 2016-07-21 pages: extension: .txt txt: ./txt/cord-002272-c7f1l13s.txt cache: ./cache/cord-002272-c7f1l13s.txt Content-Encoding UTF-8 Content-Type text/plain; charset=UTF-8 X-Parsed-By ['org.apache.tika.parser.DefaultParser', 'org.apache.tika.parser.csv.TextAndCSVParser'] X-TIKA:content_handler ToTextContentHandler X-TIKA:embedded_depth 0 X-TIKA:parse_time_millis 4 resourceName b'cord-002272-c7f1l13s.txt' === file2bib.sh === id: cord-016880-q44623s8 author: van Hoek, B. title: 22 Levertransplantatie date: 2015-01-02 pages: extension: .txt txt: ./txt/cord-016880-q44623s8.txt cache: ./cache/cord-016880-q44623s8.txt Content-Encoding UTF-8 Content-Type text/plain; charset=UTF-8 X-Parsed-By ['org.apache.tika.parser.DefaultParser', 'org.apache.tika.parser.csv.TextAndCSVParser'] X-TIKA:content_handler ToTextContentHandler X-TIKA:embedded_depth 0 X-TIKA:parse_time_millis 3 resourceName b'cord-016880-q44623s8.txt' === file2bib.sh === id: cord-032131-ghgciqfk author: Ganschow, Rainer title: Lebertransplantation und Leberversagen date: 2013 pages: extension: .txt txt: ./txt/cord-032131-ghgciqfk.txt cache: ./cache/cord-032131-ghgciqfk.txt Content-Encoding UTF-8 Content-Type text/plain; charset=UTF-8 X-Parsed-By ['org.apache.tika.parser.DefaultParser', 'org.apache.tika.parser.csv.TextAndCSVParser'] X-TIKA:content_handler ToTextContentHandler X-TIKA:embedded_depth 0 X-TIKA:parse_time_millis 3 resourceName b'cord-032131-ghgciqfk.txt' === file2bib.sh === id: cord-029138-avfvpqs5 author: Croome, Kristopher P. title: The Changing Landscapes in DCD Liver Transplantation date: 2020-07-13 pages: extension: .txt txt: ./txt/cord-029138-avfvpqs5.txt cache: ./cache/cord-029138-avfvpqs5.txt Content-Encoding UTF-8 Content-Type text/plain; charset=UTF-8 X-Parsed-By ['org.apache.tika.parser.DefaultParser', 'org.apache.tika.parser.csv.TextAndCSVParser'] X-TIKA:content_handler ToTextContentHandler X-TIKA:embedded_depth 0 X-TIKA:parse_time_millis 3 resourceName b'cord-029138-avfvpqs5.txt' === file2bib.sh === id: cord-284693-mgpxnnk0 author: Jothimani, Dinesh title: Post Liver transplant recurrent and de novo viral infections date: 2020-09-26 pages: extension: .txt txt: ./txt/cord-284693-mgpxnnk0.txt cache: ./cache/cord-284693-mgpxnnk0.txt Content-Encoding UTF-8 Content-Type text/plain; charset=UTF-8 X-Parsed-By ['org.apache.tika.parser.DefaultParser', 'org.apache.tika.parser.csv.TextAndCSVParser'] X-TIKA:content_handler ToTextContentHandler X-TIKA:embedded_depth 0 X-TIKA:parse_time_millis 4 resourceName b'cord-284693-mgpxnnk0.txt' === file2bib.sh === id: cord-340710-dmow5p7k author: Lagana, Stephen M. title: Hepatic pathology in patients dying of COVID-19: a series of 40 cases including clinical, histologic, and virologic data date: 2020-08-13 pages: extension: .txt txt: ./txt/cord-340710-dmow5p7k.txt cache: ./cache/cord-340710-dmow5p7k.txt Content-Encoding UTF-8 Content-Type text/plain; charset=UTF-8 X-Parsed-By ['org.apache.tika.parser.DefaultParser', 'org.apache.tika.parser.csv.TextAndCSVParser'] X-TIKA:content_handler ToTextContentHandler X-TIKA:embedded_depth 0 X-TIKA:parse_time_millis 3 resourceName b'cord-340710-dmow5p7k.txt' === file2bib.sh === id: cord-288721-3bv3aak6 author: Schneider, Annika title: Single organelle analysis to characterize mitochondrial function and crosstalk during viral infection date: 2019-06-11 pages: extension: .txt txt: ./txt/cord-288721-3bv3aak6.txt cache: ./cache/cord-288721-3bv3aak6.txt Content-Encoding UTF-8 Content-Type text/plain; charset=UTF-8 X-Parsed-By ['org.apache.tika.parser.DefaultParser', 'org.apache.tika.parser.csv.TextAndCSVParser'] X-TIKA:content_handler ToTextContentHandler X-TIKA:embedded_depth 0 X-TIKA:parse_time_millis 4 resourceName b'cord-288721-3bv3aak6.txt' === file2bib.sh === id: cord-309795-2kozsv4z author: Dewidar, Bedair title: Metabolic liver disease in diabetes – from mechanisms to clinical trials date: 2020-06-20 pages: extension: .txt txt: ./txt/cord-309795-2kozsv4z.txt cache: ./cache/cord-309795-2kozsv4z.txt Content-Encoding UTF-8 Content-Type text/plain; charset=UTF-8 X-Parsed-By ['org.apache.tika.parser.DefaultParser', 'org.apache.tika.parser.csv.TextAndCSVParser'] X-TIKA:content_handler ToTextContentHandler X-TIKA:embedded_depth 0 X-TIKA:parse_time_millis 3 resourceName b'cord-309795-2kozsv4z.txt' === file2bib.sh === id: cord-018318-vzzrsqsn author: Naidu, C. Sudeep title: Postoperative Liver Failure date: 2017-02-08 pages: extension: .txt txt: ./txt/cord-018318-vzzrsqsn.txt cache: ./cache/cord-018318-vzzrsqsn.txt Content-Encoding UTF-8 Content-Type text/plain; charset=UTF-8 X-Parsed-By ['org.apache.tika.parser.DefaultParser', 'org.apache.tika.parser.csv.TextAndCSVParser'] X-TIKA:content_handler ToTextContentHandler X-TIKA:embedded_depth 0 X-TIKA:parse_time_millis 5 resourceName b'cord-018318-vzzrsqsn.txt' === file2bib.sh === id: cord-340576-dabcs3w5 author: Nishikawa, Hiroki title: Liver Cirrhosis and Sarcopenia from the Viewpoint of Dysbiosis date: 2020-07-24 pages: extension: .txt txt: ./txt/cord-340576-dabcs3w5.txt cache: ./cache/cord-340576-dabcs3w5.txt Content-Encoding UTF-8 Content-Type text/plain; charset=UTF-8 X-Parsed-By ['org.apache.tika.parser.DefaultParser', 'org.apache.tika.parser.csv.TextAndCSVParser'] X-TIKA:content_handler ToTextContentHandler X-TIKA:embedded_depth 0 X-TIKA:parse_time_millis 3 resourceName b'cord-340576-dabcs3w5.txt' === file2bib.sh === id: cord-016757-3d320c0a author: nan title: Acute and chronic liver insufficiency date: 2008 pages: extension: .txt txt: ./txt/cord-016757-3d320c0a.txt cache: ./cache/cord-016757-3d320c0a.txt Content-Encoding UTF-8 Content-Type text/plain; charset=UTF-8 X-Parsed-By ['org.apache.tika.parser.DefaultParser', 'org.apache.tika.parser.csv.TextAndCSVParser'] X-TIKA:content_handler ToTextContentHandler X-TIKA:embedded_depth 0 X-TIKA:parse_time_millis 3 resourceName b'cord-016757-3d320c0a.txt' === file2bib.sh === id: cord-009987-biop7gyd author: Ali, Muhammad title: Selected hepatoprotective herbal medicines: Evidence from ethnomedicinal applications, animal models, and possible mechanism of actions date: 2017-10-19 pages: extension: .txt txt: ./txt/cord-009987-biop7gyd.txt cache: ./cache/cord-009987-biop7gyd.txt Content-Encoding UTF-8 Content-Type text/plain; charset=UTF-8 X-Parsed-By ['org.apache.tika.parser.DefaultParser', 'org.apache.tika.parser.csv.TextAndCSVParser'] X-TIKA:content_handler ToTextContentHandler X-TIKA:embedded_depth 0 X-TIKA:parse_time_millis 3 resourceName b'cord-009987-biop7gyd.txt' === file2bib.sh === id: cord-300187-fr6tme32 author: Kearns, Shawn title: Infectious Hepatopathies in Dogs and Cats date: 2009-11-26 pages: extension: .txt txt: ./txt/cord-300187-fr6tme32.txt cache: ./cache/cord-300187-fr6tme32.txt Content-Encoding UTF-8 Content-Type text/plain; charset=UTF-8 X-Parsed-By ['org.apache.tika.parser.DefaultParser', 'org.apache.tika.parser.csv.TextAndCSVParser'] X-TIKA:content_handler ToTextContentHandler X-TIKA:embedded_depth 0 X-TIKA:parse_time_millis 4 resourceName b'cord-300187-fr6tme32.txt' === file2bib.sh === id: cord-271635-tydlyc1q author: Abdel-Hamid, Nabil M. title: Herbal management of hepatocellular carcinoma through cutting the pathways of the common risk factors date: 2018-11-30 pages: extension: .txt txt: ./txt/cord-271635-tydlyc1q.txt cache: ./cache/cord-271635-tydlyc1q.txt Content-Encoding UTF-8 Content-Type text/plain; charset=UTF-8 X-Parsed-By ['org.apache.tika.parser.DefaultParser', 'org.apache.tika.parser.csv.TextAndCSVParser'] X-TIKA:content_handler ToTextContentHandler X-TIKA:embedded_depth 0 X-TIKA:parse_time_millis 3 resourceName b'cord-271635-tydlyc1q.txt' === file2bib.sh === id: cord-016130-5q9ufu28 author: Linday, Linda A. title: Nutritional Supplements and Upper Respiratory Tract Illnesses in Young Children in the United States date: 2010-12-17 pages: extension: .txt txt: ./txt/cord-016130-5q9ufu28.txt cache: ./cache/cord-016130-5q9ufu28.txt Content-Encoding UTF-8 Content-Type text/plain; charset=UTF-8 X-Parsed-By ['org.apache.tika.parser.DefaultParser', 'org.apache.tika.parser.csv.TextAndCSVParser'] X-TIKA:content_handler ToTextContentHandler X-TIKA:embedded_depth 0 X-TIKA:parse_time_millis 3 resourceName b'cord-016130-5q9ufu28.txt' === file2bib.sh === id: cord-001567-3bw7jbzq author: Borlak, Jürgen title: Proteome mapping of epidermal growth factor induced hepatocellular carcinomas identifies novel cell metabolism targets and mitogen activated protein kinase signalling events date: 2015-02-25 pages: extension: .txt txt: ./txt/cord-001567-3bw7jbzq.txt cache: ./cache/cord-001567-3bw7jbzq.txt Content-Encoding UTF-8 Content-Type text/plain; charset=UTF-8 X-Parsed-By ['org.apache.tika.parser.DefaultParser', 'org.apache.tika.parser.csv.TextAndCSVParser'] X-TIKA:content_handler ToTextContentHandler X-TIKA:embedded_depth 0 X-TIKA:parse_time_millis 4 resourceName b'cord-001567-3bw7jbzq.txt' === file2bib.sh === id: cord-022300-9w0lehal author: Hoskins, Johnny D. title: The Liver and Pancreas date: 2009-05-15 pages: extension: .txt txt: ./txt/cord-022300-9w0lehal.txt cache: ./cache/cord-022300-9w0lehal.txt Content-Encoding ISO-8859-1 Content-Type text/plain; charset=ISO-8859-1 X-Parsed-By ['org.apache.tika.parser.DefaultParser', 'org.apache.tika.parser.csv.TextAndCSVParser'] X-TIKA:content_handler ToTextContentHandler X-TIKA:embedded_depth 0 X-TIKA:parse_time_millis 4 resourceName b'cord-022300-9w0lehal.txt' === file2bib.sh === id: cord-023033-tgt69ir6 author: nan title: Poster Session (pp. 78A–178A) date: 2006-02-10 pages: extension: .txt txt: ./txt/cord-023033-tgt69ir6.txt cache: ./cache/cord-023033-tgt69ir6.txt Content-Encoding UTF-8 Content-Type text/plain; charset=UTF-8 X-Parsed-By ['org.apache.tika.parser.DefaultParser', 'org.apache.tika.parser.csv.TextAndCSVParser'] X-TIKA:content_handler ToTextContentHandler X-TIKA:embedded_depth 0 X-TIKA:parse_time_millis 3 resourceName b'cord-023033-tgt69ir6.txt' === file2bib.sh === id: cord-353633-a4pu6rlu author: Perakakis, Nikolaos title: The role of omics in the pathophysiology, diagnosis and treatment of non-alcoholic fatty liver disease date: 2020-07-23 pages: extension: .txt txt: ./txt/cord-353633-a4pu6rlu.txt cache: ./cache/cord-353633-a4pu6rlu.txt Content-Encoding UTF-8 Content-Type text/plain; charset=UTF-8 X-Parsed-By ['org.apache.tika.parser.DefaultParser', 'org.apache.tika.parser.csv.TextAndCSVParser'] X-TIKA:content_handler ToTextContentHandler X-TIKA:embedded_depth 0 X-TIKA:parse_time_millis 3 resourceName b'cord-353633-a4pu6rlu.txt' === file2bib.sh === id: cord-022483-hdmwv540 author: nan title: Gastrointestinal Disease date: 2009-06-05 pages: extension: .txt txt: ./txt/cord-022483-hdmwv540.txt cache: ./cache/cord-022483-hdmwv540.txt Content-Encoding UTF-8 Content-Type text/plain; charset=UTF-8 X-Parsed-By ['org.apache.tika.parser.DefaultParser', 'org.apache.tika.parser.csv.TextAndCSVParser'] X-TIKA:content_handler ToTextContentHandler X-TIKA:embedded_depth 0 X-TIKA:parse_time_millis 3 resourceName b'cord-022483-hdmwv540.txt' === file2bib.sh === id: cord-030369-4dn02a35 author: Peng, Liang title: Clinical Manifestations and Laboratory Tests of AECHB and Severe Hepatitis (Liver Failure) date: 2019-05-21 pages: extension: .txt txt: ./txt/cord-030369-4dn02a35.txt cache: ./cache/cord-030369-4dn02a35.txt Content-Encoding UTF-8 Content-Type text/plain; charset=UTF-8 X-Parsed-By ['org.apache.tika.parser.DefaultParser', 'org.apache.tika.parser.csv.TextAndCSVParser'] X-TIKA:content_handler ToTextContentHandler X-TIKA:embedded_depth 0 X-TIKA:parse_time_millis 6 resourceName b'cord-030369-4dn02a35.txt' === file2bib.sh === id: cord-006391-esnsa4u5 author: nan title: Abstracts 5(th) Tripartite Meeting Salzburg/Austria, September 9–11,1982 date: 1982 pages: extension: .txt txt: ./txt/cord-006391-esnsa4u5.txt cache: ./cache/cord-006391-esnsa4u5.txt Content-Encoding UTF-8 Content-Type text/plain; charset=UTF-8 X-Parsed-By ['org.apache.tika.parser.DefaultParser', 'org.apache.tika.parser.csv.TextAndCSVParser'] X-TIKA:content_handler ToTextContentHandler X-TIKA:embedded_depth 0 X-TIKA:parse_time_millis 5 resourceName b'cord-006391-esnsa4u5.txt' === file2bib.sh === id: cord-032181-gmcugd8h author: Song, Jian-Xin title: Main Complications of AECHB and Severe Hepatitis B (Liver Failure) date: 2019-05-21 pages: extension: .txt txt: ./txt/cord-032181-gmcugd8h.txt cache: ./cache/cord-032181-gmcugd8h.txt Content-Encoding UTF-8 Content-Type text/plain; charset=UTF-8 X-Parsed-By ['org.apache.tika.parser.DefaultParser', 'org.apache.tika.parser.csv.TextAndCSVParser'] X-TIKA:content_handler ToTextContentHandler X-TIKA:embedded_depth 0 X-TIKA:parse_time_millis 7 resourceName b'cord-032181-gmcugd8h.txt' === file2bib.sh === id: cord-023017-k6edtg58 author: nan title: AASLD Abstracts (pp. 282A–382A) date: 2006-02-10 pages: extension: .txt txt: ./txt/cord-023017-k6edtg58.txt cache: ./cache/cord-023017-k6edtg58.txt Content-Encoding UTF-8 Content-Type text/plain; charset=UTF-8 X-Parsed-By ['org.apache.tika.parser.DefaultParser', 'org.apache.tika.parser.csv.TextAndCSVParser'] X-TIKA:content_handler ToTextContentHandler X-TIKA:embedded_depth 0 X-TIKA:parse_time_millis 4 resourceName b'cord-023017-k6edtg58.txt' === file2bib.sh === id: cord-022555-a7ie82fs author: nan title: Digestive System, Liver, and Abdominal Cavity date: 2011-12-05 pages: extension: .txt txt: ./txt/cord-022555-a7ie82fs.txt cache: ./cache/cord-022555-a7ie82fs.txt Content-Encoding UTF-8 Content-Type text/plain; charset=UTF-8 X-Parsed-By ['org.apache.tika.parser.DefaultParser', 'org.apache.tika.parser.csv.TextAndCSVParser'] X-TIKA:content_handler ToTextContentHandler X-TIKA:embedded_depth 0 X-TIKA:parse_time_millis 6 resourceName b'cord-022555-a7ie82fs.txt' === file2bib.sh === id: cord-022754-ehq9qnoo author: nan title: Liver date: 2012-07-25 pages: extension: .txt txt: ./txt/cord-022754-ehq9qnoo.txt cache: ./cache/cord-022754-ehq9qnoo.txt Content-Encoding UTF-8 Content-Type text/plain; charset=UTF-8 X-Parsed-By ['org.apache.tika.parser.DefaultParser', 'org.apache.tika.parser.csv.TextAndCSVParser'] X-TIKA:content_handler ToTextContentHandler X-TIKA:embedded_depth 0 X-TIKA:parse_time_millis 7 resourceName b'cord-022754-ehq9qnoo.txt' === file2bib.sh === id: cord-000083-3p81yr4n author: nan title: Poster Exhibition date: 2009-01-31 pages: extension: .txt txt: ./txt/cord-000083-3p81yr4n.txt cache: ./cache/cord-000083-3p81yr4n.txt Content-Encoding UTF-8 Content-Type text/plain; charset=UTF-8 X-Parsed-By ['org.apache.tika.parser.DefaultParser', 'org.apache.tika.parser.csv.TextAndCSVParser'] X-TIKA:content_handler ToTextContentHandler X-TIKA:embedded_depth 0 X-TIKA:parse_time_millis 11 resourceName b'cord-000083-3p81yr4n.txt' Que is empty; done keyword-liver-cord === reduce.pl bib === id = cord-005949-8po9xe5g author = Streetz, K.L. title = Akutes Leberversagen: Übersicht zur aktuellen Diagnostik und Therapie date = 2013-11-06 pages = extension = .txt mime = text/plain words = 1378 sentences = 150 flesch = 45 summary = Die amerikanische "acute liver failure study group" unterscheidet in Bezug auf die Zeit zwischen dem Auftreten von Koagulopathie und beginnender hepatischer Enzephalopathie weiterhin zwischen dem hyperakuten (<7 Tage), dem akuten (7-28 Tage) und dem subakuten (28 Tage -6 Monate) Leberversagen [9] . Die etablierte Therapie des häufigen paracetamolinduzierten ALV besteht in der intravenösen Gabe von N-Acetylcystein (NAC) in Form eines 72-stündigen Reduktionsschemas (NAC: 150 mg/kg/h für 1 h, dann 12,5 mg/kg/h für 4 h und 6,25 mg/kg/h für 67 h). Interessanterweise wurde in einer prospektiven multizentrischen Studie gezeigt, dass es beim nicht durch Paracetamol bedingtem ALV unter Gabe von NAC zumindest bei Patienten mit niedriggradiger hepatischer Enzephalopathie (°I-II) ebenfalls zu einer Verbesserung des transplantatfreien Überlebens kommt [10] . Hier wurde gezeigt, dass 84% der Patienten mit ALV nach Erhalt einer frühen Transplantation überlebten, während die Überlebensrate ohne Lebertransplantation bei nur 34% lag. cache = ./cache/cord-005949-8po9xe5g.txt txt = ./txt/cord-005949-8po9xe5g.txt === reduce.pl bib === id = cord-014770-cgtzlra1 author = Brandt, Lawrence J. title = Book reviews date = 1995 pages = extension = .txt mime = text/plain words = 5384 sentences = 264 flesch = 48 summary = The volume combines some basic reviews, such as chapters on the pathophysiology of viral diarrhea and gastrointestinal tract immunology, with detailed exploration of more focused topics, such as rotavirus proteins. While interesting and one of the more clinically applicable sections of the book, the inclusion of a chapter on bacterial diarrhea in a volume dedicated to viral gastroenteritis is somewhat puzzling. While this book has certain outstanding features, there are some shortcomings which warrant mention, most notably a paucity of references beyond 1990 in some chapters and the failure to recognize viral pathogens which, through gastrointestinal tract infection, cause significant disease other than diarrhea. The final chapter in the book is devoted to the therapeutic aspects of gastrointestinal motility, including biofeedback training for fecal incontinence. Once again, adequate references are provided for those who desire more in-depth study, The next several chapters begin at the oropharynx and proceed through the gastrointestinal tract, presenting a discussion of the motility of each area. cache = ./cache/cord-014770-cgtzlra1.txt txt = ./txt/cord-014770-cgtzlra1.txt === reduce.pl bib === id = cord-016130-5q9ufu28 author = Linday, Linda A. title = Nutritional Supplements and Upper Respiratory Tract Illnesses in Young Children in the United States date = 2010-12-17 pages = extension = .txt mime = text/plain words = 11336 sentences = 528 flesch = 47 summary = Our clinical research demonstrates that daily supplementation with a flavored cod liver oil (which meets European purity standards) and a children's multivitamin-mineral with trace metals, including Se, can decrease morbidity from upper respiratory tract illnesses, otitis media, and sinusitis in young children living in the United States. This chapter discusses the role of essential fatty acids, vitamins, and trace metals in the pathophysiology of inflammation; reviews our clinical research on the use of a lemon-flavored cod liver oil (which meets European purity standards) and a children's chewable multivitamin-mineral with Se for the prevention and adjunctive treatment of these disorders; reviews the history of cod liver oil, including its importance in the discovery of vitamin D and the anti-infective properties of vitamin A; and discusses the current clinical use of these supplements. cache = ./cache/cord-016130-5q9ufu28.txt txt = ./txt/cord-016130-5q9ufu28.txt === reduce.pl bib === id = cord-018801-amet0wx4 author = Park, Caroline title = Care of the Patient with Liver Failure Requiring Transplantation date = 2018-05-04 pages = extension = .txt mime = text/plain words = 4703 sentences = 237 flesch = 30 summary = Depending on acuity, patients with decompensated chronic or acute fulminant liver failure generally require preoperative intensive care unit admission to manage organ dysfunction. Depending on acuity, patients with decompensated chronic or acute fulminant liver failure generally require preoperative intensive care unit (ICU) admission to manage organ dysfunction. In patients that develop AKI post-liver transplantation, treatment includes the prevention of hypotension and decreased use of unnecessary blood products. Early postoperative infections in liver transplant patients are typically bacterial and related to the donor's status (previous infections from advanced cirrhosis), the surgical procedure itself, prolonged use of invasive catheters, and duration of mechanical ventilation. The resulting lack of blood flow and developing ischemia and necrosis from hepatic artery thrombosis present with signs and symptoms similar to fulminant liver failure patients with elevated liver serum tests, coagulopathy, and severe metabolic acidosis. cache = ./cache/cord-018801-amet0wx4.txt txt = ./txt/cord-018801-amet0wx4.txt === reduce.pl bib === === reduce.pl bib === id = cord-017603-wq4cgqs2 author = Shanmugam, Naresh title = Acute Liver Failure in Children date = 2018-10-16 pages = extension = .txt mime = text/plain words = 4424 sentences = 248 flesch = 40 summary = Trying to address this issue, Bhaduri and Vergani defined ALF in children as "a rare multisystem disorder in which severe impairment of liver function, with or without encephalopathy, occurs in association with hepatocellular necrosis in a patient with no recognized underlying chronic liver disease" [2] . They used the following criteria to define acute liver failure (ALF) in children: (1) hepatic-based coagulopathy defined as a prothrombin time (PT) ≥ 15 s or international normalized ratio (INR) ≥ 1.5 not corrected by vitamin K in the presence of clinical hepatic encephalopathy (HE) or a PT ≥ 20 s or INR ≥ 2.0 regardless of the presence or absence of clinical hepatic encephalopathy (HE), (2) biochemical evidence of acute liver injury and (3) no known evidence of chronic liver disease [3] . A similar study in children failed to show any benefit, and Paediatric Acute Liver Failure study group does not recommend routine use of in non-acetaminophen-induced ALF in children [33] . cache = ./cache/cord-017603-wq4cgqs2.txt txt = ./txt/cord-017603-wq4cgqs2.txt === reduce.pl bib === id = cord-018318-vzzrsqsn author = Naidu, C. Sudeep title = Postoperative Liver Failure date = 2017-02-08 pages = extension = .txt mime = text/plain words = 9063 sentences = 524 flesch = 42 summary = They focussed on serum bilirubin (SB) and prothrombin time (PT) as important prognostic markers of postoperative liver functional status and proposed the '50-50' criteria for the defi nition of PLF, i.e. the combination of PT >50 % of baseline normal and SB >50 μmol/L on postoperative day (POD) 5 (the '50-50' criteria) was found to be strongly predictive of mortality. In a study, mortality was signifi cantly higher in patients who had resection of hepatocellular carcinoma (HCC) in cirrhosis associated with active hepatitis (8.7 versus 1.5 %; p < 0.05) [ 13 ] . PLF and postoperative renal dysfunction are independent predictors of 90-day mortality following liver resection but the predictive value for mortality is significantly higher when both systems fail simultaneously. The patient's liver status, hepatic reserve potential and functional aspect need to be investigated along with the metabolic and haematological derangements, which may lead to PLF. cache = ./cache/cord-018318-vzzrsqsn.txt txt = ./txt/cord-018318-vzzrsqsn.txt === reduce.pl bib === id = cord-029138-avfvpqs5 author = Croome, Kristopher P. title = The Changing Landscapes in DCD Liver Transplantation date = 2020-07-13 pages = extension = .txt mime = text/plain words = 6309 sentences = 304 flesch = 47 summary = Initial reports examining the use of liver grafts from DCD described inferior longterm outcomes when compared with donation after brain death donors (DBD). More recent single center publications from high volume DCD programs have demonstrated equivalent outcomes between DCD and DBD liver transplantation (LT), with appropriate donor and recipient selection [5] [6] [7] . A previous publication demonstrated that after the implementation of the Share 35 policy, more HCC patients have received livers from DCD donors [22] , potentially as the result of the highest quality organs being preferentially utilized by higher MELD recipients with broader sharing. As the collective experience with DCD LT increased, a concept of functional donor warm ischemic time (fDWIT) arose from the notion that individual events during DCD procurement, such as variations in hemodynamics, mandatory wait period, time from incision to cannulation of the aorta and cross-clamp, all of which are included in total DWIT, may have different impacts on the outcome of the liver graft [25, 26] . cache = ./cache/cord-029138-avfvpqs5.txt txt = ./txt/cord-029138-avfvpqs5.txt === reduce.pl bib === id = cord-002272-c7f1l13s author = Sauter, Kristin A. title = Macrophage colony-stimulating factor (CSF1) controls monocyte production and maturation and the steady-state size of the liver in pigs date = 2016-07-21 pages = extension = .txt mime = text/plain words = 6589 sentences = 374 flesch = 52 summary = title: Macrophage colony-stimulating factor (CSF1) controls monocyte production and maturation and the steady-state size of the liver in pigs Combined with earlier data from the mouse, this study supports the existence of a CSF1-dependent feedback loop, linking macrophages of the liver with bone marrow and blood monocytes, to mediate homeostatic control of the size of the liver. The expected increase in half-life was confirmed, and CSF1-Fc administration to mice produced substantial increases in circulating monocyte and tissue macrophage numbers, at much lower doses than the native protein. Cluster 2 (Fig. 9B) , the set of genes reduced in the CSF1-Fc-treated pigs, most likely reflects the functional zonation of the liver between periportal and perivenous regions of liver lobules (8, 19, 48) and the selective proliferation of cells derived from portal progenitors that has been observed in regenerating liver (15, 34, 36) . cache = ./cache/cord-002272-c7f1l13s.txt txt = ./txt/cord-002272-c7f1l13s.txt === reduce.pl bib === id = cord-016880-q44623s8 author = van Hoek, B. title = 22 Levertransplantatie date = 2015-01-02 pages = extension = .txt mime = text/plain words = 6891 sentences = 636 flesch = 60 summary = Uit analyse van patiënten die getransplanteerd zijn terwijl ze buiten de Milaan-criteria vielen, blijkt dat met name micro-angio-invasie een slechte prognostische marker is en dat de overleving bij grotere of meer dan drie tumoren nog goed kan zijn als er geen micro-angio-invasie is. [29] Bij een hemodynamisch instabiele patiënt kan OLT -of auxiliaire levertransplantatie met een grote resectie van de natieve lever [30] -beter zijn omdat resectie van de necrotische lever het toxic liver-syndroom -door cytokines -kan tegengaan. [48] Het Epstein-Barr-virus (EBV) kan (bij 1% van de levertransplantaties) leiden tot posttransplantatielymfomen (PTLD); die zijn tegenwoordig vaak curatief te behandelen en voor een deel mogelijk te voorkomen door EBV-DNA-metingen in het eerste jaar, met zonodig aanpassen van de immuunsuppressie. Bij de levende donor wordt een resectie verricht van de linkslaterale segmenten van de lever, die vervolgens gebruikt worden voor transplantatie bij het kind. cache = ./cache/cord-016880-q44623s8.txt txt = ./txt/cord-016880-q44623s8.txt === reduce.pl bib === id = cord-001567-3bw7jbzq author = Borlak, Jürgen title = Proteome mapping of epidermal growth factor induced hepatocellular carcinomas identifies novel cell metabolism targets and mitogen activated protein kinase signalling events date = 2015-02-25 pages = extension = .txt mime = text/plain words = 13983 sentences = 721 flesch = 40 summary = title: Proteome mapping of epidermal growth factor induced hepatocellular carcinomas identifies novel cell metabolism targets and mitogen activated protein kinase signalling events Importantly, 11 out of 54 mouse tumour specific proteins were likewise uniquely expressed in human HCC and 49 disease regulated proteins identified in EGF induced liver cancer were similarly regulated in human HCC, as determined by immunhistochemistry using different antibodies and the information given in the publically available Human Protein Atlas depository. Likewise, the genes coding for igals3, i.e. a beta-galactoside-binding protein frequently overexpressed in cancers and pcbp1 that is involved in transcription and functions as an inhibitor of invasion [65] were up-regulated in transgenic nontumour livers (ur-Tr-nT) whereas transcript expression of aars, a member of tRNA synthases and anaxa6, a calcium-dependent, phospholipid-binding protein with important roles in the tumour microenvironment and metastasis were repressed (dr-Tr-nT). cache = ./cache/cord-001567-3bw7jbzq.txt txt = ./txt/cord-001567-3bw7jbzq.txt === reduce.pl bib === id = cord-006391-esnsa4u5 author = nan title = Abstracts 5(th) Tripartite Meeting Salzburg/Austria, September 9–11,1982 date = 1982 pages = extension = .txt mime = text/plain words = 44844 sentences = 2433 flesch = 50 summary = In our parallel tests using an excision-sample technique [2] which is considerably more sensitive than the DGHM procedure, we have observed the following mean reductions in the counts of accessible bacteria: iodine in ethanol, 96%; povidone-iodine, 89%; chlorhexidine in ethanol, 88%; iso-propanol, The purpose of this study was to compare radiation injury in Guinea Pig small bowel (1) devoid of contents (2) containing bile (3) containing pancreatic juice. Studies in vitro employing isolated perfused rat pancreas and stomach revealed following results: Mean basal pancreatic somatostatin release in normal, diabetic and transplanted rats were 12___3, 24-t-7, and 17__+4 pg/ml, respectively. As these changes appear closely correlated to the blood glucose levels which show a 30 % decrease at 4 h and progressive restoration towards normal values up to 24 h, attempts have been made to alter the insulin/glucagon ratio by glucose infusion after PH and study its relation to liver regeneration. cache = ./cache/cord-006391-esnsa4u5.txt txt = ./txt/cord-006391-esnsa4u5.txt === reduce.pl bib === id = cord-023033-tgt69ir6 author = nan title = Poster Session (pp. 78A–178A) date = 2006-02-10 pages = extension = .txt mime = text/plain words = 16102 sentences = 855 flesch = 45 summary = Methods: We performed a retrospective analysis comparing outcomes, and the incidence, timing, and severity of histologic recurrence of HCV following transplantation in patients who underwent living donor liver transplant compared to recipients of cadaveric organs. Local liver immune responses are thought to play a major role in chronic autoimmune diseases directed at biliary epithelium.Using the apical sodium dependent bile acid transporter (ASBT) promoter to drive biliary epithelial cell -specific expression of a membrane form of ovalbumin (OVA), we have previously developed OVA-BIL transgenic mice. Thus, our AIM was to ascertain whether Kupffer cells express death ligands and contribute to hepatocyte apoptosis and liver fibrosis in the bile duct ligated mouse, an animal model of cholestasis. Control experiments confirmed that Y2 protein inhibited IFNa-induced ISRE-mediated signaling in Huh-T7 cells; relative luciferase activity was reduced from 653 (pH771 IFNP nAb increased HCV core Ag replication by 42% and 23% compared to no treatment (p=O.O1). cache = ./cache/cord-023033-tgt69ir6.txt txt = ./txt/cord-023033-tgt69ir6.txt === reduce.pl bib === id = cord-033914-a9e3rncp author = Kauffman-Ortega, E. title = In memoriam Ludwig van Beethoven. Clinical history and possible diagnoses of the genius of musical composition in silence() date = 2020-10-17 pages = extension = .txt mime = text/plain words = 1721 sentences = 93 flesch = 48 summary = His paternal grandmother, Josepha, and his father, Johann van Beethoven, suffered from alcohol use disorder, which led to his father's death when Ludwig was 21 years old. 1 Numerous pathologies in the differential diagnosis have been proposed for Beethoven's sensorineural hearing loss, and the most sustainable are: 1) lead poisoning, based on the presence of residuals of lead 100 times higher than normal in his hair and bones, according to an analysis performed in the United States in the mid 1990s, 4 2) Cogan's syndrome, characterized by bilateral sensorineural hearing loss and interstitial keratitis secondary to vasculitis, albeit there is no evidence of vestibular dysfunction in Beethoven's texts; that syndrome can be associated with idiopathic inflammatory bowel disease and reactive arthritis, 5 and 3) Paget's disease is supported by the frontal bone prominence, tinnitus, and headache. Alcohol consumption appears to be the most probable cause of Beethoven's cirrhosis of the liver, despite the macronodular appearance described in the autopsy. cache = ./cache/cord-033914-a9e3rncp.txt txt = ./txt/cord-033914-a9e3rncp.txt === reduce.pl bib === id = cord-003921-8r8z0otz author = Nakamura, Kojiro title = The Evolving Role of Neutrophils in Liver Transplant Ischemia-Reperfusion Injury date = 2019-01-29 pages = extension = .txt mime = text/plain words = 6688 sentences = 318 flesch = 25 summary = PURPOSE OF REVIEW: Hepatic ischemia-reperfusion injury (IRI), an inevitable event during liver transplantation, represents a major risk factor for the primary graft dysfunction as well as the development of acute and chronic rejection. In IRI-LT pathophysiology, both Kupffer cells (donor-origin) and liver-infiltrating bone marrow-derived macrophages (recipient-origin) play dominant roles in priming innate immune responses [9] [10] [11] , with the majority of studies focusing on macrophage regulation [12, 13] . Indeed, hepatocyte-specific HMGB1 deficient mice showed decreased hepatic necrosis and neutrophil accumulation, whereas the number of their macrophages remained unchanged in acetaminophen-induced liver injury model [28] . In addition, CXCL1 blocking antibody alleviated hepatic infiltration in necrotic cellinduced neutrophil mobilization model [31] , whereas in a carbon tetrachloride (CCl4)-induced acute liver injury, defective CXCL2 expression in TLR2-knockout or S100A9-knockout mice was accompanied by suppressed hepatic neutrophil recruitment [32] . CD4 T cells promote tissue inflammation via CD40 signaling without de novo activation in a murine model of liver ischemia/reperfusion injury cache = ./cache/cord-003921-8r8z0otz.txt txt = ./txt/cord-003921-8r8z0otz.txt === reduce.pl bib === id = cord-033821-i14dmmps author = Guo, Yue-Cheng title = Antihepatic Fibrosis Drugs in Clinical Trials date = 2020-08-24 pages = extension = .txt mime = text/plain words = 5042 sentences = 306 flesch = 40 summary = 11 Treatment based on the etiology may not completely attenuate all fibrosis patients, as there are currently no effective managements for eliminating the cause of certain liver diseases, such as autoimmune hepatitis. In a multicenter, randomized, placebo-controlled trial, 19 patients with NASH exhibited improvements of liver histological features after treatment with OCA (25 mg, 72 weeks). Currently, two active phase II clinical trials (NCT03486912, NCT03486899) are investigating the efficacy and safety of pegbelfermin in patients with NASH-related fibrosis as determined by liver biopsy. A phase II clinical trial 51 showed that pirfenidone (1200 mg daily, 24 months) improved inflammation, fibrosis, and steatosis in patients with hepatitis C virusrelated cirrhosis. 52 A phase II clinical trial (NCT02499562) has explored the effective dose and safety of hydronidone capsules in patients with liver fibrosis induced by hepatitis B virus infection in Shanghai General Hospital, Shanghai, China. cache = ./cache/cord-033821-i14dmmps.txt txt = ./txt/cord-033821-i14dmmps.txt === reduce.pl bib === id = cord-005892-3yuznrdv author = Hübener, P. title = Das akut-auf-chronische Leberversagen als diagnostische und therapeutische Herausforderung der Intensivmedizin date = 2017-02-16 pages = extension = .txt mime = text/plain words = 2152 sentences = 228 flesch = 38 summary = Acute-on-chronic liver failure (ACLF) is an emerging clinical syndrome in patients with underlying liver disease that is usually triggered by one or multiple insults and characterized by progressive hepatic and nonhepatic organ failure, a significant risk of infections, and high short-term mortality rates. Im Rahmen dieses ärztlichen Entscheidungsprozesses müssen neben der unmittelbaren Schwere der Erkrankung beispielsweise auch der mutmaßliche Patientenwunsch, jeweilige lokale und nationale Überlebensraten, eine potenzielle Reversibilität der Or-Das akut-auf-chronische Leberversagen als diagnostische und therapeutische Herausforderung der Intensivmedizin Zusammenfassung Das akut-auf-chronische Leberversagen ("acute-on-chronic liver failure", ACLF) ist ein emergentes Krankheitssyndrom, das durch einen oder mehrere akute Trigger bei vorgeschädigter Leber ausgelöst wird und vom progressiven hepatalen und nichthepatalen Organversagen, einem gravierenden Risiko infektiöser Komplikationen sowie hoher kurzfristiger Letalität gekennzeichnet ist. Leberversagen · Zirrhose · Infektion · Organversagen · Transplantation Acute-on-chronic liver failure: a diagnostic and therapeutic challenge for intensive care Abstract Acute-on-chronic liver failure (ACLF) is an emerging clinical syndrome in patients with underlying liver disease that is usually triggered by one or multiple insults and characterized by progressive hepatic and nonhepatic organ failure, a significant risk of infections, and high short-term mortality rates. cache = ./cache/cord-005892-3yuznrdv.txt txt = ./txt/cord-005892-3yuznrdv.txt === reduce.pl bib === id = cord-280234-anlytu3q author = Memar, Elmira Haji Esmaeil title = Fulminant hepatic failure: a rare and devastating manifestation of Coronavirus disease 2019 in an 11-year-old boy date = 2020-09-29 pages = extension = .txt mime = text/plain words = 1546 sentences = 83 flesch = 42 summary = Although several typical manifestation of novel coronavirus disease 2019 (COVID-19) including respiratory symptoms, weakness, fever, and fatigue have been reported, some rare and novel manifestations have also been observed, particularly in children. In this study, we report a novel pediatric case of fulminant hepatic failure associated with COVIDAlthough there have been a significantly smaller number of reported cases of COVID-19 in the pediatric population compared with the adults, the number of infected children has seen a moderate increase [2, 7] . Owing to the acute fulminant hepatic failure in our patient, the only treatment option was liver transplantation; however, because of the progressive course of the disease and its rapid progression to stage 4 with encephalopathy and brain death, he died. In conclusion, in patients with fulminant hepatic failure, especially in cases with symptoms including fever, respiratory distress, and diarrhea, we should rule out COVID-19 infection as the underlying cause. cache = ./cache/cord-280234-anlytu3q.txt txt = ./txt/cord-280234-anlytu3q.txt === reduce.pl bib === === reduce.pl bib === id = cord-016757-3d320c0a author = nan title = Acute and chronic liver insufficiency date = 2008 pages = extension = .txt mime = text/plain words = 9786 sentences = 705 flesch = 46 summary = Hepatic coma can be subdivided according to its aetiology as follows: (1.) hepatocyte disintegration coma (ϭ endogenous coma due to the loss of parenchyma), (2 ( ( .) liver cell failure coma (ϭ exogenous coma due to metabolic disorders, almost always in the presence of cirrhosis), (3.) electrolyte coma (ϭ so-called "false" coma due to dyselectrolytaemia, almost always iatrogenic), and (4.) mixed forms of coma. Acute liver failure (ALF) is defined as an acute clinical picture with jaundice due to a most severe disorder in the liver function and/or massive liver cell necrosis which, without any pre-existing liver disease, culminates in hepatic coma (ϭ endogenous coma) within 8 weeks. 11) Consequently, severe damage to liver cells and widespread necrosis are usually the result of a network of altered cellular and humoral reactions, which for their part are often the initial cause of acute liver failure due to their synergistic and interactive effects (H. Fulminant hepatic failure caused by acute fatty liver of pregnancy treated by orthotopic liver transplantation cache = ./cache/cord-016757-3d320c0a.txt txt = ./txt/cord-016757-3d320c0a.txt === reduce.pl bib === id = cord-022300-9w0lehal author = Hoskins, Johnny D. title = The Liver and Pancreas date = 2009-05-15 pages = extension = .txt mime = text/plain words = 12535 sentences = 704 flesch = 39 summary = Several different types of congenital PSS occur in young dogs and cats, including but not limited to (1) persistent patent fetal ductus venosus, (2) direct portal vein to caudal vena cava, (3) direct portal vein to azygos vein, (4) combination of portal vein with caudal vena cava into the azygos vein, (5) left gastric vein to vena caval shunt, (6) portal vein hypoplasia or atresia with secondary anomalous vessel, and (7) anomalous malformation of the caudal vena cava (Center et aI, 1995) . Ultrasonographic findings in puppies with congenital PSS include small liver, reduced visibility of intrahepatic portal vasculature, and an anomalous blood vessel draining into the caudal vena cava or sometimes into the azygos vein (Lamb, 1996) . A chronic active liver disease associated with an age-related accumulation of hepatic copper occurs in Bedlington terrier dogs (Hultgren et al, 1986 ). cache = ./cache/cord-022300-9w0lehal.txt txt = ./txt/cord-022300-9w0lehal.txt === reduce.pl bib === id = cord-277535-u283k70i author = Vaja, Rakesh title = Drugs and the liver date = 2020-09-22 pages = extension = .txt mime = text/plain words = 4012 sentences = 239 flesch = 49 summary = Additionally, drugs can also modify how the liver functions and cause dysfunction or even failure of the organ both by a direct effect on the liver or by alteration in liver blood flow. Furthermore, once a patient has been recognized to be suffering with liver dysfunction or failure drug choice and dosing regime will need to be rationalized. After reading this article you should: C understand the mechanisms of drug metabolism by the liver C have an appreciation of alterations to drug choice and dosing regimens in patients with liver disease due to their altered pharmacokinetics C know the management of a patient with paracetamol overdose There are many different isoforms of CYP450, classified according to their amino acid sequencing into families, subfamilies and individual genes. NSAIDS are contraindicated for systemic use in most liver disease patients, because of increased bioavalibilty, the high risk of precipitating gastrointestinal bleeding and renal failure. cache = ./cache/cord-277535-u283k70i.txt txt = ./txt/cord-277535-u283k70i.txt === reduce.pl bib === id = cord-018225-dozmy3lb author = Hawker, Felicity H. title = The liver in critical illness date = 2008 pages = extension = .txt mime = text/plain words = 6814 sentences = 319 flesch = 45 summary = The paper by Harrison and co-workers, again from the King's Liver Unit, investigates the effects of n-acetylcysteine in patients with acute liver failure, and the findings of this study have resulted in widespread use of this agent in this setting. The incidence of hypoxic hepatitis was prospectively studied for 1 year in a group of high-risk patients suffering from low cardiac output in a coronary care unit. In intensive care patients, a rapid decrease in MEGX test values is associated with increased risk of developing multiple organ failure, and a poor outcome, and consequently may have a role in investigation of the role of the liver in the multiple organ failure syndrome. We studied the effect of acetylcysteine on systemic hemodynamics and oxygen transport in 12 patients with acetaminophen-induced fulminant hepatic failure, and 8 patients with acute liver failure from other causes. The increase in oxygen delivery and consumption in response to acetylcysteine may account for its beneficial effect on survival in patients with fulminant hepatic failure induced by acetaminophen. cache = ./cache/cord-018225-dozmy3lb.txt txt = ./txt/cord-018225-dozmy3lb.txt === reduce.pl bib === id = cord-323736-zup9cp6s author = Ko, Sheung‐Fat title = Hepatic (31)P‐magnetic resonance spectroscopy identified the impact of melatonin‐pretreated mitochondria in acute liver ischaemia‐reperfusion injury date = 2020-07-21 pages = extension = .txt mime = text/plain words = 4529 sentences = 244 flesch = 39 summary = This study tested the hypothesis that (31)P‐magnetic resonance spectroscopy ((31)P‐MRS) findings could provide reliable living images to accurately identify the degree of acute liver IRI and melatonin‐pretreated mitochondria was an innovative treatment for protecting the liver from IRI in rat. [1] [2] [3] Studies have further displayed that several key factors contribute to the hepatic injury at the initiation and during the progression of liver IRI, including those of elevation of anaerobic metabolism, dysfunction of mitochondria, insult of oxidative stress, overload of intracellular calcium, activation of liver Kupffer cells, infiltration of immune cells and release of inflammatory cytokines. Additionally, this study further tested whether the 31 P-MRS examination could provide reliable living images to accurately identify the degree of ATP consumption/depletion in hepatocytes, that is an indicator of acute liver ischaemia-reperfusion in rodent. Melatonin-pretreated mitochondria effectively protected liver against IRI and 31 P-MRS was a reliable tool for measuring the mitochondrial/ATP consumption in living animals. Hepatic 31 P-magnetic resonance spectroscopy identified the impact of melatonin-pretreated mitochondria in acute liver ischaemia-reperfusion injury cache = ./cache/cord-323736-zup9cp6s.txt txt = ./txt/cord-323736-zup9cp6s.txt === reduce.pl bib === id = cord-262152-gdnc51m5 author = Chaibi, Sayma title = Liver Function Test Abnormalities Are Associated With A Poorer Prognosis In Covid-19 Patients: Results Of A French Cohort date = 2020-10-19 pages = extension = .txt mime = text/plain words = 2769 sentences = 173 flesch = 51 summary = title: Liver Function Test Abnormalities Are Associated With A Poorer Prognosis In Covid-19 Patients: Results Of A French Cohort AIM: To assess the impact of liver function test (LFT) abnormalities on the prognosis of patients with coronavirus disease 2019 (COVID-19) in a French cohort of hospitalized patients. Similar results were obtained for patients with cholestatic liver injury (Table Table 5 shows the association of factors with the composite severity endpoint (admission to ICU, respiratory failure requiring mechanical ventilation, CT scan injury >50% and global mortality). Severe infection is known to be more frequent among those patients, but they had mostly imbalanced diabetes or hypertension, which was not the case in our study Global mortality was also similar (16.0%), yet the number of admissions to ICU (15.3%) was higher than previously reported 1 . cache = ./cache/cord-262152-gdnc51m5.txt txt = ./txt/cord-262152-gdnc51m5.txt === reduce.pl bib === id = cord-261608-4sjlg0p0 author = Trejo-Paredes, Camila title = COVID-19-INDUCED LIVER INJURY: A CLINICAL DISTRACTION? date = 2020-10-31 pages = extension = .txt mime = text/plain words = 455 sentences = 42 flesch = 45 summary = title: COVID-19-INDUCED LIVER INJURY: A CLINICAL DISTRACTION? His hospital course was also complicated by acute renal failure requiring renal replacement therapy, coagulopathy, and encephalopathy which coincided with liver injury trailing behind the peak of inflammatory markers. Emerging data support the hypothesis that liver injury in COVID-19 is often the result of SARS-CoV-2 directly binding to ACE2+ cholangiocytes, leading to cholangiohepatitis. In addition, cytokine storm may further exacerbate the hepatic injury in COVID-19 (2). Hepatic congestion in ventilated patients, shock liver and particularly, drug-induced liver injury (DILI) remains an important consideration in COVID-19 patients. CONCLUSIONS: COVID-19 induced viral hepatitis is now being increasingly identified as a self-resolving complication and the physician should be mindful of it and in the right setting, it may only be a clinical distraction. We should be cognizant of other potential causes of liver injury in COVID-19 patients like concurrent infection, sepsis-induced and DILI. Liver injury in COVID-19: The current evidence COVID-19 and the liver: little cause for concern. cache = ./cache/cord-261608-4sjlg0p0.txt txt = ./txt/cord-261608-4sjlg0p0.txt === reduce.pl bib === id = cord-291851-xesef17i author = Wong, Yu-Jun title = A systematic review and meta-analysis of the COVID-19 associated liver injury date = 2020-08-31 pages = extension = .txt mime = text/plain words = 4382 sentences = 275 flesch = 52 summary = Our meta-analysis aims to compare the risks and clinical outcomes of COVID-19 associated liver injury among adults with severe and non-severe COVID-19. The objective of this meta-analysis is to compare the risk and clinical outcome of COVID-19 associated liver injury between COVID-19 patients with severe and non-severe COVID-19. In this meta-analysis, we included all studies that met the following inclusion criteria: (1) population: adult patients infected with the COVID-19, (2) reported outcome data on liver enzymes derangement (3) reported outcome data on the risk or severity of liver injury between severe and non-severe COVID-19. We extracted data on the demographic of study populations (age, gender, sample size, the proportion of subjects with baseline chronic liver disease and the use of Lopinavir/ritonavir) as well as the pattern of COVID-19 associated liver injury (ALT, AST, bilirubin, albumin and GGT) from all included studies. and performed a meta-analysis on the severity and risk of COVID-19 associated liver injury in these patients. cache = ./cache/cord-291851-xesef17i.txt txt = ./txt/cord-291851-xesef17i.txt === reduce.pl bib === id = cord-292501-2jv7xkfn author = Jiang, Saiping title = Liver Injury in Critically Ill and Non-critically Ill COVID-19 Patients: A Multicenter, Retrospective, Observational Study date = 2020-06-23 pages = extension = .txt mime = text/plain words = 4406 sentences = 237 flesch = 45 summary = Multivariable regression showed that the number of concomitant medications (odds ratio [OR]: 1.12, 95% confidence interval [CI]: 1.05-1.21) and the combination treatment of lopinavir/ritonavir and arbidol (OR: 3.58, 95% CI: 1.44-9.52) were risk factors for liver injury in non-critically ill patients. Multivariable regression showed that the number of concomitant medications (odds ratio [OR]: 1.12, 95% confidence interval [CI]: 1.05-1.21) and the combination treatment of lopinavir/ritonavir and arbidol (OR: 3.58, 95% CI: 1.44-9.52) were risk factors for liver injury in non-critically ill patients. In the non-critically ill group, the univariate logistic analyses showed that the combination treatment of lopinavir/ritonavir and arbidol and the number of concomitant medications were significantly associated with liver injury ( Table 4) . Drug factors, including the combination treatment of lopinavir/ritonavir and arbidol and the number of concomitant medications were independent risk factors for liver injury in non-critically ill patients with COVID-19, which may be due to drug interactions at the metabolic level. cache = ./cache/cord-292501-2jv7xkfn.txt txt = ./txt/cord-292501-2jv7xkfn.txt === reduce.pl bib === id = cord-025168-be7zube4 author = Saleh, Mahshid title = Perspective of placenta derived mesenchymal stem cells in acute liver failure date = 2020-05-24 pages = extension = .txt mime = text/plain words = 6533 sentences = 361 flesch = 41 summary = Adipose tissue-derived mesenchymal stem cells (AD-MSCs) are isolated from adipose tissue by liposuction, are capable of differentiation to hepatocytelike cells in the presence of HGF, FGF-1, and FGF-4 factors and participate in the regeneration of hepatocytes and vasculogenesis [61] . Several studies have shown that MSCs secrete tropic factors and can be effective in reducing inflammation, fibrosis and apoptosis of liver cells as well as repairing damaged tissue by stimulating angiogenesis [74] . It can be argued that the beneficial effects of MSCs in liver diseases (including ALF) are not limited to hepatocyte repair, but rather the tropical factors released by Fig. 1 Mesenchymal stem cells and its effects on acute liver failure them modulate the deleterious effects of the immune response [142] . Bone marrow-derived mesenchymal stem cells inhibits hepatocyte apoptosis after acute liver injury In vivo hepatic differentiation potential of human umbilical cord-derived mesenchymal stem cells: therapeutic effect on liver fibrosis/cirrhosis cache = ./cache/cord-025168-be7zube4.txt txt = ./txt/cord-025168-be7zube4.txt === reduce.pl bib === id = cord-309795-2kozsv4z author = Dewidar, Bedair title = Metabolic liver disease in diabetes – from mechanisms to clinical trials date = 2020-06-20 pages = extension = .txt mime = text/plain words = 8642 sentences = 421 flesch = 35 summary = NAFLD, which affects about 25% of the population [3] , comprises a broad range of abnormalities ranging from simple fatty liver (steatosis) to non-alcoholic steatohepatitis (NASH), characterized by inflammation, necrosis, and hepatocellular ballooning, and progression to liver fibrosis, cirrhosis, and hepatocellular carcinoma (HCC) [2] . In general, both hyperglycemia and toxic lipids such as ceramides, DAG, FFA, and cholesterol can induce deleterious effects on liver cells (glucolipotoxicity), which might initiate NAFLD progression from simple steatosis to NASH and fibrosis via various mechanisms, including cell death, oxidative stress, endoplasmic reticulum (ER) stress and mitochondrial disorders [46] . BL, baseline; CCR2/5, C-C chemokine receptors type 2 and type 5; FXR, farnesoid X receptor; HbA 1c , glycated haemoglobin; LXR, Liver X receptor; MPC, mitochondrial pyruvate carrier; NA, data not available; NAFLD, non-alcoholic fatty liver disease; NFS, NAFLD fibrosis score; PPAR, peroxisome proliferator-activated receptor; NASH, non-alcoholic steatohepatitis; SCD, stearoyl-CoA desaturase; SGLT, sodium-glucose cotransporter; THR, thyroid hormone receptor; T2DM, type 2 diabetes. Potential Nexus of Non-alcoholic Fatty Liver Disease and Type 2 Diabetes Mellitus: Insulin Resistance Between Hepatic and Peripheral Tissues cache = ./cache/cord-309795-2kozsv4z.txt txt = ./txt/cord-309795-2kozsv4z.txt === reduce.pl bib === id = cord-275637-ea6w2kqv author = Roca-Fernandez, A. title = HIGH LIVER FAT ASSOCIATES WITH HIGHER RISK OF DEVELOPING SYMPTOMATIC COVID-19 INFECTION - INITIAL UK BIOBANK OBSERVATIONS date = 2020-06-05 pages = extension = .txt mime = text/plain words = 2912 sentences = 160 flesch = 47 summary = Conclusions UK Biobank data demonstrated an association between pre-existing liver disease and obesity with severe COVID-19, with higher proportions of liver fat in obese individuals a likely risk factor for symptomatic disease and severity. The aim of this study was to test the hypothesis that liver disease, and specifically liver fat accumulation, is a risk factor for developing symptomatic COVID-19. . https://doi.org/10.1101/2020.06.04.20122457 doi: medRxiv preprint Furthermore, the 32.7% of obese patients with liver fat ≥10% had a higher likelihood of being symptomatic and testing positive for COVID-19 (OR: 2.96, p=0.02). Our study demonstrates that in addition to the previouslyreported risk factors of male gender, non-white-British ethnicity, and obesity (1-3), liver fat is also a significant risk factor for having symptomatic COVID-19, with a person testing positive for COVID-19 being 1.85 times more likely to have pre-existing severe fatty liver disease. cache = ./cache/cord-275637-ea6w2kqv.txt txt = ./txt/cord-275637-ea6w2kqv.txt === reduce.pl bib === id = cord-328147-61gtx2h2 author = Lopez-Mendez, Ivan title = Association of liver steatosis and fibrosis with clinical outcomes in patients with SARS-CoV-2 infection (COVID-19) date = 2020-10-21 pages = extension = .txt mime = text/plain words = 2662 sentences = 156 flesch = 52 summary = In Mexico, 72.5% of the adult population is overweight and 9.4% have T2DM(4) Additionally, the prevalence of hepatic steatosis in Mexico ranges from 14 .4% to 62.9%, (5) and he prevalence of liver fibrosis has been reported in 8.1% (noninvasive assessment).(6) Currently, Mexico City is one of the most affected regions in the world with rising numbers of cases and deaths caused by COVID-19, and we have very few data regarding GI symptoms and LFT abnormalities and their prognostic value in Mexican patients. They also represent a challenge for therapeutic maneuvers such as imaging diagnosis, intubation, mechanical ventilation, and pronation, among others.(11) A meta-analysis including 3,207 patients with COVID-19 described that underlying chronic conditions such as hypertension, diabetes, and cardiovascular and respiratory diseases were higher in critical/non-surviving patients; clinical manifestations such as fever and dyspnea were also associated with the progression of the disease.(12) We found similar results in our study, with dyspnea as the most important associated symptom for ICU admission with OR 4.07 (CI95% 1.6-9.86). cache = ./cache/cord-328147-61gtx2h2.txt txt = ./txt/cord-328147-61gtx2h2.txt === reduce.pl bib === id = cord-305956-l02xdq87 author = Alqahtani, Saleh A title = Liver injury in COVID-19: The current evidence date = 2020-05-26 pages = extension = .txt mime = text/plain words = 3062 sentences = 198 flesch = 44 summary = These reports highlighted that beyond severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), a complicated course of the disease or even viral infection itself can lead to involvement of other organs and multiorgan failure. The current review summarizes the pathophysiology and potentially specific role of COVID-19 in liver disease based on the available data and case series published, ahead of print and non-peer-reviewed preprints as of 2 April. In this study, 47.3% of the discharged patients showed elevated LFTs at baseline, and 23.7% developed abnormalities during hospitalization, suggesting emerging liver injury from drugs or during the course of the infection. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: A single-centered, retrospective, observational study Clinical findings in a group of patients infected with the 2019 novel coronavirus (SARS-Cov-2) outside of Wuhan, China: Retrospective case series cache = ./cache/cord-305956-l02xdq87.txt txt = ./txt/cord-305956-l02xdq87.txt === reduce.pl bib === id = cord-032131-ghgciqfk author = Ganschow, Rainer title = Lebertransplantation und Leberversagen date = 2013 pages = extension = .txt mime = text/plain words = 6539 sentences = 800 flesch = 40 summary = 16.2) handelt es sich um eine Erkrankung des frühen Säuglingsalters, bei der insbesondere die großen Gallengänge außerhalb der Leber (extrahepatische Gallengangatresie) zerstört werden, es können aber auch die intrahepatischen Gallenwege mit betroffen sein. Bislang wurden keine verlässlichen immunologischen Parameter identifiziert, die ein komplettes Absetzen der Immunsuppression nach einigen Therapiejahren bei selektiven Patienten rechtfertigen würden, so dass derzeit von einer lebenslangen immunsuppressiven Therapie ausgegangen werden muss. Durch eine frühzeitige Vorstellung von Kindern mit akutem oder chronischem Leberversagen in einem geeigneten Transplantationszentrum und unter Ausnutzung sämtlicher möglicher Transplantationstechniken sollte es möglich sein, die Mortalität auf der Lebertransplantationswarteliste für Kinder auf Null zu senken. So ist eine Autoimmunhepatitis, vor allem bei jüngeren Kindern, mit einer schlechten Prognose (selbst nach Lebertransplantation) assoziiert, wenn diese nicht kurzfristig auf eine immunsuppressive Therapie (Steroid, Azathioprin) anspricht (Vogel et al. cache = ./cache/cord-032131-ghgciqfk.txt txt = ./txt/cord-032131-ghgciqfk.txt === reduce.pl bib === id = cord-022555-a7ie82fs author = nan title = Digestive System, Liver, and Abdominal Cavity date = 2011-12-05 pages = extension = .txt mime = text/plain words = 66452 sentences = 3846 flesch = 48 summary = One study found that, of cats investigated for gastrointestinal disease, 9 of 33 cats (27%) had no pathology recognized proximal to the jejunum (i.e., the effective length of diagnostic endoscopes would have precluded diagnosis), and other organs were affected in 9 of 10 cats with inflammatory bowel diseases and 7 of 8 cats with intestinal small cell lymphoma. 60, 64 Quantification of serum cobalamin levels is recommended in cats with clinical signs of small bowel diarrhea, ones suspected to have an infiltrative disease of the small intestine (inflammatory bowel disease or gastrointestinal lymphoma), or ones with pancreatic dysfunction. Survey radiographs may be normal in cats with esophagitis and strictures, but are useful to rule out other causes for the clinical signs, such as a foreign body, or to detect related problems, such as aspiration pneumonia. 8, 29 Other non-neoplastic causes reported for gastric or gastroduodenal ulceration in cats include parasites (e.g., Ollulanus tricuspis, Toxocara cati, Aonchotheca putorii, Gnathostoma spp.), bacterial infections, toxins, inflammatory bowel disease, and foreign bodies. cache = ./cache/cord-022555-a7ie82fs.txt txt = ./txt/cord-022555-a7ie82fs.txt === reduce.pl bib === id = cord-324509-5c6fzdjm author = Huang, Haijun title = The association between markers of liver injury and clinical outcomes in patients with COVID‐19 in Wuhan date = 2020-07-22 pages = extension = .txt mime = text/plain words = 2150 sentences = 139 flesch = 48 summary = 7 Some studies have reported the clinical characteristics of patients with coronavirus disease 2019 (COVID19) , including some factors that may lead to COVID-19-related liver damage and the relationship between liver function damage and disease prognosis. Therefore, we retrospectively analysed the clinical characteristics and dynamic changes in liver function based on different liver function levels at admission and different prognosis, in the purpose of finding out risk factors related to liver injury, and associations between markers of liver injury and clinical outcomes in COVID-19, including mortality and mechanical ventilation. 13, 17 One study had suggested that the dynamic changes in liver enzyme levels in severe patients were more significant, and AST was the parameter most correlated with mortality. In our study, the dynamic changes of ALT and AST levels were more significant in patients with liver injury and in the fatal group. cache = ./cache/cord-324509-5c6fzdjm.txt txt = ./txt/cord-324509-5c6fzdjm.txt === reduce.pl bib === id = cord-271635-tydlyc1q author = Abdel-Hamid, Nabil M. title = Herbal management of hepatocellular carcinoma through cutting the pathways of the common risk factors date = 2018-11-30 pages = extension = .txt mime = text/plain words = 10051 sentences = 543 flesch = 36 summary = They can inhibit the liver cancer development and progression in several ways as protecting against liver carcinogens, enhancing effects of chemotherapeutic drugs, inhibiting tumor cell growth and metastasis, and suppression of oxidative stress and chronic inflammation. The co-treatment with LPP, orally, in NAFLD in rats, showed a significant improvement in the hepatic histology, reduction in the fibrosis, oxidative stress, inflammation, accumulation of fats and apoptosis, through modulating the transcriptional factors NF-κB and activator protein-1 (AP-1). The major polyphenol of green tea, epigallocatechin-3-gallate (EGCG), was used in CCl 4 -treated mice and showed a significant therapeutic potential in hepatic damage, inflammation and oxidative stress induced by CCl 4 in a dose-dependent manner at both biochemical and histological levels [34] . It was also reported that co-treatment of the whole green tea extract with alcohol administration showed an effective reduction of the hepatic oxidative stress and reduced form of nicotinamide adenine dinucleotide phosphate (NADPH) oxidase systems in experimental alcohol-induced liver injury [35] . cache = ./cache/cord-271635-tydlyc1q.txt txt = ./txt/cord-271635-tydlyc1q.txt === reduce.pl bib === id = cord-318755-fip8wj6y author = El Kassas, Mohamed title = Liver transplantation in the era of COVID-19 date = 2020-05-12 pages = extension = .txt mime = text/plain words = 4268 sentences = 221 flesch = 38 summary = Management of immunosuppressive therapy and drug-drug interactions in liver transplant recipients infected with COVID-19 should be cautiously practiced to prevent rejection and effectively treat the underlying infection. Although healthcare facilities are overwhelmed with management of COVID-19 patients & health resources are being rapidly consumed, the American Association for the Study of Liver Diseases (AASLD), recommended against postponing transplantation. Patients with advanced liver disease and those after LTX represent vulnerable patient cohorts with an increased risk of infection and/or a severe course of COVID-19 Because of the immunosuppressed state they have [59] . Available data on coronavirus before and during outbreaks suggest that immunosuppressed patients are not at increased risk of severe pulmonary disease compared to the general population; however, immunosuppression may prolong viral shedding in post-transplant patients with COVID-19 if they are already infected [36, 60] . cache = ./cache/cord-318755-fip8wj6y.txt txt = ./txt/cord-318755-fip8wj6y.txt === reduce.pl bib === id = cord-284693-mgpxnnk0 author = Jothimani, Dinesh title = Post Liver transplant recurrent and de novo viral infections date = 2020-09-26 pages = extension = .txt mime = text/plain words = 6339 sentences = 366 flesch = 41 summary = Advanced recipient age, diabetes mellitus, severe liver disease (Child Pugh >10), IL-28B polymorphism, high HCV RNA >10 7 IU/ml, ischemic/reperfusion injury, CMV, donor age >65 years, cold ischaemic time over 8 hours and warm ischemia over 90 minutes, marginal graft, DCD donor, higher immunosuppression in particular high dose corticosteroids for acute cellular rejection, use of anti-thymocyte globulin were significantly associated with rHCV in the liver allograft 15, 16 . Initial studies with sofosbuvir and ribavirin combination therapy for post-transplant rHCV showed poor drug tolerance, however, the main adverse event was anaemia related to ribavirin in 62% of patients, and subsequent hepatic decompensation related to the low haemoglobin 38 . A study by Pellicelli et al., showed significant adverse events including hepatic decompensation and 25% mortality in those with advanced disease following treatment with daclatasvir and sofosbuvir for post-transplant rHCV 51 . cache = ./cache/cord-284693-mgpxnnk0.txt txt = ./txt/cord-284693-mgpxnnk0.txt === reduce.pl bib === id = cord-279667-ikfduu2k author = Ronnje, Louise title = Complicated COVID-19 in pregnancy: a case report with severe liver and coagulation dysfunction promptly improved by delivery date = 2020-09-04 pages = extension = .txt mime = text/plain words = 3361 sentences = 207 flesch = 50 summary = title: Complicated COVID-19 in pregnancy: a case report with severe liver and coagulation dysfunction promptly improved by delivery Severe COVID-19 promptly improved by the termination of the pregnancy or atypical HELLP (Hemolysis, Elevated Liver Enzymes and Low Platelet Count) exacerbated by concomitant COVID-19 infection could not be ruled out. CONCLUSIONS: This case adds to the growing body of evidence which raises concerns about the possible negative maternal outcomes of COVID-19 infection during pregnancy and advocates for pregnant women to be recognized as a vulnerable group during the current pandemic. We report a case of severe COVID-19 during in third trimester pregnancy, which led to an emergency Caesarean section and preterm delivery at 32 + 6 weeks of gestational age. Atypical presentation of HELLP could not be ruled out and the importance of a multidisciplinary team in the treatment and management of severe COVID-19 during pregnancy is critical for positive patient outcome. cache = ./cache/cord-279667-ikfduu2k.txt txt = ./txt/cord-279667-ikfduu2k.txt === reduce.pl bib === id = cord-030369-4dn02a35 author = Peng, Liang title = Clinical Manifestations and Laboratory Tests of AECHB and Severe Hepatitis (Liver Failure) date = 2019-05-21 pages = extension = .txt mime = text/plain words = 35858 sentences = 1603 flesch = 38 summary = Once pulmonary infection is present, the disease condition will likely deteriorate, directly causing death; (3) a majority of infections are nosocomial infection, and pathogens are usually resistant to common antibiotics, making therapy challenging; (4) the pathogens causing infection are diverse but mainly Gram-negative bacteria, although the incidence of Gram-positive and fungal infections is increasing; (5) infection is closely related to the prognosis for liver failure patients. Although their clinical manifestation differ significantly, the "coexistence of acute and chronic failures" is shared by failures of all those organs; (2) CLF classification has been generally recognized at home and abroad, and the necessity of classification are further proved by the difference between CLF and the other three types; (3) CLF cases are relatively large in proportion (nearly 30%), which is still increasing (since the proportion of ALF/SALF are lowering); (4) Complications of CLF are common and are found in various forms, with bad prognosis; (5) In CLF patients with correlation to HBV, virus replication are commonly found, which is closely related to decompensation. cache = ./cache/cord-030369-4dn02a35.txt txt = ./txt/cord-030369-4dn02a35.txt === reduce.pl bib === id = cord-022483-hdmwv540 author = nan title = Gastrointestinal Disease date = 2009-06-05 pages = extension = .txt mime = text/plain words = 19315 sentences = 1127 flesch = 44 summary = In the neonatal period, commonly reported causes of abdominal pain are meconium impaction, small-intestinal volvulus, enteritis or colitis, uroperitoneum, intussusception, gastric ulcers, and ileus secondary to prematurity, septicemia, or neonatal encephalopathy. Lower-intestinal contrast studies (i.e., barium enema) have been reported to have 100% sensitivity and 100% specificity for identifying mechanical obstruction (meconium impaction, atresia coli) of the transverse colon or small colon in foals less than 30 days of age ( Figure 11-14) . The only published study on 20 foals less than two weeks of age with acute abdominal pain reported that an exploratory celiotomy revealed functional ileus (45%), meconium impaction (25%), large-colon displacement (15%), small intestine displaced around the base of the cecum (10%), ruptured gastric ulcer, and small colon obstructed by the ovarian ligament. 8 These reports underscore the difficulty in definitively identifying the cause of abdominal pain prior to exploratory celiotomy in neonatal foals, as clearly some of these cases, such as enteritis and functional ileus, would not be considered to be predominantly surgical diseases. cache = ./cache/cord-022483-hdmwv540.txt txt = ./txt/cord-022483-hdmwv540.txt === reduce.pl bib === id = cord-290412-m6fesoyb author = Zhao, Chang-qing title = Traditional Chinese medicine for treatment of liver diseases: progress, challenges and opportunities date = 2014-09-30 pages = extension = .txt mime = text/plain words = 4271 sentences = 211 flesch = 43 summary = In this article, we introduce TCM herbal preparations from the Chinese materia medica (such as Fuzheng Huayu) that are typically used for the treatment of liver diseases. TCM is widely applied in the treatment of liver diseases in China by both Chinese medicine doctors and Western medicine doctors because its ability to protect hepatocytes, inhibit hepatic inflammation and reduce fibrosis in the liver. Several patent drugs (Chinese herbal formulas) for treatment Clinical observations showed that FZHYC can effectively improve liver function and decrease the expression of fibrosis biomarkers such as serum hyaluronic acid, collagen type IV, procollagen type III and laminin, in chronic liver disease patients with fibrosis or cirrhosis [43, 44] . Randomized controlled multicenter clinical trial for integrated treatment of community-acquired pneumonia based on traditional Chinese medicine syndrome differentiation Optimized project of traditional Chinese medicine in treating chronic kidney disease stage 3: a multicenter double-blinded randomized controlled trial cache = ./cache/cord-290412-m6fesoyb.txt txt = ./txt/cord-290412-m6fesoyb.txt === reduce.pl bib === id = cord-324529-xbrdtxnz author = Wang, Ming title = Clinical characteristics and risk factors of liver injury in COVID-19: a retrospective cohort study from Wuhan, China date = 2020-10-07 pages = extension = .txt mime = text/plain words = 4045 sentences = 223 flesch = 49 summary = title: Clinical characteristics and risk factors of liver injury in COVID-19: a retrospective cohort study from Wuhan, China This study was designed to evaluate the clinical characteristics and risk factors of COVID-19-associated liver injury. extracted the currently largest cohort regarding 1099 mainly moderate SARS-CoV-2 infected patients and showed 39.4% with severe disease had elevated AST and 28.1% had elevated ALT, and the proportion was 18.2% and 19.8% in patients with non-severe disease [6] .Given that the number of patients in these studies is relatively small, information about the clinical characteristics of liver injury in these patients is scarce. The present study showed that liver injury was more prevalent in male, severe or critically ill patients with percutaneous oxygen saturation ≤ 93% or peak temperature ≥ 38.5 °C on admission, and comprehensively delineated the risk factors for COVID-19-associated liver injury. cache = ./cache/cord-324529-xbrdtxnz.txt txt = ./txt/cord-324529-xbrdtxnz.txt === reduce.pl bib === id = cord-327601-4uqgwlnx author = Bangash, Mansoor N. title = SARS-CoV-2: is the liver merely a bystander to severe disease? date = 2020-06-02 pages = extension = .txt mime = text/plain words = 979 sentences = 61 flesch = 43 summary = 1 Their study shows SARS-CoV-2 positive patients with ≥1 week history of increased aminotransferases have worse acute pulmonary disease (radiological and physiological) than those without. Considering that Interleukin (IL)-6 and C-reactive protein (CRP) are similar between patients with normal and prolonged abnormal liver aminotransferases, the authors speculate that liver injury is a direct effect of SARS-CoV-2 viral hepatitis rather than an indirect immune mediated injury. The fact that increases in liver aminotransferases occur and tend to parallel the severity of pulmonary disease remains unquestioned 2 , however, whether the liver injury is a true viral hepatitis rather than a bystander to the multi-organ pathophysiology of critical illness requires further discussion. Based on the above perspectives, we feel that raised liver aminotransferases associated with SARS-CoV-2 positivity are more likely attributable to illness severity, in which host response and iatrogenic harm (i.e. drugs, ventilation) drive bystander liver injury, thus explaining its association with mortality and in an analogous fashion to patterns seen in sepsis. cache = ./cache/cord-327601-4uqgwlnx.txt txt = ./txt/cord-327601-4uqgwlnx.txt === reduce.pl bib === id = cord-340576-dabcs3w5 author = Nishikawa, Hiroki title = Liver Cirrhosis and Sarcopenia from the Viewpoint of Dysbiosis date = 2020-07-24 pages = extension = .txt mime = text/plain words = 8153 sentences = 464 flesch = 41 summary = In individuals with chronic liver diseases (CLDs), metabolic or nutritional dysfunctions including protein-energy malnutrition (PEM) or muscle abnormalities are frequently found, which can be related to disabilities, poor quality of life, or mortality [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] . LC-related complications themselves such as hepatocellular carcinoma (HCC), ascites, spontaneous bacterial peritonitis (SBP), varices, hepatic encephalopathy (HE), and acute or chronic liver failure (ACLF) can cause sarcopenia [22, 40] . LC-related complications themselves such as hepatocellular carcinoma (HCC), ascites, spontaneous bacterial peritonitis (SBP), varices, hepatic encephalopathy (HE), and acute or chronic liver failure (ACLF) can cause sarcopenia [22, 40] . Cumulative evidence has highlighted the relevance of increase in intestinal permeability (i.e., leaky gut syndrome) and consequent bacterial translocation in the development of CLDs. Particularly, in recent hypotheses regarding patients with non-alcoholic fatty liver disease (NAFLD), intestinal permeability impairment, dietary habits, and gut dysbiosis are considered to be the main pathogenic triggers [85] [86] [87] . cache = ./cache/cord-340576-dabcs3w5.txt txt = ./txt/cord-340576-dabcs3w5.txt === reduce.pl bib === id = cord-288721-3bv3aak6 author = Schneider, Annika title = Single organelle analysis to characterize mitochondrial function and crosstalk during viral infection date = 2019-06-11 pages = extension = .txt mime = text/plain words = 5604 sentences = 309 flesch = 39 summary = Thus, single-organelle and multi-parameter resolution allows to explore altered energy metabolism and antiviral defence by tagged mitochondria selectively in virus-infected cells and will be instrumental to identify viral immune escape and to develop and monitor novel mitochondrial-targeted therapies. When challenged with high concentrations of calcium (100 µM), mitochondria isolated from virus-infected livers are much more fragile shown by time-dependent loss of membrane potential and change of their morphology indicated by decrease in side-scatter (Fig. 2F ). Number of viable mitochondria detected per second by flow-cytometry declined after calcium challenge, consistent with loss of mitochondrial integrity, and did so much faster in samples from virus-infected livers (Fig. 2F ). In order to further evaluate mitochondrial functionality, we challenged mitochondria with Ca 2+ as stress test and performed time kinetic measurements of DilC 1 (5) fluorescence and side-scatter of mito-DsRed + and mito-DsRed − mitochondria isolated from Ad-CMV-mitoRL infected livers. cache = ./cache/cord-288721-3bv3aak6.txt txt = ./txt/cord-288721-3bv3aak6.txt === reduce.pl bib === id = cord-332827-gll4nqdd author = Peixe, Paula title = Hepatology in the COVID Era: Another C Virus, again Challenging the Liver date = 2020-04-30 pages = extension = .txt mime = text/plain words = 3989 sentences = 221 flesch = 52 summary = In published series, liver disease was not identified as a risk factor for SARS-Cov2 infection [11] [12] [13] [14] [15] . The authors state that NAFLD patients also had a higher risk of progression to severe COVID-19 and present an increased viral clearance time. Immune-mediated liver diseases, particularly autoimmune hepatitis, have not been mentioned as risk factors for COVID-19, but the immunosuppressive treatment required has triggered fears about the risk of infection in patients. Extensive records and targeted studies are needed to explore multiple open-ended questions such as the severity and mortality of COVID-19 and episodes of acute-on-chronic or decompensation associated with the presence of this disease (ascites, hepatic encephalopathy, digestive bleeding, kidney dysfunction, and the risk of infection) or the response to treatment [25, 26] . However, it is not yet possible to say whether transplantation-associated immunosuppression can alter the predisposition for the acquisition of SARS-Cov2 infection or how COVID-19 evolves in these patients. cache = ./cache/cord-332827-gll4nqdd.txt txt = ./txt/cord-332827-gll4nqdd.txt === reduce.pl bib === id = cord-283120-hyzk59qv author = Sharma, Ashish title = Liver disease and outcomes among COVID-19 hospitalized patients- a systematic review and meta-analysis date = 2020-10-16 pages = extension = .txt mime = text/plain words = 2630 sentences = 157 flesch = 48 summary = In this meta-analysis, we aim to study the occurrence and association of liver injury, comorbid liver disease and elevated liver enzymes in COVID-19 confirmed hospitalizations with outcomes. MATERIALS AND METHODS: Data from observational studies describing comorbid chronic liver disease, acute liver injury, elevated aspartate aminotransferase (AST), alanine aminotransferase (ALT) levels and outcomes of COVID-19 hospitalized patients from December 1, 2019, to June 30, 2020 was extracted following PRISMA guidelines. The aim of the study is to evaluate the role of the comorbid chronic liver disease (CM-CLD), elevated liver enzymes and COVID-19 associated acute liver injury (COVID-19 ALI) in predicting the outcomes in confirmed COVID-19 hospitalized patients. The Maentel-Haenszel formula was used to calculate dichotomous variables to obtain odds ratios (ORs) along with its 95% confidence intervals to describe the association of comorbid liver disease, elevated liver enzymes, acute liver injury and outcomes of COVID-19 patients in each study. cache = ./cache/cord-283120-hyzk59qv.txt txt = ./txt/cord-283120-hyzk59qv.txt === reduce.pl bib === id = cord-340710-dmow5p7k author = Lagana, Stephen M. title = Hepatic pathology in patients dying of COVID-19: a series of 40 cases including clinical, histologic, and virologic data date = 2020-08-13 pages = extension = .txt mime = text/plain words = 4539 sentences = 275 flesch = 48 summary = title: Hepatic pathology in patients dying of COVID-19: a series of 40 cases including clinical, histologic, and virologic data Here we report the clinical and histologic findings related to the liver in 40 patients who died of complications of COVID-19. In conclusion, we found patients dying of COVID-19 had biochemical evidence of hepatitis (of variable severity) and demonstrated histologic findings of macrovesicular steatosis and mild acute hepatitis (lobular necroinflammation) and mild portal inflammation. A more recent study performed core needle biopsies on the livers of four patients and reported nonspecific findings, attributed to preexisting disease or perimortem injury [4] . Histologically, the most frequently encountered findings were macrovesicular steatosis, mild acute hepatitis, and minimal-to-mild portal inflammation. Nonetheless, based on the pattern of injury observed and the results of the PCR analysis, SARS-CoV-2 seems to involve the liver, and is associated with, possibly causal of, macrovesicular steatosis and acute hepatitis. cache = ./cache/cord-340710-dmow5p7k.txt txt = ./txt/cord-340710-dmow5p7k.txt === reduce.pl bib === id = cord-009987-biop7gyd author = Ali, Muhammad title = Selected hepatoprotective herbal medicines: Evidence from ethnomedicinal applications, animal models, and possible mechanism of actions date = 2017-10-19 pages = extension = .txt mime = text/plain words = 7368 sentences = 422 flesch = 37 summary = & Thonn., Salvia miltiorrhiza Bunge., Astragalus membranaceus (Fisch.) Bunge, Capparis spinosa (L.), Cichorium intybus (L.), Solanum nigrum (L.), Sapindus mukorossi Gaertn., Ginkgo biloba (L.), Woodfordia fruticosa (L.) Kurz, Vitex trifolia (L.), Schisandra chinensis (Turcz.) Baill., Cuscuta chinensis (Lam.), Lycium barbarum, Angelica sinensis (Oliv.) Diels, and Litsea coreana (H. Herbal medicines are claimed to both treat and prevent diseases, which adds to a deep belief that these Abbreviations: ALT, alanine aminotransaminase; ASP, Angelica sinensis polysaccharides; AST, aspartate transaminase; EGF, epidermal growth factor; HBV, Hepatitis B virus; LBPs, Lycium barbarum polysaccharides; WF4, Woodfordia fruticosa flower extract. cache = ./cache/cord-009987-biop7gyd.txt txt = ./txt/cord-009987-biop7gyd.txt === reduce.pl bib === id = cord-342930-f7cw2ca6 author = Portincasa, Piero title = Hepatic consequences of COVID-19 infection. Lapping or biting? date = 2020-06-01 pages = extension = .txt mime = text/plain words = 3010 sentences = 160 flesch = 44 summary = Although the most frequent and critical clinical 15 presentation is secondary to the involvement of the lung (fever, cough), the infection by SARS16 CoV-2 virus may lead to a systemic and multi-organ disease [10] , also involving the gastrointestinal 17 tract (nausea/vomiting, or diarrhea) [11, 12] . Although the level of serum transaminases could be already elevated before the onset of COVID-14 19, results from clinical reports and autopsy studies [26, 49, 50] suggest that liver dysfunction can 15 be an expression of a worse disease evolution, and that an isolated elevation of transaminases alone 16 is likely to be the indirect expression of a systemic inflammation. In one study, patients 17 developing abnormal liver tests had higher risks of progressing to severe disease [51] , and the 18 finding is associated with longer hospital stay [62] . Non-alcoholic fatty liver diseases in patients with 19 COVID-19: A retrospective study cache = ./cache/cord-342930-f7cw2ca6.txt txt = ./txt/cord-342930-f7cw2ca6.txt === reduce.pl bib === id = cord-303046-unksl7p4 author = Pawlotsky, Jean-Michel title = COVID-19 and the liver-related deaths to come date = 2020-06-11 pages = extension = .txt mime = text/plain words = 1899 sentences = 78 flesch = 36 summary = As a result of lockdowns and suspension of usual clinical care activities for the benefit of patients with COVID-19, the SARS-CoV-2 pandemic is having a major effect on the management of patients with chronic liver diseases, in particular those with cirrhosis, hepatocellular carcinoma and in liver transplantation programmes. The COVID-19 pandemic will also negatively affect the care and management of patients with hepatocellular carcinoma, generating delayed diagnosis, deferred treatment (including medical and surgical, such as access to liver transplantation), loss to follow-up and, ultimately, increased mortality. Most COviD-19-induced liver-mortality will be delayed, resulting from deferred care for liver diseases, reduced funding for public health interventions and the global economic crisis, which will lead to increases in alcohol and drug use and in blood-borne virus transmissions, while access to care and funding are reduced. cache = ./cache/cord-303046-unksl7p4.txt txt = ./txt/cord-303046-unksl7p4.txt === reduce.pl bib === id = cord-022754-ehq9qnoo author = nan title = Liver date = 2012-07-25 pages = extension = .txt mime = text/plain words = 87886 sentences = 5297 flesch = 39 summary = Conversely, in cases of chronic end-stage liver disease, such as cirrhosis, serum hepatic enzyme activities may not be markedly increased, or may even be within the reference interval as a result of the replacement of hepatocytes with fibrous tissue. World Small Animal Veterinary Association (WSAVA) Standards for the Clinical and Histological Diagnosis of Canine and Feline Liver Disease suggest that the cytologic evaluation of bile forms part of the minimum diagnostic requirement for cats with extrahepatic cholestasis and for dogs guidance. 32 Hyperglobulinemia can be seen in dogs with cirrhosis, but it remains to be determined whether this corresponds with increased autoantibodies as occurs in humans with autoimmune hepatitis, or whether it reflects nonspecific systemic antibody production in response to antigens from the portal blood which bypass the liver through acquired PSSs. 83 Mild nonregenerative anemia may be a reflection of chronic disease. cache = ./cache/cord-022754-ehq9qnoo.txt txt = ./txt/cord-022754-ehq9qnoo.txt === reduce.pl bib === id = cord-023017-k6edtg58 author = nan title = AASLD Abstracts (pp. 282A–382A) date = 2006-02-10 pages = extension = .txt mime = text/plain words = 65796 sentences = 3553 flesch = 51 summary = 14/55 (25%) patients in AC who did not discontinue by week 24 received ribavirin dose reduction in comparison to 31/108 ( The clinical outcome in response to combination therapy for treatment of chronic hepatitis C virus (HCV) infection appears to be different for Caucasian versus African American patients. Over the period of combination therapy, most patients in which serum virus titers were reduced to non detectable levels had significant increases in T cell responses to HCV proteins. CHRONIC Background: Recent large prospective trials demonstrated that the combination therapy of interferon (1FN)-alphalribavirin significantly increased the ratio of a sustained virological response in patients with chronic hepatitis C in comparison with IFN monotherapy, especially in patients with high HCV-RNA titer and genotype lb. Results: Patients with chronic HCV infection showed higher MxA gene expression levels than healthy controls, indicating that hepatitis C virus induces IFN production. cache = ./cache/cord-023017-k6edtg58.txt txt = ./txt/cord-023017-k6edtg58.txt === reduce.pl bib === id = cord-300187-fr6tme32 author = Kearns, Shawn title = Infectious Hepatopathies in Dogs and Cats date = 2009-11-26 pages = extension = .txt mime = text/plain words = 5800 sentences = 444 flesch = 36 summary = Although bacterial infections are probably the most common cause of infectious hepatitis, the clinician should be aware of other potential organisms and other commonly involved systems. Therefore, this article includes a description of common bacterial, mycobacterial, viral, fungal, protozoal, parasitic, and rickettsial diseases in dogs and cats. Mycobacterial disease is often subclinical in dogs and cats, but signs may be associated with granuloma formation in various organs. 39, 40 Nontuberculous mycobacterium, including those in the Mycobacterium avium complex, are saprophytic opportunistic organisms primarily implicated in disseminated disease in cats [41] [42] [43] [44] [45] and occasionally in dogs. No clear dissemination pattern has been identified because of low case numbers, but affected organs include the internal lymph nodes, liver, lungs, eyes, bone, muscles, and CNS. Infection results in disseminated disease, including protozoal hepatitis. Bacterial culture results from liver, gallbladder, or bile in 248 dogs and cats evaluated for hepatobiliary disease: 1998-2003 cache = ./cache/cord-300187-fr6tme32.txt txt = ./txt/cord-300187-fr6tme32.txt === reduce.pl bib === === reduce.pl bib === === reduce.pl bib === === reduce.pl bib === id = cord-032181-gmcugd8h author = Song, Jian-Xin title = Main Complications of AECHB and Severe Hepatitis B (Liver Failure) date = 2019-05-21 pages = extension = .txt mime = text/plain words = 51165 sentences = 2516 flesch = 37 summary = 3. Hepatorenal syndrome, which is characterized by renal failure, hemodynamic changes in arterial circulation and abnormalities in the endogenous vascular system, is a common clinical complication of end-stage liver disease, and one of the important indicators for the prognosis of patients with severe hepatitis. The latest report indicated that basic laboratory examinations for coagulation function testing in common use at present, such as PT, APTT, international normalized ratio (INR) etc., have little correlation with occurrence of gastrointestinal bleeding in these patients, thereby revealing the importance to search and pay close attention to those complicating disease upregulating bleeding risk, such as bacterial infection, renal failure, hemodynamic change after portal hypertension, dysfunction of endotheliocyte as well as macrophagocyte and so on [107] . cache = ./cache/cord-032181-gmcugd8h.txt txt = ./txt/cord-032181-gmcugd8h.txt === reduce.pl bib === id = cord-353633-a4pu6rlu author = Perakakis, Nikolaos title = The role of omics in the pathophysiology, diagnosis and treatment of non-alcoholic fatty liver disease date = 2020-07-23 pages = extension = .txt mime = text/plain words = 14722 sentences = 701 flesch = 32 summary = Non-alcoholic fatty liver disease (NAFLD) is a multifaceted metabolic disorder, whose spectrum covers clinical, histological and pathophysiological developments ranging from simple steatosis to non-alcoholic steatohepatitis (NASH) and liver fibrosis, potentially evolving into cirrhosis, hepatocellular carcinoma and liver failure. The disease is characterized initially by hepatic lipid accumulation (nonalcoholic fatty liver; NAFL), that can often progress to non-alcoholic steatohepatitis (NASH), liver fibrosis or cirrhosis, as outlined in detail elsewhere in this special issue [1] . Several studies have assessed the impact of epigenetic modifications in the development and progress of NAFLD ( Figure 2 ) as well as in the association of NAFLD with other metabolic diseases by focusing on DNA methylation, histone modifications and miRNA expression profiles that can significantly affect transcriptional activity. Proteomic analysis to identify differentially expressed proteins between subjects with metabolic healthy obesity and non-alcoholic fatty liver disease cache = ./cache/cord-353633-a4pu6rlu.txt txt = ./txt/cord-353633-a4pu6rlu.txt === reduce.pl bib === === reduce.pl bib === === reduce.pl bib === id = cord-000083-3p81yr4n author = nan title = Poster Exhibition date = 2009-01-31 pages = extension = .txt mime = text/plain words = 112815 sentences = 7542 flesch = 56 summary = R. China Background: The objective of this study was to evaluate the early virologic response for prediction of achievement of HBeAg seroconversion and hepatitis B virus (HBV) DNA negativity after two years of lamivudine treatment in chronic hepatitis B (CHB) patients. Methods: A total of 620 patients who tested positive for hepatitis B surface antigen and were referred to Chiba University Hospital between February 1985 and March 2008 were included in the study, and their following characteristics were analyzed: age, gender, the status of HBeAg, ALT, HBV-DNA level, and PLT. Methods: A total of 60 patients with chronic hepatitis B, 32 (53.3%) were HBeAg positive (group A) while 28(46.7%) were HBeAg negative (group B) were included in this study after meeting the following criteria: age 18 to 60 years, HBsAg positive for more than 6 months, serum HBV-DNA was >5 log(10) copies/mL and ALT more than two times the upper normal limit. cache = ./cache/cord-000083-3p81yr4n.txt txt = ./txt/cord-000083-3p81yr4n.txt ===== Reducing email addresses cord-003921-8r8z0otz cord-284693-mgpxnnk0 cord-290412-m6fesoyb Creating transaction Updating adr table ===== Reducing keywords cord-005949-8po9xe5g cord-014770-cgtzlra1 cord-016130-5q9ufu28 cord-018801-amet0wx4 cord-018414-6ffhm895 cord-018318-vzzrsqsn cord-017603-wq4cgqs2 cord-002272-c7f1l13s cord-016880-q44623s8 cord-032131-ghgciqfk cord-029138-avfvpqs5 cord-006391-esnsa4u5 cord-001567-3bw7jbzq cord-033914-a9e3rncp cord-023033-tgt69ir6 cord-003921-8r8z0otz cord-262152-gdnc51m5 cord-005892-3yuznrdv cord-033821-i14dmmps cord-018225-dozmy3lb cord-280234-anlytu3q cord-016757-3d320c0a cord-018620-3kqx8arn cord-323736-zup9cp6s cord-022300-9w0lehal cord-277535-u283k70i cord-261608-4sjlg0p0 cord-291851-xesef17i cord-275637-ea6w2kqv cord-025168-be7zube4 cord-292501-2jv7xkfn cord-328147-61gtx2h2 cord-309795-2kozsv4z cord-305956-l02xdq87 cord-022555-a7ie82fs cord-324509-5c6fzdjm cord-271635-tydlyc1q cord-318755-fip8wj6y cord-284693-mgpxnnk0 cord-279667-ikfduu2k cord-022483-hdmwv540 cord-030369-4dn02a35 cord-290412-m6fesoyb cord-324529-xbrdtxnz cord-327601-4uqgwlnx cord-340576-dabcs3w5 cord-288721-3bv3aak6 cord-332827-gll4nqdd cord-283120-hyzk59qv cord-340710-dmow5p7k cord-009987-biop7gyd cord-303046-unksl7p4 cord-342930-f7cw2ca6 cord-355395-rckzi8vz cord-022754-ehq9qnoo cord-023017-k6edtg58 cord-300187-fr6tme32 cord-348024-n8wn4och cord-339786-elrzlbsg cord-032181-gmcugd8h cord-342808-yonbowkb cord-340325-0oh40b6r cord-000083-3p81yr4n cord-353633-a4pu6rlu Creating transaction Updating wrd table ===== Reducing urls cord-016130-5q9ufu28 cord-002272-c7f1l13s cord-001567-3bw7jbzq cord-323736-zup9cp6s cord-292501-2jv7xkfn cord-275637-ea6w2kqv parallel: Warning: No more processes: Decreasing number of running jobs to 13. parallel: Warning: Raising ulimit -u or /etc/security/limits.conf may help. cord-305956-l02xdq87 cord-022555-a7ie82fs cord-279667-ikfduu2k cord-324529-xbrdtxnz cord-288721-3bv3aak6 cord-332827-gll4nqdd cord-303046-unksl7p4 cord-022754-ehq9qnoo Creating transaction Updating url table ===== Reducing named entities parallel: Warning: Only enough available processes to run 16 jobs in parallel. parallel: Warning: Raising ulimit -u or /etc/security/limits.conf parallel: Warning: or /proc/sys/kernel/pid_max may help. cord-005949-8po9xe5g cord-016130-5q9ufu28 cord-014770-cgtzlra1 cord-018801-amet0wx4 cord-018414-6ffhm895 cord-017603-wq4cgqs2 cord-018318-vzzrsqsn cord-029138-avfvpqs5 cord-002272-c7f1l13s cord-016880-q44623s8 cord-032131-ghgciqfk cord-033914-a9e3rncp cord-001567-3bw7jbzq cord-006391-esnsa4u5 cord-023033-tgt69ir6 cord-005892-3yuznrdv cord-033821-i14dmmps cord-262152-gdnc51m5 cord-003921-8r8z0otz cord-280234-anlytu3q cord-016757-3d320c0a cord-018225-dozmy3lb cord-323736-zup9cp6s parallel: Warning: No more processes: Decreasing number of running jobs to 15. parallel: Warning: Raising ulimit -u or /etc/security/limits.conf may help. cord-018620-3kqx8arn cord-022300-9w0lehal cord-277535-u283k70i cord-261608-4sjlg0p0 cord-291851-xesef17i cord-292501-2jv7xkfn cord-025168-be7zube4 cord-309795-2kozsv4z cord-275637-ea6w2kqv cord-328147-61gtx2h2 cord-305956-l02xdq87 cord-022555-a7ie82fs cord-324509-5c6fzdjm cord-271635-tydlyc1q cord-318755-fip8wj6y cord-284693-mgpxnnk0 cord-279667-ikfduu2k cord-022483-hdmwv540 cord-030369-4dn02a35 cord-290412-m6fesoyb cord-327601-4uqgwlnx cord-324529-xbrdtxnz cord-340576-dabcs3w5 cord-332827-gll4nqdd cord-288721-3bv3aak6 cord-283120-hyzk59qv cord-340710-dmow5p7k cord-009987-biop7gyd parallel: Warning: No more processes: Decreasing number of running jobs to 14. parallel: Warning: Raising ulimit -u or /etc/security/limits.conf may help. cord-342930-f7cw2ca6 cord-303046-unksl7p4 cord-022754-ehq9qnoo cord-023017-k6edtg58 cord-300187-fr6tme32 cord-339786-elrzlbsg cord-355395-rckzi8vz cord-348024-n8wn4och cord-342808-yonbowkb cord-353633-a4pu6rlu cord-340325-0oh40b6r cord-032181-gmcugd8h cord-000083-3p81yr4n Creating transaction Updating ent table ===== Reducing parts of speech cord-005949-8po9xe5g cord-014770-cgtzlra1 cord-018801-amet0wx4 cord-017603-wq4cgqs2 cord-016130-5q9ufu28 cord-029138-avfvpqs5 cord-018318-vzzrsqsn cord-002272-c7f1l13s cord-033914-a9e3rncp cord-016880-q44623s8 cord-032131-ghgciqfk cord-018414-6ffhm895 cord-001567-3bw7jbzq cord-262152-gdnc51m5 cord-280234-anlytu3q cord-005892-3yuznrdv cord-033821-i14dmmps cord-018225-dozmy3lb cord-003921-8r8z0otz cord-016757-3d320c0a cord-023033-tgt69ir6 cord-323736-zup9cp6s cord-277535-u283k70i cord-261608-4sjlg0p0 cord-291851-xesef17i cord-292501-2jv7xkfn cord-025168-be7zube4 cord-275637-ea6w2kqv cord-328147-61gtx2h2 cord-022300-9w0lehal cord-305956-l02xdq87 cord-309795-2kozsv4z cord-018620-3kqx8arn cord-324509-5c6fzdjm cord-318755-fip8wj6y cord-279667-ikfduu2k cord-271635-tydlyc1q cord-284693-mgpxnnk0 cord-290412-m6fesoyb cord-324529-xbrdtxnz cord-022483-hdmwv540 cord-327601-4uqgwlnx cord-006391-esnsa4u5 cord-340576-dabcs3w5 cord-288721-3bv3aak6 cord-332827-gll4nqdd cord-030369-4dn02a35 cord-283120-hyzk59qv cord-340710-dmow5p7k cord-009987-biop7gyd cord-342930-f7cw2ca6 cord-303046-unksl7p4 cord-300187-fr6tme32 cord-355395-rckzi8vz cord-348024-n8wn4och cord-339786-elrzlbsg cord-342808-yonbowkb cord-340325-0oh40b6r cord-353633-a4pu6rlu cord-022555-a7ie82fs cord-032181-gmcugd8h cord-023017-k6edtg58 cord-022754-ehq9qnoo cord-000083-3p81yr4n Creating transaction Updating pos table Building ./etc/reader.txt cord-022754-ehq9qnoo cord-032181-gmcugd8h cord-000083-3p81yr4n cord-022754-ehq9qnoo cord-030369-4dn02a35 cord-353633-a4pu6rlu number of items: 64 sum of words: 760,658 average size in words: 13,344 average readability score: 43 nouns: liver; patients; disease; cells; treatment; hepatitis; study; cats; infection; failure; cell; blood; serum; dogs; results; injury; therapy; levels; cases; group; transplantation; cirrhosis; fibrosis; expression; protein; risk; factors; function; response; studies; activity; bile; analysis; diagnosis; time; level; signs; methods; weeks; virus; effect; diseases; factor; tissue; effects; system; days; acid; patient; type verbs: using; increase; including; associated; shown; induced; causing; occurred; reported; compared; treat; reduce; find; decrease; follow; developing; results; led; suggest; relating; performing; identifying; require; considered; based; see; determined; observed; improve; evaluated; detecting; affected; infected; demonstrates; indicated; involves; assessing; die; receives; remaining; given; presented; provides; regulated; appear; describes; made; inhibiting; activated; expressed adjectives: hepatic; clinical; chronic; acute; severe; high; normal; portal; non; significant; viral; important; positive; higher; common; specific; inflammatory; intestinal; different; human; small; low; renal; primary; present; fatty; anti; abdominal; immune; early; negative; hepatocellular; metabolic; large; biliary; first; several; bacterial; many; diagnostic; systemic; possible; effective; gastrointestinal; lower; total; similar; major; secondary; vascular adverbs: also; however; significantly; well; often; usually; respectively; therefore; even; commonly; especially; still; mainly; highly; particularly; previously; generally; recently; clinically; approximately; frequently; less; typically; critically; prior; furthermore; directly; alone; relatively; currently; rapidly; rather; specifically; rarely; daily; finally; additionally; potentially; primarily; now; later; first; moreover; markedly; always; much; effectively; almost; least; easily pronouns: it; we; its; their; they; our; he; i; them; his; itself; one; us; her; she; you; themselves; your; my; me; him; pm.sec-; mg; aptt; slr; paravision5.1; ourselves; immpress; imagej; ihscs; igg4; himself; herself; f\1rther; em; csf1-fc; 6a; 3times proper nouns: HCV; HBV; HCC; B; COVID-19; C; mg; NAFLD; RNA; Liver; IFN; T; ALF; SARS; DNA; PCR; kg; ALT; van; NASH; China; CHB; der; L; hepatitis; een; HE; AST; Hepatitis; A; Disease; II; ALP; CoV-2; Group; Kupffer; University; Fig; LT; Hospital; SVR; DCD; Table; LC; M; •; C.; United; J; IRI keywords: liver; patient; covid-19; cell; disease; acute; sars; failure; study; hepatic; hcv; alf; result; nash; nafld; hepatitis; hcc; cat; blood; treatment; transplantation; svr; rna; portal; pcr; method; level; infection; increase; ifn; group; dog; dna; alt; severe; iri; intestinal; injury; hsc; hrs; hbv; gastrointestinal; effect; diarrhea; day; conclusion; clinical; chronic; chb; cd8 one topic; one dimension: liver file(s): https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7096005/ titles(s): Akutes Leberversagen: Übersicht zur aktuellen Diagnostik und Therapie three topics; one dimension: liver; liver; cats file(s): https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7165819/, https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7161409/, https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7121307/ titles(s): AASLD Abstracts (pp. 282A–382A) | Liver | 22 Levertransplantatie five topics; three dimensions: liver patients failure; liver patients disease; patients hcv liver; cats may hbv; liver dogs hepatic file(s): https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7498917/, https://doi.org/10.1016/j.metabol.2020.154320, https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7165819/, https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7158306/, https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7161409/ titles(s): Main Complications of AECHB and Severe Hepatitis B (Liver Failure) | The role of omics in the pathophysiology, diagnosis and treatment of non-alcoholic fatty liver disease | AASLD Abstracts (pp. 282A–382A) | Digestive System, Liver, and Abdominal Cavity | Liver Type: cord title: keyword-liver-cord date: 2021-05-25 time: 15:28 username: emorgan patron: Eric Morgan email: emorgan@nd.edu input: keywords:liver ==== make-pages.sh htm files ==== make-pages.sh complex files ==== make-pages.sh named enities ==== making bibliographics id: cord-271635-tydlyc1q author: Abdel-Hamid, Nabil M. title: Herbal management of hepatocellular carcinoma through cutting the pathways of the common risk factors date: 2018-11-30 words: 10051.0 sentences: 543.0 pages: flesch: 36.0 cache: ./cache/cord-271635-tydlyc1q.txt txt: ./txt/cord-271635-tydlyc1q.txt summary: They can inhibit the liver cancer development and progression in several ways as protecting against liver carcinogens, enhancing effects of chemotherapeutic drugs, inhibiting tumor cell growth and metastasis, and suppression of oxidative stress and chronic inflammation. The co-treatment with LPP, orally, in NAFLD in rats, showed a significant improvement in the hepatic histology, reduction in the fibrosis, oxidative stress, inflammation, accumulation of fats and apoptosis, through modulating the transcriptional factors NF-κB and activator protein-1 (AP-1). The major polyphenol of green tea, epigallocatechin-3-gallate (EGCG), was used in CCl 4 -treated mice and showed a significant therapeutic potential in hepatic damage, inflammation and oxidative stress induced by CCl 4 in a dose-dependent manner at both biochemical and histological levels [34] . It was also reported that co-treatment of the whole green tea extract with alcohol administration showed an effective reduction of the hepatic oxidative stress and reduced form of nicotinamide adenine dinucleotide phosphate (NADPH) oxidase systems in experimental alcohol-induced liver injury [35] . abstract: Abstract Hepatocellular carcinoma (HCC) is considered the most frequent tumor that associated with high mortality rate. Several risk factors contribute to the pathogenesis of HCC, such as chronic persistent infection with hepatitis C virus or hepatitis B virus, chronic untreated inflammation of liver with different etiology, oxidative stress and fatty liver disease. Several treatment protocols are used in the treatment of HCC but they also associated with diverse side effects. Many natural products are helpful in the co-treatment and prevention of HCC. Several mechanisms are involved in the action of these herbal products and their bioactive compounds in the prevention and co-treatment of HCC. They can inhibit the liver cancer development and progression in several ways as protecting against liver carcinogens, enhancing effects of chemotherapeutic drugs, inhibiting tumor cell growth and metastasis, and suppression of oxidative stress and chronic inflammation. In this review, we will discuss the utility of diverse natural products in the prevention and co-treatment of HCC, through its capturing of the common risk factors known to lead to HCC and shed the light on their possible mechanisms of action. Our theory assumes that shutting down the risk factor to cancer development pathways is a critical strategy in cancer prevention and management. We recommend the use of these plants side by side to recent chemical medications and after stopping these chemicals, as a maintenance therapy to avoid HCC progression and decrease its global incidence. url: https://api.elsevier.com/content/article/pii/S075333221834280X doi: 10.1016/j.biopha.2018.08.104 id: cord-009987-biop7gyd author: Ali, Muhammad title: Selected hepatoprotective herbal medicines: Evidence from ethnomedicinal applications, animal models, and possible mechanism of actions date: 2017-10-19 words: 7368.0 sentences: 422.0 pages: flesch: 37.0 cache: ./cache/cord-009987-biop7gyd.txt txt: ./txt/cord-009987-biop7gyd.txt summary: & Thonn., Salvia miltiorrhiza Bunge., Astragalus membranaceus (Fisch.) Bunge, Capparis spinosa (L.), Cichorium intybus (L.), Solanum nigrum (L.), Sapindus mukorossi Gaertn., Ginkgo biloba (L.), Woodfordia fruticosa (L.) Kurz, Vitex trifolia (L.), Schisandra chinensis (Turcz.) Baill., Cuscuta chinensis (Lam.), Lycium barbarum, Angelica sinensis (Oliv.) Diels, and Litsea coreana (H. Herbal medicines are claimed to both treat and prevent diseases, which adds to a deep belief that these Abbreviations: ALT, alanine aminotransaminase; ASP, Angelica sinensis polysaccharides; AST, aspartate transaminase; EGF, epidermal growth factor; HBV, Hepatitis B virus; LBPs, Lycium barbarum polysaccharides; WF4, Woodfordia fruticosa flower extract. abstract: Insight into the hepatoprotective effects of medicinally important plants is important, both for physicians and researchers. Main reasons for the use of herbal medicine include their lesser cost compared with conventional drugs, lesser undesirable drug reactions and thus high safety, and reduced side effects. The present review focuses on the composition, pharmacology, and results of experimental trials of selected medicinal plants: Silybum marianum (L.) Gaertn., Glycyrrhiza glabra, Phyllanthus amarus Schumach. & Thonn., Salvia miltiorrhiza Bunge., Astragalus membranaceus (Fisch.) Bunge, Capparis spinosa (L.), Cichorium intybus (L.), Solanum nigrum (L.), Sapindus mukorossi Gaertn., Ginkgo biloba (L.), Woodfordia fruticosa (L.) Kurz, Vitex trifolia (L.), Schisandra chinensis (Turcz.) Baill., Cuscuta chinensis (Lam.), Lycium barbarum, Angelica sinensis (Oliv.) Diels, and Litsea coreana (H. Lev.). The probable modes of action of these plants include immunomodulation, stimulation of hepatic DNA synthesis, simulation of superoxide dismutase and glutathione reductase to inhibit oxidation in hepatocytes, reduction of intracellular reactive oxygen species by enhancing levels of antioxidants, suppression of ethanol‐induced lipid accumulation, inhibition of nucleic acid polymerases to downregulate viral mRNA transcription and translation, free radical scavenging and reduction of hepatic fibrosis by decreasing the levels of transforming growth factor beta‐1, and collagen synthesis in hepatic cells. However, further research is needed to identify, characterize, and standardize the active ingredients, useful compounds, and their preparations for the treatment of liver diseases. url: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7167792/ doi: 10.1002/ptr.5957 id: cord-305956-l02xdq87 author: Alqahtani, Saleh A title: Liver injury in COVID-19: The current evidence date: 2020-05-26 words: 3062.0 sentences: 198.0 pages: flesch: 44.0 cache: ./cache/cord-305956-l02xdq87.txt txt: ./txt/cord-305956-l02xdq87.txt summary: These reports highlighted that beyond severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), a complicated course of the disease or even viral infection itself can lead to involvement of other organs and multiorgan failure. The current review summarizes the pathophysiology and potentially specific role of COVID-19 in liver disease based on the available data and case series published, ahead of print and non-peer-reviewed preprints as of 2 April. In this study, 47.3% of the discharged patients showed elevated LFTs at baseline, and 23.7% developed abnormalities during hospitalization, suggesting emerging liver injury from drugs or during the course of the infection. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: A single-centered, retrospective, observational study Clinical findings in a group of patients infected with the 2019 novel coronavirus (SARS-Cov-2) outside of Wuhan, China: Retrospective case series abstract: Patients with novel coronavirus disease 2019 (COVID-19) experience various degrees of liver function abnormalities. Liver injury requires extensive work-up and continuous surveillance and can be multifactorial and heterogeneous in nature. In the context of COVID-19, clinicians will have to determine whether liver injury is related to an underlying liver disease, drugs used for the treatment of COVID-19, direct effect of the virus, or a complicated disease course. Recent studies proposed several theories on potential mechanisms of liver injury in these patients. This review summarizes current evidence related to hepatobiliary complications in COVID-19, provides an overview of the available case series and critically elucidates the proposed mechanisms and provides recommendations for clinicians. url: https://doi.org/10.1177/2050640620924157 doi: 10.1177/2050640620924157 id: cord-327601-4uqgwlnx author: Bangash, Mansoor N. title: SARS-CoV-2: is the liver merely a bystander to severe disease? date: 2020-06-02 words: 979.0 sentences: 61.0 pages: flesch: 43.0 cache: ./cache/cord-327601-4uqgwlnx.txt txt: ./txt/cord-327601-4uqgwlnx.txt summary: 1 Their study shows SARS-CoV-2 positive patients with ≥1 week history of increased aminotransferases have worse acute pulmonary disease (radiological and physiological) than those without. Considering that Interleukin (IL)-6 and C-reactive protein (CRP) are similar between patients with normal and prolonged abnormal liver aminotransferases, the authors speculate that liver injury is a direct effect of SARS-CoV-2 viral hepatitis rather than an indirect immune mediated injury. The fact that increases in liver aminotransferases occur and tend to parallel the severity of pulmonary disease remains unquestioned 2 , however, whether the liver injury is a true viral hepatitis rather than a bystander to the multi-organ pathophysiology of critical illness requires further discussion. Based on the above perspectives, we feel that raised liver aminotransferases associated with SARS-CoV-2 positivity are more likely attributable to illness severity, in which host response and iatrogenic harm (i.e. drugs, ventilation) drive bystander liver injury, thus explaining its association with mortality and in an analogous fashion to patterns seen in sepsis. abstract: nan url: https://www.sciencedirect.com/science/article/pii/S016882782030355X?v=s5 doi: 10.1016/j.jhep.2020.05.035 id: cord-001567-3bw7jbzq author: Borlak, Jürgen title: Proteome mapping of epidermal growth factor induced hepatocellular carcinomas identifies novel cell metabolism targets and mitogen activated protein kinase signalling events date: 2015-02-25 words: 13983.0 sentences: 721.0 pages: flesch: 40.0 cache: ./cache/cord-001567-3bw7jbzq.txt txt: ./txt/cord-001567-3bw7jbzq.txt summary: title: Proteome mapping of epidermal growth factor induced hepatocellular carcinomas identifies novel cell metabolism targets and mitogen activated protein kinase signalling events Importantly, 11 out of 54 mouse tumour specific proteins were likewise uniquely expressed in human HCC and 49 disease regulated proteins identified in EGF induced liver cancer were similarly regulated in human HCC, as determined by immunhistochemistry using different antibodies and the information given in the publically available Human Protein Atlas depository. Likewise, the genes coding for igals3, i.e. a beta-galactoside-binding protein frequently overexpressed in cancers and pcbp1 that is involved in transcription and functions as an inhibitor of invasion [65] were up-regulated in transgenic nontumour livers (ur-Tr-nT) whereas transcript expression of aars, a member of tRNA synthases and anaxa6, a calcium-dependent, phospholipid-binding protein with important roles in the tumour microenvironment and metastasis were repressed (dr-Tr-nT). abstract: BACKGROUND: Hepatocellular carcinoma (HCC) is on the rise and the sixth most common cancer worldwide. To combat HCC effectively research is directed towards its early detection and the development of targeted therapies. Given the fact that epidermal growth factor (EGF) is an important mitogen for hepatocytes we searched for disease regulated proteins to improve an understanding of the molecular pathogenesis of EGF induced HCC. Disease regulated proteins were studied by 2DE MALDI-TOF/TOF and a transcriptomic approach, by immunohistochemistry and advanced bioinformatics. RESULTS: Mapping of EGF induced liver cancer in a transgenic mouse model identified n = 96 (p < 0.05) significantly regulated proteins of which n = 54 were tumour-specific. To unravel molecular circuits linked to aberrant EGFR signalling diverse computational approaches were employed and this defined n = 7 key nodes using n = 82 disease regulated proteins for network construction. STRING analysis revealed protein-protein interactions of > 70% disease regulated proteins with individual proteins being validated by immunohistochemistry. The disease regulated network proteins were mapped to distinct pathways and bioinformatics provided novel insight into molecular circuits associated with significant changes in either glycolysis and gluconeogenesis, argine and proline metabolism, protein processing in endoplasmic reticulum, Hif- and MAPK signalling, lipoprotein metabolism, platelet activation and hemostatic control as a result of aberrant EGF signalling. The biological significance of the findings was corroborated with gene expression data derived from tumour tissues to evntually define a rationale by which tumours embark on intriguing changes in metabolism that is of utility for an understanding of tumour growth. Moreover, among the EGF tumour specific proteins n = 11 were likewise uniquely expressed in human HCC and for n = 49 proteins regulation in human HCC was confirmed using the publically available Human Protein Atlas depository, therefore demonstrating clinical significance. CONCLUSION: Novel insight into the molecular pathogenesis of EGF induced liver cancer was obtained and among the 37 newly identified proteins several are likely candidates for the development of molecularly targeted therapies and include the nucleoside diphosphate kinase A, bifunctional ATP-dependent dihydroyacetone kinase and phosphatidylethanolamine-binding protein1, the latter being an inhibitor of the Raf-1 kinase. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12864-015-1312-z) contains supplementary material, which is available to authorized users. url: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4357185/ doi: 10.1186/s12864-015-1312-z id: cord-014770-cgtzlra1 author: Brandt, Lawrence J. title: Book reviews date: 1995 words: 5384.0 sentences: 264.0 pages: flesch: 48.0 cache: ./cache/cord-014770-cgtzlra1.txt txt: ./txt/cord-014770-cgtzlra1.txt summary: The volume combines some basic reviews, such as chapters on the pathophysiology of viral diarrhea and gastrointestinal tract immunology, with detailed exploration of more focused topics, such as rotavirus proteins. While interesting and one of the more clinically applicable sections of the book, the inclusion of a chapter on bacterial diarrhea in a volume dedicated to viral gastroenteritis is somewhat puzzling. While this book has certain outstanding features, there are some shortcomings which warrant mention, most notably a paucity of references beyond 1990 in some chapters and the failure to recognize viral pathogens which, through gastrointestinal tract infection, cause significant disease other than diarrhea. The final chapter in the book is devoted to the therapeutic aspects of gastrointestinal motility, including biofeedback training for fecal incontinence. Once again, adequate references are provided for those who desire more in-depth study, The next several chapters begin at the oropharynx and proceed through the gastrointestinal tract, presenting a discussion of the motility of each area. abstract: nan url: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7087769/ doi: 10.1007/bf02065002 id: cord-262152-gdnc51m5 author: Chaibi, Sayma title: Liver Function Test Abnormalities Are Associated With A Poorer Prognosis In Covid-19 Patients: Results Of A French Cohort date: 2020-10-19 words: 2769.0 sentences: 173.0 pages: flesch: 51.0 cache: ./cache/cord-262152-gdnc51m5.txt txt: ./txt/cord-262152-gdnc51m5.txt summary: title: Liver Function Test Abnormalities Are Associated With A Poorer Prognosis In Covid-19 Patients: Results Of A French Cohort AIM: To assess the impact of liver function test (LFT) abnormalities on the prognosis of patients with coronavirus disease 2019 (COVID-19) in a French cohort of hospitalized patients. Similar results were obtained for patients with cholestatic liver injury (Table Table 5 shows the association of factors with the composite severity endpoint (admission to ICU, respiratory failure requiring mechanical ventilation, CT scan injury >50% and global mortality). Severe infection is known to be more frequent among those patients, but they had mostly imbalanced diabetes or hypertension, which was not the case in our study Global mortality was also similar (16.0%), yet the number of admissions to ICU (15.3%) was higher than previously reported 1 . abstract: AIM: To assess the impact of liver function test (LFT) abnormalities on the prognosis of patients with coronavirus disease 2019 (COVID-19) in a French cohort of hospitalized patients. PATIENTS AND METHOD: From March 13 to April 22, 2020, we collected on a computerized and anonymized database, medical records, laboratory data and clinical outcomes of patients hospitalized for confirmed cases of COVID-19 infection (RT–PCR and/or CT-scan). Patients were followed up until April 22 2020 or until death or discharge. We have considered for statistical analysis, LFT abnormalities with levels greater than two times the upper limit of normal. Composite endpoint included admission to ICU, mechanical ventilation, severe radiologic injury and death to define disease severity. RESULTS: Among 281 patients (median age 60 years) with COVID-19, 102 (36.3%) had abnormal LFT. Hypertension (45.6%) and diabetes (29.5%) were the main comorbidities. 20.2% were taken liver-toxic drugs at the admission and 27.4% were given drugs known to induce hepatic cytolysis during hospitalization. Patients with elevated levels of ALT or AST were significantly more severe with a higher rate of admission to ICU (40.0% vs 6.0%, p < 0.0001), and global mortality (26.7% vs 12.1%, p = 0.03). In multivariate analysis, obesity and cytolytic profil were associated with the composite endpoint (respectively 2.37 [1.21; 4.64], p = 0.01 and OR 6.20, 95% confidence interval [1.84, 20.95], p-value 0.003) CONCLUSION: Most of liver injuries are mild and transient during COVID-19. LFT abnormalities are associated with a poorer prognosis and could be a relevant biomarker for early detection of severe infection. url: https://www.sciencedirect.com/science/article/pii/S2210740120302977?v=s5 doi: 10.1016/j.clinre.2020.10.002 id: cord-029138-avfvpqs5 author: Croome, Kristopher P. title: The Changing Landscapes in DCD Liver Transplantation date: 2020-07-13 words: 6309.0 sentences: 304.0 pages: flesch: 47.0 cache: ./cache/cord-029138-avfvpqs5.txt txt: ./txt/cord-029138-avfvpqs5.txt summary: Initial reports examining the use of liver grafts from DCD described inferior longterm outcomes when compared with donation after brain death donors (DBD). More recent single center publications from high volume DCD programs have demonstrated equivalent outcomes between DCD and DBD liver transplantation (LT), with appropriate donor and recipient selection [5] [6] [7] . A previous publication demonstrated that after the implementation of the Share 35 policy, more HCC patients have received livers from DCD donors [22] , potentially as the result of the highest quality organs being preferentially utilized by higher MELD recipients with broader sharing. As the collective experience with DCD LT increased, a concept of functional donor warm ischemic time (fDWIT) arose from the notion that individual events during DCD procurement, such as variations in hemodynamics, mandatory wait period, time from incision to cannulation of the aorta and cross-clamp, all of which are included in total DWIT, may have different impacts on the outcome of the liver graft [25, 26] . abstract: PURPOSE OF REVIEW: The transplant community continues to look for ways to help address the discordance between donor liver graft availability and patients on the liver transplant waiting list. Donation after circulatory death (DCD) donor livers represents one potential means to help address this discordance. The present review describes the changing landscape of DCD liver transplantation (LT). RECENT FINDINGS: The number of DCD LTs performed annually within the USA has continued to grow on an annual basis. Importantly, national data has demonstrated that outcomes with DCD LT have been improving. This improvement has been driven by better understanding of how to successfully utilize these organs through better donor and recipient matching and careful evaluation of both hemodynamics during withdrawal of life support and the refinement of the procurement operation. SUMMARY: Despite these improvements in outcome, ischemic cholangiopathy (IC) continues to be the Achilles heel of DCD LT. Emerging technologies such as various forms of machine perfusion may allow for reduction of complications and better prognostication of the risk associated with DCD liver grafts. url: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7357263/ doi: 10.1007/s40472-020-00283-1 id: cord-309795-2kozsv4z author: Dewidar, Bedair title: Metabolic liver disease in diabetes – from mechanisms to clinical trials date: 2020-06-20 words: 8642.0 sentences: 421.0 pages: flesch: 35.0 cache: ./cache/cord-309795-2kozsv4z.txt txt: ./txt/cord-309795-2kozsv4z.txt summary: NAFLD, which affects about 25% of the population [3] , comprises a broad range of abnormalities ranging from simple fatty liver (steatosis) to non-alcoholic steatohepatitis (NASH), characterized by inflammation, necrosis, and hepatocellular ballooning, and progression to liver fibrosis, cirrhosis, and hepatocellular carcinoma (HCC) [2] . In general, both hyperglycemia and toxic lipids such as ceramides, DAG, FFA, and cholesterol can induce deleterious effects on liver cells (glucolipotoxicity), which might initiate NAFLD progression from simple steatosis to NASH and fibrosis via various mechanisms, including cell death, oxidative stress, endoplasmic reticulum (ER) stress and mitochondrial disorders [46] . BL, baseline; CCR2/5, C-C chemokine receptors type 2 and type 5; FXR, farnesoid X receptor; HbA 1c , glycated haemoglobin; LXR, Liver X receptor; MPC, mitochondrial pyruvate carrier; NA, data not available; NAFLD, non-alcoholic fatty liver disease; NFS, NAFLD fibrosis score; PPAR, peroxisome proliferator-activated receptor; NASH, non-alcoholic steatohepatitis; SCD, stearoyl-CoA desaturase; SGLT, sodium-glucose cotransporter; THR, thyroid hormone receptor; T2DM, type 2 diabetes. Potential Nexus of Non-alcoholic Fatty Liver Disease and Type 2 Diabetes Mellitus: Insulin Resistance Between Hepatic and Peripheral Tissues abstract: Abstract Non-alcoholic fatty liver disease (NAFLD) comprises fatty liver (steatosis), non-alcoholic steatohepatitis (NASH) and fibrosis/cirrhosis and may lead to end-stage liver failure or hepatocellular carcinoma. NAFLD is tightly associated with the most frequent metabolic disorders, such as obesity, metabolic syndrome, and type 2 diabetes mellitus (T2DM). Both multisystem diseases share several common mechanisms. Alterations of tissue communications include excessive lipid and later cytokine release by dysfunctional adipose tissue, intestinal dysbiosis and ectopic fat deposition in skeletal muscle. On the hepatocellular level, this leads to insulin resistance due to abnormal lipid handling and mitochondrial function. Over time, cellular oxidative stress and activation of inflammatory pathways, again supported by multiorgan crosstalk, determine NAFLD progression. Recent studies show that particularly the severe insulin resistant diabetes (SIRD) subgroup (cluster) associates with NAFLD and its accelerated progression and increases the risk of diabetes-related cardiovascular and kidney diseases, underpinning the critical role of insulin resistance. Consequently, lifestyle modification and certain drug classes used to treat T2DM have demonstrated effectiveness for treating NAFLD, but also some novel therapeutic concepts may be beneficial for both NAFLD and T2DM. This review addresses the bidirectional relationship between mechanisms underlying T2DM and NAFLD, the relevance of novel biomarkers for improving the diagnostic modalities and the identification of subgroups at specific risk of disease progression. Also, the role of metabolism-related drugs in NAFLD is discussed in light of the recent clinical trials. Finally, this review highlights some challenges to be addressed by future studies on NAFLD in the context of T2DM. url: https://www.sciencedirect.com/science/article/pii/S0026049520301633?v=s5 doi: 10.1016/j.metabol.2020.154299 id: cord-318755-fip8wj6y author: El Kassas, Mohamed title: Liver transplantation in the era of COVID-19 date: 2020-05-12 words: 4268.0 sentences: 221.0 pages: flesch: 38.0 cache: ./cache/cord-318755-fip8wj6y.txt txt: ./txt/cord-318755-fip8wj6y.txt summary: Management of immunosuppressive therapy and drug-drug interactions in liver transplant recipients infected with COVID-19 should be cautiously practiced to prevent rejection and effectively treat the underlying infection. Although healthcare facilities are overwhelmed with management of COVID-19 patients & health resources are being rapidly consumed, the American Association for the Study of Liver Diseases (AASLD), recommended against postponing transplantation. Patients with advanced liver disease and those after LTX represent vulnerable patient cohorts with an increased risk of infection and/or a severe course of COVID-19 Because of the immunosuppressed state they have [59] . Available data on coronavirus before and during outbreaks suggest that immunosuppressed patients are not at increased risk of severe pulmonary disease compared to the general population; however, immunosuppression may prolong viral shedding in post-transplant patients with COVID-19 if they are already infected [36, 60] . abstract: Liver transplantation is considered the ultimate solution for patients with end-stage chronic liver disease or acute liver failure. Patients with liver transplant need special care starting from preoperative preparation, surgical intervention ending with postoperative care. Transplanted patients have to receive immunosuppressive therapy to prevent rejection. Such a state of immune suppression could predispose to different types of infections in liver transplant recipients. Currently, the world is suffering a pandemic caused by a new strain of the coronavirus family called COVID-19. Certain infection control precautions are needed to protect immunocompromised and vulnerable patients, including liver transplant candidates and recipients from acquiring COVID-19 infection. Restricting non-transplant elective surgical procedures, managing transplant patients in separate outpatient clinics, and in-patient wards can prevent transmission of infection both to patients and healthcare workers. Telemedicine can help in the triage of patients to screen for symptoms of COVID-19 before their regular appointment. Management of immunosuppressive therapy and drug-drug interactions in liver transplant recipients infected with COVID-19 should be cautiously practiced to prevent rejection and effectively treat the underlying infection. In this report, we are trying to summarize available evidence about different aspects of the management of liver transplant candidates and recipients in the era of COVID-19. url: https://doi.org/10.1016/j.ajg.2020.04.019 doi: 10.1016/j.ajg.2020.04.019 id: cord-342808-yonbowkb author: Francque, Sven title: Innovative liver research continues during the current pandemic date: 2020-05-24 words: nan sentences: nan pages: flesch: nan cache: txt: summary: abstract: nan url: https://api.elsevier.com/content/article/pii/S2589555920300550 doi: 10.1016/j.jhepr.2020.100121 id: cord-032131-ghgciqfk author: Ganschow, Rainer title: Lebertransplantation und Leberversagen date: 2013 words: 6539.0 sentences: 800.0 pages: flesch: 40.0 cache: ./cache/cord-032131-ghgciqfk.txt txt: ./txt/cord-032131-ghgciqfk.txt summary: 16.2) handelt es sich um eine Erkrankung des frühen Säuglingsalters, bei der insbesondere die großen Gallengänge außerhalb der Leber (extrahepatische Gallengangatresie) zerstört werden, es können aber auch die intrahepatischen Gallenwege mit betroffen sein. Bislang wurden keine verlässlichen immunologischen Parameter identifiziert, die ein komplettes Absetzen der Immunsuppression nach einigen Therapiejahren bei selektiven Patienten rechtfertigen würden, so dass derzeit von einer lebenslangen immunsuppressiven Therapie ausgegangen werden muss. Durch eine frühzeitige Vorstellung von Kindern mit akutem oder chronischem Leberversagen in einem geeigneten Transplantationszentrum und unter Ausnutzung sämtlicher möglicher Transplantationstechniken sollte es möglich sein, die Mortalität auf der Lebertransplantationswarteliste für Kinder auf Null zu senken. So ist eine Autoimmunhepatitis, vor allem bei jüngeren Kindern, mit einer schlechten Prognose (selbst nach Lebertransplantation) assoziiert, wenn diese nicht kurzfristig auf eine immunsuppressive Therapie (Steroid, Azathioprin) anspricht (Vogel et al. abstract: Es kann geschätzt werden, dass etwa 2 von 10.000 Neugeborenen oder 1–2 Neugeborene pro 1 Mio. Einwohner jährlich auf eine Lebertransplantation angewiesen sein werden. url: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7498809/ doi: 10.1007/978-3-642-24710-1_19 id: cord-033821-i14dmmps author: Guo, Yue-Cheng title: Antihepatic Fibrosis Drugs in Clinical Trials date: 2020-08-24 words: 5042.0 sentences: 306.0 pages: flesch: 40.0 cache: ./cache/cord-033821-i14dmmps.txt txt: ./txt/cord-033821-i14dmmps.txt summary: 11 Treatment based on the etiology may not completely attenuate all fibrosis patients, as there are currently no effective managements for eliminating the cause of certain liver diseases, such as autoimmune hepatitis. In a multicenter, randomized, placebo-controlled trial, 19 patients with NASH exhibited improvements of liver histological features after treatment with OCA (25 mg, 72 weeks). Currently, two active phase II clinical trials (NCT03486912, NCT03486899) are investigating the efficacy and safety of pegbelfermin in patients with NASH-related fibrosis as determined by liver biopsy. A phase II clinical trial 51 showed that pirfenidone (1200 mg daily, 24 months) improved inflammation, fibrosis, and steatosis in patients with hepatitis C virusrelated cirrhosis. 52 A phase II clinical trial (NCT02499562) has explored the effective dose and safety of hydronidone capsules in patients with liver fibrosis induced by hepatitis B virus infection in Shanghai General Hospital, Shanghai, China. abstract: Liver fibrosis is not an independent disease. It refers to the abnormal proliferation of connective tissues in the liver caused by various pathogenic factors. Thus far, liver fibrosis has been considered to be associated with a set of factors, such as viral infection, alcohol abuse, non-alcoholic fatty liver disease, and autoimmune hepatitis, as well as genetic diseases. To date, clinical therapeutics for liver fibrosis still face challenges, as elimination of potential causes and conventional antifibrotic drugs cannot alleviate fibrosis in most patients. Recently, potential therapeutic targets of liver fibrosis, such as metabolism, inflammation, cell death and the extracellular matrix, have been explored through basic and clinical research. Therefore, it is extremely urgent to review the antihepatic fibrosis therapeutics for treatment of liver fibrosis in current clinical trials. url: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7562798/ doi: 10.14218/jcth.2020.00023 id: cord-339786-elrzlbsg author: Gurala, Dhineshreddy title: Acute Liver Failure in a COVID-19 Patient Without any Preexisting Liver Disease date: 2020-08-26 words: nan sentences: nan pages: flesch: nan cache: txt: summary: abstract: In December 2019, an outbreak of novel coronavirus started in Wuhan, China, which gradually spread to the entire world. The World Health Organization (WHO) on February 11, 2020, officially announced the name for the disease as coronavirus disease 2019, abbreviated as COVID-19. It is caused by severe respiratory distress syndrome coronavirus 2 (SARS-CoV-2). The WHO declared SARS-CoV-2 as a pandemic on March 11, 2020. SARS-CoV-2 mainly causes fever as well as respiratory symptoms such as cough and shortness of breath. Gastrointestinal/hepatic sequelae such as diarrhea, nausea, vomiting, and elevated liver enzymes have been reported as well. Studies and data so far on coronavirus infections from China, Singapore, and other countries showed that liver enzymes elevation could be seen in 20-50% of cases. More severe disease can correlate with the worsening of liver enzymes. However, acute liver failure in patients with COVID-19 has not been described. Herein we report a case of acute liver failure in an elderly patient with COVID-19 infection who did not have a history of preexisting liver disease. url: https://doi.org/10.7759/cureus.10045 doi: 10.7759/cureus.10045 id: cord-018225-dozmy3lb author: Hawker, Felicity H. title: The liver in critical illness date: 2008 words: 6814.0 sentences: 319.0 pages: flesch: 45.0 cache: ./cache/cord-018225-dozmy3lb.txt txt: ./txt/cord-018225-dozmy3lb.txt summary: The paper by Harrison and co-workers, again from the King''s Liver Unit, investigates the effects of n-acetylcysteine in patients with acute liver failure, and the findings of this study have resulted in widespread use of this agent in this setting. The incidence of hypoxic hepatitis was prospectively studied for 1 year in a group of high-risk patients suffering from low cardiac output in a coronary care unit. In intensive care patients, a rapid decrease in MEGX test values is associated with increased risk of developing multiple organ failure, and a poor outcome, and consequently may have a role in investigation of the role of the liver in the multiple organ failure syndrome. We studied the effect of acetylcysteine on systemic hemodynamics and oxygen transport in 12 patients with acetaminophen-induced fulminant hepatic failure, and 8 patients with acute liver failure from other causes. The increase in oxygen delivery and consumption in response to acetylcysteine may account for its beneficial effect on survival in patients with fulminant hepatic failure induced by acetaminophen. abstract: The liver is in some ways the forgotten organ in intensive care practice. Very many more laboratory and clinical studies have investigated the role, function, and support of the lung, heart, brain, and kidney in critical illness than have studied the liver. Nevertheless, in the time of the Greek scholars, there was already acknowledgement of the role of the liver in non-hepatic diseases such as systemic sepsis, and an understanding that such involvement confers a poorer prognosis – hence the inclusion of the wisdom of Hippocrates in this compilation of classic papers. In the review article by Matuschak and Rinaldo, the reasons why liver dysfunction is associated with a poorer outcome in critical illness are explored, and the concept of the liver being a ‘driving force’ in multiple organ dysfunction is developed. In addition, jaundice without significant liver dysfunction is associated with left ventricular dysfunction, at least in the dog model developed by Professor Otto Better and his colleagues in Israel. This observation is relevant to the progressive resistance to inotropic and vasopressor agents in jaundiced critically ill patients. url: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7123050/ doi: 10.1007/978-1-84800-145-9_7 id: cord-022300-9w0lehal author: Hoskins, Johnny D. title: The Liver and Pancreas date: 2009-05-15 words: 12535.0 sentences: 704.0 pages: flesch: 39.0 cache: ./cache/cord-022300-9w0lehal.txt txt: ./txt/cord-022300-9w0lehal.txt summary: Several different types of congenital PSS occur in young dogs and cats, including but not limited to (1) persistent patent fetal ductus venosus, (2) direct portal vein to caudal vena cava, (3) direct portal vein to azygos vein, (4) combination of portal vein with caudal vena cava into the azygos vein, (5) left gastric vein to vena caval shunt, (6) portal vein hypoplasia or atresia with secondary anomalous vessel, and (7) anomalous malformation of the caudal vena cava (Center et aI, 1995) . Ultrasonographic findings in puppies with congenital PSS include small liver, reduced visibility of intrahepatic portal vasculature, and an anomalous blood vessel draining into the caudal vena cava or sometimes into the azygos vein (Lamb, 1996) . A chronic active liver disease associated with an age-related accumulation of hepatic copper occurs in Bedlington terrier dogs (Hultgren et al, 1986 ). abstract: nan url: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7155544/ doi: 10.1016/b978-0-7216-7665-4.50015-2 id: cord-324509-5c6fzdjm author: Huang, Haijun title: The association between markers of liver injury and clinical outcomes in patients with COVID‐19 in Wuhan date: 2020-07-22 words: 2150.0 sentences: 139.0 pages: flesch: 48.0 cache: ./cache/cord-324509-5c6fzdjm.txt txt: ./txt/cord-324509-5c6fzdjm.txt summary: 7 Some studies have reported the clinical characteristics of patients with coronavirus disease 2019 (COVID19) , including some factors that may lead to COVID-19-related liver damage and the relationship between liver function damage and disease prognosis. Therefore, we retrospectively analysed the clinical characteristics and dynamic changes in liver function based on different liver function levels at admission and different prognosis, in the purpose of finding out risk factors related to liver injury, and associations between markers of liver injury and clinical outcomes in COVID-19, including mortality and mechanical ventilation. 13, 17 One study had suggested that the dynamic changes in liver enzyme levels in severe patients were more significant, and AST was the parameter most correlated with mortality. In our study, the dynamic changes of ALT and AST levels were more significant in patients with liver injury and in the fatal group. abstract: BACKGROUND: The outbreak of coronavirus disease 2019 (COVID‐19) is a critical challenge for public health. The effect of COVID‐19 on liver injury has not been fully presented. AIMS: To evaluate the dynamic changes in liver function and the relationship between liver function damage and prognosis in patients with COVID‐19. METHODS: Retrospective analysis of clinical data of 675 patients with COVID‐19 in Zhongnan Hospital of Wuhan University from January 3 to March 8, 2020. Patients were classified as normal, abnormal liver function and liver injury. RESULTS: Of 675 patients, 253 (37.5%) had abnormal liver function during hospitalisation, and 52 (7.7%) had liver injury. The dynamic changes of ALT and AST levels were more significant in patients with liver injury and in those who died. AST >3‐fold ULN had the highest risk of death and mechanical ventilation. Compared to patients with normal AST levels, mortality and risk of mechanical ventilation significantly increased 19.27‐fold (95% confidence interval [CI], 4.89‐75.97; P < 0.0001) and 116.72‐fold (95% CI, 31.58‐431.46; P < 0.0001), respectively, in patients with AST above 3‐fold ULN. Increased leucocytes, decreased lymphocytes and female sex were independently associated with liver injury. CONCLUSIONS: The dynamic changes in liver function may have a significant correlation with the severity and prognosis of COVID‐19. Increased index of liver injury was closely related to mortality and need for mechanical ventilation. Therefore, these indicators should be closely monitored during hospitalisation. url: https://www.ncbi.nlm.nih.gov/pubmed/32697870/ doi: 10.1111/apt.15962 id: cord-005892-3yuznrdv author: Hübener, P. title: Das akut-auf-chronische Leberversagen als diagnostische und therapeutische Herausforderung der Intensivmedizin date: 2017-02-16 words: 2152.0 sentences: 228.0 pages: flesch: 38.0 cache: ./cache/cord-005892-3yuznrdv.txt txt: ./txt/cord-005892-3yuznrdv.txt summary: Acute-on-chronic liver failure (ACLF) is an emerging clinical syndrome in patients with underlying liver disease that is usually triggered by one or multiple insults and characterized by progressive hepatic and nonhepatic organ failure, a significant risk of infections, and high short-term mortality rates. Im Rahmen dieses ärztlichen Entscheidungsprozesses müssen neben der unmittelbaren Schwere der Erkrankung beispielsweise auch der mutmaßliche Patientenwunsch, jeweilige lokale und nationale Überlebensraten, eine potenzielle Reversibilität der Or-Das akut-auf-chronische Leberversagen als diagnostische und therapeutische Herausforderung der Intensivmedizin Zusammenfassung Das akut-auf-chronische Leberversagen ("acute-on-chronic liver failure", ACLF) ist ein emergentes Krankheitssyndrom, das durch einen oder mehrere akute Trigger bei vorgeschädigter Leber ausgelöst wird und vom progressiven hepatalen und nichthepatalen Organversagen, einem gravierenden Risiko infektiöser Komplikationen sowie hoher kurzfristiger Letalität gekennzeichnet ist. Leberversagen · Zirrhose · Infektion · Organversagen · Transplantation Acute-on-chronic liver failure: a diagnostic and therapeutic challenge for intensive care Abstract Acute-on-chronic liver failure (ACLF) is an emerging clinical syndrome in patients with underlying liver disease that is usually triggered by one or multiple insults and characterized by progressive hepatic and nonhepatic organ failure, a significant risk of infections, and high short-term mortality rates. abstract: Acute-on-chronic liver failure (ACLF) is an emerging clinical syndrome in patients with underlying liver disease that is usually triggered by one or multiple insults and characterized by progressive hepatic and nonhepatic organ failure, a significant risk of infections, and high short-term mortality rates. Despite our incomplete understanding of the underlying pathophysiology, ACLF requires timely diagnostic and therapeutic measures aiming at the identification and elimination of causative factors as well as the prevention of complications to improve the prognosis of affected patients. url: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7095908/ doi: 10.1007/s00063-017-0263-3 id: cord-292501-2jv7xkfn author: Jiang, Saiping title: Liver Injury in Critically Ill and Non-critically Ill COVID-19 Patients: A Multicenter, Retrospective, Observational Study date: 2020-06-23 words: 4406.0 sentences: 237.0 pages: flesch: 45.0 cache: ./cache/cord-292501-2jv7xkfn.txt txt: ./txt/cord-292501-2jv7xkfn.txt summary: Multivariable regression showed that the number of concomitant medications (odds ratio [OR]: 1.12, 95% confidence interval [CI]: 1.05-1.21) and the combination treatment of lopinavir/ritonavir and arbidol (OR: 3.58, 95% CI: 1.44-9.52) were risk factors for liver injury in non-critically ill patients. Multivariable regression showed that the number of concomitant medications (odds ratio [OR]: 1.12, 95% confidence interval [CI]: 1.05-1.21) and the combination treatment of lopinavir/ritonavir and arbidol (OR: 3.58, 95% CI: 1.44-9.52) were risk factors for liver injury in non-critically ill patients. In the non-critically ill group, the univariate logistic analyses showed that the combination treatment of lopinavir/ritonavir and arbidol and the number of concomitant medications were significantly associated with liver injury ( Table 4) . Drug factors, including the combination treatment of lopinavir/ritonavir and arbidol and the number of concomitant medications were independent risk factors for liver injury in non-critically ill patients with COVID-19, which may be due to drug interactions at the metabolic level. abstract: Background: Liver injury commonly occurs in patients with COVID-19. There is limited data describing the course of liver injury occurrence in patients with different disease severity, and the causes and risk factors are unknown. We aim to investigate the incidence, characteristics, risk factors, and clinical outcomes of liver injury in patients with COVID-19. Methods: This retrospective observational study was conducted in three hospitals (Zhejiang, China). From January 19, 2020 to February 20, 2020, patients confirmed with COVID-19 (≥18 years) and without liver injury were enrolled and divided into non-critically ill and critically ill groups. The incidence and characteristics of liver injury were compared between the two groups. Demographics, clinical characteristics, treatments, and treatment outcomes between patients with or without liver injury were compared within each group. The multivariable logistic regression model was used to explore the risk factors for liver injury. Results: The mean age of 131 enrolled patients was 51.2 years (standard deviation [SD]: 16.1 years), and 70 (53.4%) patients were male. A total of 76 patients developed liver injury (mild, 40.5%; moderate, 15.3%; severe, 2.3%) with a median occurrence time of 10.0 days. Critically ill patients had higher and earlier occurrence (81.5 vs. 51.9%, 12.0 vs. 5.0 days; p < 0.001), greater injury severity (p < 0.001), and slower recovery (50.0 vs. 61.1%) of liver function than non-critically ill patients. Multivariable regression showed that the number of concomitant medications (odds ratio [OR]: 1.12, 95% confidence interval [CI]: 1.05–1.21) and the combination treatment of lopinavir/ritonavir and arbidol (OR: 3.58, 95% CI: 1.44–9.52) were risk factors for liver injury in non-critically ill patients. The metabolism of arbidol can be significantly inhibited by lopinavir/ritonavir in vitro (p < 0.005), which may be the underlying cause of drug-related liver injury. Liver injury was related to increased length of hospital stay (mean difference [MD]: 3.2, 95% CI: 1.3–5.2) and viral shedding duration (MD: 3.0, 95% CI: 1.0–4.9). Conclusions: Critically ill patients with COVID-19 suffered earlier occurrence, greater injury severity, and slower recovery from liver injury than non-critically ill patients. Drug factors were related to liver injury in non-critically ill patients. Liver injury was related to prolonged hospital stay and viral shedding duration in patients with COVID-19. Clinical Trial Registration: World Health Organization International Clinical Trials Registry Platform, ChiCTR2000030593. Registered March 8, 2020. url: https://www.ncbi.nlm.nih.gov/pubmed/32656222/ doi: 10.3389/fmed.2020.00347 id: cord-284693-mgpxnnk0 author: Jothimani, Dinesh title: Post Liver transplant recurrent and de novo viral infections date: 2020-09-26 words: 6339.0 sentences: 366.0 pages: flesch: 41.0 cache: ./cache/cord-284693-mgpxnnk0.txt txt: ./txt/cord-284693-mgpxnnk0.txt summary: Advanced recipient age, diabetes mellitus, severe liver disease (Child Pugh >10), IL-28B polymorphism, high HCV RNA >10 7 IU/ml, ischemic/reperfusion injury, CMV, donor age >65 years, cold ischaemic time over 8 hours and warm ischemia over 90 minutes, marginal graft, DCD donor, higher immunosuppression in particular high dose corticosteroids for acute cellular rejection, use of anti-thymocyte globulin were significantly associated with rHCV in the liver allograft 15, 16 . Initial studies with sofosbuvir and ribavirin combination therapy for post-transplant rHCV showed poor drug tolerance, however, the main adverse event was anaemia related to ribavirin in 62% of patients, and subsequent hepatic decompensation related to the low haemoglobin 38 . A study by Pellicelli et al., showed significant adverse events including hepatic decompensation and 25% mortality in those with advanced disease following treatment with daclatasvir and sofosbuvir for post-transplant rHCV 51 . abstract: Survival following liver transplantation has changed dramatically owing to improvement in surgical techniques, peri-operative care and optimal immunosuppressive therapy. Post-Liver transplant (LT) de novo or recurrent viral infection continues to cause major allograft dysfunction, leading to poor graft and patient survival in untreated patients. Availability of highly effective antiviral drugs has significantly improved post-LT survival. Patients transplanted for chronic hepatitis B infection should receive life-long nucleos(t)ide analogues, with or without HBIg for effective viral control. Patients with chronic hepatitis C should be commenced on directly acting antiviral (DAA) drugs prior to transplantation. DAA therapy for post-LT recurrent hepatitis C infection is associated with close to 100% sustained virological response (SVR), irrespective of genotype. De novo chronic Hepatitis E infection is an increasingly recognised cause of allograft dysfunction in LT recipients. Untreated chronic HEV infection of the graft may lead to liver fibrosis and allograft failure. Similarly, CMV and EBV can reactivate leading to systemic illness following liver transplantation. With COVID-19 pandemic, post-transplant patients are at risk of SARS-Co-V2 infection. Majority of the LT recipients require hospitalisation, and the mortality in this population is around 20%. Early recognition of allograft dysfunction and identification of viral aetiology is essential in the management of post-LT de novo or recurrent infections. Optimising immunosuppression is an important step in reducing the severity of allograft damage in the treatment of post-transplant viral infections. Viral clearance or control can be achieved by early initiation of high potency antiviral therapy. url: https://doi.org/10.1016/j.bpg.2020.101689 doi: 10.1016/j.bpg.2020.101689 id: cord-018414-6ffhm895 author: Kang, Yoogoo title: Anesthesia Management of Liver Transplantation date: 2016-07-22 words: nan sentences: nan pages: flesch: nan cache: txt: summary: abstract: Anesthesia for liver transplantation pertains to a continuum of critical care of patients with end-stage liver disease. Hence, anesthesiologists, armed with a comprehensive understanding of pathophysiology and physiologic effects of liver transplantation on recipients, are expected to maintain homeostasis of all organ function. Specifically, patients with fulminant hepatic failure develop significant changes in cerebral function, and cerebral perfusion is maintained by monitoring cerebral blood flow and cerebral metabolic rate of oxygen, and intracranial pressure. Hyperdynamic circulation is challenged by the postreperfusion syndrome, which may lead to cardiovascular collapse. The goal of circulatory support is to maintain tissue perfusion via optimal preload, contractility, and heart rate using the guidance of right-heart catheterization and transesophageal echocardiography. Portopulmonary hypertension and hepatopulmonary syndrome have high morbidity and mortality, and they should be properly evaluated preoperatively. Major bleeding is a common occurrence, and euvolemia is maintained using a rapid infusion device. Pre-existing coagulopathy is compounded by dilution, fibrinolysis, heparin effect, and excessive activation. It is treated using selective component or pharmacologic therapy based on the viscoelastic properties of whole blood. Hypocalcemia and hyperkalemia from massive transfusion, lack of hepatic function, and the postreperfusion syndrome should be aggressively treated. Close communication between all parties involved in liver transplantation is also equally valuable in achieving a successful outcome. url: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7123279/ doi: 10.1007/978-3-319-07209-8_9 id: cord-033914-a9e3rncp author: Kauffman-Ortega, E. title: In memoriam Ludwig van Beethoven. Clinical history and possible diagnoses of the genius of musical composition in silence() date: 2020-10-17 words: 1721.0 sentences: 93.0 pages: flesch: 48.0 cache: ./cache/cord-033914-a9e3rncp.txt txt: ./txt/cord-033914-a9e3rncp.txt summary: His paternal grandmother, Josepha, and his father, Johann van Beethoven, suffered from alcohol use disorder, which led to his father''s death when Ludwig was 21 years old. 1 Numerous pathologies in the differential diagnosis have been proposed for Beethoven''s sensorineural hearing loss, and the most sustainable are: 1) lead poisoning, based on the presence of residuals of lead 100 times higher than normal in his hair and bones, according to an analysis performed in the United States in the mid 1990s, 4 2) Cogan''s syndrome, characterized by bilateral sensorineural hearing loss and interstitial keratitis secondary to vasculitis, albeit there is no evidence of vestibular dysfunction in Beethoven''s texts; that syndrome can be associated with idiopathic inflammatory bowel disease and reactive arthritis, 5 and 3) Paget''s disease is supported by the frontal bone prominence, tinnitus, and headache. Alcohol consumption appears to be the most probable cause of Beethoven''s cirrhosis of the liver, despite the macronodular appearance described in the autopsy. abstract: nan url: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7568669/ doi: 10.1016/j.rgmxen.2020.10.006 id: cord-300187-fr6tme32 author: Kearns, Shawn title: Infectious Hepatopathies in Dogs and Cats date: 2009-11-26 words: 5800.0 sentences: 444.0 pages: flesch: 36.0 cache: ./cache/cord-300187-fr6tme32.txt txt: ./txt/cord-300187-fr6tme32.txt summary: Although bacterial infections are probably the most common cause of infectious hepatitis, the clinician should be aware of other potential organisms and other commonly involved systems. Therefore, this article includes a description of common bacterial, mycobacterial, viral, fungal, protozoal, parasitic, and rickettsial diseases in dogs and cats. Mycobacterial disease is often subclinical in dogs and cats, but signs may be associated with granuloma formation in various organs. 39, 40 Nontuberculous mycobacterium, including those in the Mycobacterium avium complex, are saprophytic opportunistic organisms primarily implicated in disseminated disease in cats [41] [42] [43] [44] [45] and occasionally in dogs. No clear dissemination pattern has been identified because of low case numbers, but affected organs include the internal lymph nodes, liver, lungs, eyes, bone, muscles, and CNS. Infection results in disseminated disease, including protozoal hepatitis. Bacterial culture results from liver, gallbladder, or bile in 248 dogs and cats evaluated for hepatobiliary disease: 1998-2003 abstract: This article serves to review the various infectious diseases that affect the liver primarily or as a part of systemic infection. Although bacterial infections are probably the most common cause of infectious hepatitis, the clinician should be aware of other potential organisms and other commonly involved systems. Therefore, this article includes a description of common bacterial, mycobacterial, viral, fungal, protozoal, parasitic, and rickettsial diseases in dogs and cats. url: https://www.ncbi.nlm.nih.gov/pubmed/19945087/ doi: 10.1053/j.tcam.2009.06.004 id: cord-323736-zup9cp6s author: Ko, Sheung‐Fat title: Hepatic (31)P‐magnetic resonance spectroscopy identified the impact of melatonin‐pretreated mitochondria in acute liver ischaemia‐reperfusion injury date: 2020-07-21 words: 4529.0 sentences: 244.0 pages: flesch: 39.0 cache: ./cache/cord-323736-zup9cp6s.txt txt: ./txt/cord-323736-zup9cp6s.txt summary: This study tested the hypothesis that (31)P‐magnetic resonance spectroscopy ((31)P‐MRS) findings could provide reliable living images to accurately identify the degree of acute liver IRI and melatonin‐pretreated mitochondria was an innovative treatment for protecting the liver from IRI in rat. [1] [2] [3] Studies have further displayed that several key factors contribute to the hepatic injury at the initiation and during the progression of liver IRI, including those of elevation of anaerobic metabolism, dysfunction of mitochondria, insult of oxidative stress, overload of intracellular calcium, activation of liver Kupffer cells, infiltration of immune cells and release of inflammatory cytokines. Additionally, this study further tested whether the 31 P-MRS examination could provide reliable living images to accurately identify the degree of ATP consumption/depletion in hepatocytes, that is an indicator of acute liver ischaemia-reperfusion in rodent. Melatonin-pretreated mitochondria effectively protected liver against IRI and 31 P-MRS was a reliable tool for measuring the mitochondrial/ATP consumption in living animals. Hepatic 31 P-magnetic resonance spectroscopy identified the impact of melatonin-pretreated mitochondria in acute liver ischaemia-reperfusion injury abstract: Acute liver ischaemia‐reperfusion injury (IRI), commonly encountered during liver resection and transplantation surgery, is strongly associated with unfavourable clinical outcome. However, a prompt and accurate diagnosis and the treatment of this entity remain formidable challenges. This study tested the hypothesis that (31)P‐magnetic resonance spectroscopy ((31)P‐MRS) findings could provide reliable living images to accurately identify the degree of acute liver IRI and melatonin‐pretreated mitochondria was an innovative treatment for protecting the liver from IRI in rat. Adult male SD rats were categorized into group 1 (sham‐operated control), group 2 (IRI only) and group 3 (IRI + melatonin [ie mitochondrial donor rat received intraperitoneal administration of melatonin] pretreated mitochondria [10 mg/per rat by portal vein]). By the end of study period at 72 hours, (31)P‐MRS showed that, as compared with group 1, the hepatic levels of ATP and NADH were significantly lower in group 2 than in groups 1 and 3, and significantly lower in group 3 than in group 1. The liver protein expressions of mitochondrial‐electron‐transport‐chain complexes and mitochondrial integrity exhibited an identical pattern to (31)P‐MRS finding. The protein expressions of oxidative stress, inflammatory, cellular stress signalling and mitochondrial‐damaged biomarkers displayed an opposite finding of (31)P‐MRS, whereas the protein expressions of antioxidants were significantly progressively increased from groups 1 to 3. Microscopic findings showed that the fibrotic area/liver injury score and inflammatory and DNA‐damaged biomarkers exhibited an identical pattern of cellular stress signalling. Melatonin‐pretreated mitochondria effectively protected liver against IRI and (31)P‐MRS was a reliable tool for measuring the mitochondrial/ATP consumption in living animals. url: https://www.ncbi.nlm.nih.gov/pubmed/32691975/ doi: 10.1111/jcmm.15617 id: cord-340710-dmow5p7k author: Lagana, Stephen M. title: Hepatic pathology in patients dying of COVID-19: a series of 40 cases including clinical, histologic, and virologic data date: 2020-08-13 words: 4539.0 sentences: 275.0 pages: flesch: 48.0 cache: ./cache/cord-340710-dmow5p7k.txt txt: ./txt/cord-340710-dmow5p7k.txt summary: title: Hepatic pathology in patients dying of COVID-19: a series of 40 cases including clinical, histologic, and virologic data Here we report the clinical and histologic findings related to the liver in 40 patients who died of complications of COVID-19. In conclusion, we found patients dying of COVID-19 had biochemical evidence of hepatitis (of variable severity) and demonstrated histologic findings of macrovesicular steatosis and mild acute hepatitis (lobular necroinflammation) and mild portal inflammation. A more recent study performed core needle biopsies on the livers of four patients and reported nonspecific findings, attributed to preexisting disease or perimortem injury [4] . Histologically, the most frequently encountered findings were macrovesicular steatosis, mild acute hepatitis, and minimal-to-mild portal inflammation. Nonetheless, based on the pattern of injury observed and the results of the PCR analysis, SARS-CoV-2 seems to involve the liver, and is associated with, possibly causal of, macrovesicular steatosis and acute hepatitis. abstract: The novel coronavirus SARS-CoV-2 (coronavirus disease 19, or COVID-19) primarily causes pulmonary injury, but has been implicated to cause hepatic injury, both by serum markers and histologic evaluation. The histologic pattern of injury has not been completely described. Studies quantifying viral load in the liver are lacking. Here we report the clinical and histologic findings related to the liver in 40 patients who died of complications of COVID-19. A subset of liver tissue blocks were subjected to polymerase chain reaction (PCR) for viral ribonucleic acid (RNA). Peak levels of alanine aminotransferase (ALT) and aspartate aminotransferase (AST) were elevated; median ALT peak 68 U/l (normal up to 46 U/l) and median AST peak 102 U/l (normal up to 37 U/l). Macrovesicular steatosis was the most common finding, involving 30 patients (75%). Mild lobular necroinflammation and portal inflammation were present in 20 cases each (50%). Vascular pathology, including sinusoidal microthrombi, was infrequent, seen in six cases (15%). PCR of liver tissue was positive in 11 of 20 patients tested (55%). In conclusion, we found patients dying of COVID-19 had biochemical evidence of hepatitis (of variable severity) and demonstrated histologic findings of macrovesicular steatosis and mild acute hepatitis (lobular necroinflammation) and mild portal inflammation. We also identified viral RNA in a sizeable subset of liver tissue samples. url: https://doi.org/10.1038/s41379-020-00649-x doi: 10.1038/s41379-020-00649-x id: cord-348024-n8wn4och author: Lei, Fang title: Longitudinal association between markers of liver injury and mortality in COVID‐19 in China date: 2020-05-02 words: nan sentences: nan pages: flesch: nan cache: txt: summary: abstract: Coronavirus disease 2019 (COVID‐19) is a new infectious disease. To reveal the hepatic injury related to this disease and its clinical significance, we conducted a multicenter retrospective cohort study that included 5,771 adult patients with COVID‐19 pneumonia in Hubei Province. We reported the distributional and temporal patterns of liver injury indicators in these patients and determined their associated factors and death risk. Longitudinal liver function tests were retrospectively analyzed and correlated with the risk factors and death. Liver injury dynamic patterns differed in alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (ALP), and total bilirubin (TBIL). AST elevated first, followed by ALT, in severe patients. ALP modestly increased during hospitalization and largely remained in the normal range. The fluctuation in TBIL levels was mild in the non‐severe and the severe group. AST abnormality was associated with the highest mortality risk compared to other indicators of liver injury during hospitalization. Common factors associated with elevated liver injury indicators were lymphocyte count decrease, neutrophil count increase, and male gender. CONCLUSION: The dynamic patterns of liver injury indicators and their potential risk factors may provide an important explanation for the COVID‐19‐associated liver injury. Because elevated liver injury indicators, particularly AST, are strongly associated with the mortality risk, our study indicates that these parameters should be monitored during hospitalization. url: https://doi.org/10.1002/hep.31301 doi: 10.1002/hep.31301 id: cord-016130-5q9ufu28 author: Linday, Linda A. title: Nutritional Supplements and Upper Respiratory Tract Illnesses in Young Children in the United States date: 2010-12-17 words: 11336.0 sentences: 528.0 pages: flesch: 47.0 cache: ./cache/cord-016130-5q9ufu28.txt txt: ./txt/cord-016130-5q9ufu28.txt summary: Our clinical research demonstrates that daily supplementation with a flavored cod liver oil (which meets European purity standards) and a children''s multivitamin-mineral with trace metals, including Se, can decrease morbidity from upper respiratory tract illnesses, otitis media, and sinusitis in young children living in the United States. This chapter discusses the role of essential fatty acids, vitamins, and trace metals in the pathophysiology of inflammation; reviews our clinical research on the use of a lemon-flavored cod liver oil (which meets European purity standards) and a children''s chewable multivitamin-mineral with Se for the prevention and adjunctive treatment of these disorders; reviews the history of cod liver oil, including its importance in the discovery of vitamin D and the anti-infective properties of vitamin A; and discusses the current clinical use of these supplements. abstract: KEY POINTS: In the United States, children have lower blood levels than adults of eicosapentaenoic acid (EPA), an important ω-3 fatty acid that helps decrease inflammation; vitamin A, the “anti-infective” vitamin; and selenium (Se), a trace metal that is an intrinsic part of glutathione peroxidase, an important free-radical scavenging enzyme. EPA, vitamin A, and Se are important in controlling inflammation and can be supplied by oral nutritional supplements. Cod liver oil contains EPA (and other important ω-3 fatty acids), and vitamin A as well as vitamin D. Fish oil contains ω-3 fatty acids (including EPA) but no vitamins. Our clinical research demonstrates that daily supplementation with a flavored cod liver oil (which meets European purity standards) and a children’s multivitamin-mineral with trace metals, including Se, can decrease morbidity from upper respiratory tract illnesses, otitis media, and sinusitis in young children living in the United States. These supplements can be used by practitioners on an individual basis, when clinically indicated; the supplements can be purchased in the United States without a prescription. Socioeconomically disadvantaged children are at risk for micronutrient deficiencies. However, their families may not be able to afford to purchase these supplements, which are not available through Medicaid, The Special Supplemental Nutrition Program for Women, Infants and Children, or the Food Stamp Program. If our results are confirmed in larger studies, a system change will be needed to provide these supplements to nutritionally vulnerable, socioeconomically disadvantaged children living in the United States. url: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7120316/ doi: 10.1007/978-1-59259-880-9_21 id: cord-328147-61gtx2h2 author: Lopez-Mendez, Ivan title: Association of liver steatosis and fibrosis with clinical outcomes in patients with SARS-CoV-2 infection (COVID-19) date: 2020-10-21 words: 2662.0 sentences: 156.0 pages: flesch: 52.0 cache: ./cache/cord-328147-61gtx2h2.txt txt: ./txt/cord-328147-61gtx2h2.txt summary: In Mexico, 72.5% of the adult population is overweight and 9.4% have T2DM(4) Additionally, the prevalence of hepatic steatosis in Mexico ranges from 14 .4% to 62.9%, (5) and he prevalence of liver fibrosis has been reported in 8.1% (noninvasive assessment).(6) Currently, Mexico City is one of the most affected regions in the world with rising numbers of cases and deaths caused by COVID-19, and we have very few data regarding GI symptoms and LFT abnormalities and their prognostic value in Mexican patients. They also represent a challenge for therapeutic maneuvers such as imaging diagnosis, intubation, mechanical ventilation, and pronation, among others.(11) A meta-analysis including 3,207 patients with COVID-19 described that underlying chronic conditions such as hypertension, diabetes, and cardiovascular and respiratory diseases were higher in critical/non-surviving patients; clinical manifestations such as fever and dyspnea were also associated with the progression of the disease.(12) We found similar results in our study, with dyspnea as the most important associated symptom for ICU admission with OR 4.07 (CI95% 1.6-9.86). abstract: INTRODUCTION AND OBJECTIVES: Liver function tests (LFT) abnormalities are reported in up to 50% of COVID-19 patients, metabolic comorbidities are associated with poorer outcomes. The aim of the study is to determine prevalence of liver steatosis and fibrosis in patients with COVID-19 and their association with clinical outcomes. MATERIAL AND METHODS: Retrospective study in hospitalized COVID-19 patients. Risk for liver steatosis was estimated by HSI > 36, and risk for advanced liver fibrosis with APRI > 1.0, NAFLD FS > 0.675 and/or FIB-4 > 3.25. Clinical outcomes were admission to Intensive Care Unit (ICU) and mortality. RESULTS: Of 155 patients, 71.6% were male (n = 111), and 28.4% (n = 44) were obese. Abnormal LFT were present in 96.8% (n = 150), prevalence of steatosis was 42.6% (n = 66) and of significative liver fibrosis was 44.5% (n = 69). Liver fibrosis by FIB-4 was associated with risk of ICU admission (OR 1.74 [95%CI 1.74-2.68; p = 0.023]) and mortality (OR 6.45 [95%CI 2.01-20.83, p = 0.002]), no independent associations were found. CONCLUSIONS: The prevalence of steatosis and significant liver fibrosis was high in COVID-19 patients but was not associated with clinical outcomes. url: https://api.elsevier.com/content/article/pii/S1665268120301861 doi: 10.1016/j.aohep.2020.09.015 id: cord-280234-anlytu3q author: Memar, Elmira Haji Esmaeil title: Fulminant hepatic failure: a rare and devastating manifestation of Coronavirus disease 2019 in an 11-year-old boy date: 2020-09-29 words: 1546.0 sentences: 83.0 pages: flesch: 42.0 cache: ./cache/cord-280234-anlytu3q.txt txt: ./txt/cord-280234-anlytu3q.txt summary: Although several typical manifestation of novel coronavirus disease 2019 (COVID-19) including respiratory symptoms, weakness, fever, and fatigue have been reported, some rare and novel manifestations have also been observed, particularly in children. In this study, we report a novel pediatric case of fulminant hepatic failure associated with COVIDAlthough there have been a significantly smaller number of reported cases of COVID-19 in the pediatric population compared with the adults, the number of infected children has seen a moderate increase [2, 7] . Owing to the acute fulminant hepatic failure in our patient, the only treatment option was liver transplantation; however, because of the progressive course of the disease and its rapid progression to stage 4 with encephalopathy and brain death, he died. In conclusion, in patients with fulminant hepatic failure, especially in cases with symptoms including fever, respiratory distress, and diarrhea, we should rule out COVID-19 infection as the underlying cause. abstract: Although several typical manifestation of novel coronavirus disease 2019 (COVID-19) including respiratory symptoms, weakness, fever, and fatigue have been reported, some rare and novel manifestations have also been observed, particularly in children. We report a pediatric case of fulminant hepatic failure associated with COVID-19. Although the patient was treated for acute fulminant hepatic failure in the context of COVID-19, he died following the progression of the disease to stage 4 hepatic failure with encephalopathy and brain death. url: https://www.ncbi.nlm.nih.gov/pubmed/33069564/ doi: 10.1016/j.arcped.2020.09.009 id: cord-018318-vzzrsqsn author: Naidu, C. Sudeep title: Postoperative Liver Failure date: 2017-02-08 words: 9063.0 sentences: 524.0 pages: flesch: 42.0 cache: ./cache/cord-018318-vzzrsqsn.txt txt: ./txt/cord-018318-vzzrsqsn.txt summary: They focussed on serum bilirubin (SB) and prothrombin time (PT) as important prognostic markers of postoperative liver functional status and proposed the ''50-50'' criteria for the defi nition of PLF, i.e. the combination of PT >50 % of baseline normal and SB >50 μmol/L on postoperative day (POD) 5 (the ''50-50'' criteria) was found to be strongly predictive of mortality. In a study, mortality was signifi cantly higher in patients who had resection of hepatocellular carcinoma (HCC) in cirrhosis associated with active hepatitis (8.7 versus 1.5 %; p < 0.05) [ 13 ] . PLF and postoperative renal dysfunction are independent predictors of 90-day mortality following liver resection but the predictive value for mortality is significantly higher when both systems fail simultaneously. The patient''s liver status, hepatic reserve potential and functional aspect need to be investigated along with the metabolic and haematological derangements, which may lead to PLF. abstract: Technical innovations in surgical techniques, anaesthesia, critical care and a spatial understanding of the intra-hepatic anatomy of the liver, have led to an increasing number of liver resections being performed all over the world. However, the number of complications directly attributed to the procedure and leading to inadequate or poor hepatic functional status in the postoperative period remains a matter of concern. There has always been a problem of arriving at a consensus in the definition of the term: postoperative liver failure (PLF). The burgeoning rate of living donor liver transplants, with lives of perfectly healthy donors involved, has mandated a consensual definition, uniform diagnosis and protocol for management of PLF. The absence of a uniform definition has led to poor comparison among various trials. PLF remains a dreaded complication in resection of the liver, with a reported incidence of up to 8 % [1], and mortality rates of up to 30–70 % have been quoted [2]. Several studies have quoted a lower incidence of PLF in eastern countries, but when it occurs the mortality is as high as in the West [3]. url: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7123164/ doi: 10.1007/978-981-10-2678-2_3 id: cord-003921-8r8z0otz author: Nakamura, Kojiro title: The Evolving Role of Neutrophils in Liver Transplant Ischemia-Reperfusion Injury date: 2019-01-29 words: 6688.0 sentences: 318.0 pages: flesch: 25.0 cache: ./cache/cord-003921-8r8z0otz.txt txt: ./txt/cord-003921-8r8z0otz.txt summary: PURPOSE OF REVIEW: Hepatic ischemia-reperfusion injury (IRI), an inevitable event during liver transplantation, represents a major risk factor for the primary graft dysfunction as well as the development of acute and chronic rejection. In IRI-LT pathophysiology, both Kupffer cells (donor-origin) and liver-infiltrating bone marrow-derived macrophages (recipient-origin) play dominant roles in priming innate immune responses [9] [10] [11] , with the majority of studies focusing on macrophage regulation [12, 13] . Indeed, hepatocyte-specific HMGB1 deficient mice showed decreased hepatic necrosis and neutrophil accumulation, whereas the number of their macrophages remained unchanged in acetaminophen-induced liver injury model [28] . In addition, CXCL1 blocking antibody alleviated hepatic infiltration in necrotic cellinduced neutrophil mobilization model [31] , whereas in a carbon tetrachloride (CCl4)-induced acute liver injury, defective CXCL2 expression in TLR2-knockout or S100A9-knockout mice was accompanied by suppressed hepatic neutrophil recruitment [32] . CD4 T cells promote tissue inflammation via CD40 signaling without de novo activation in a murine model of liver ischemia/reperfusion injury abstract: PURPOSE OF REVIEW: Hepatic ischemia-reperfusion injury (IRI), an inevitable event during liver transplantation, represents a major risk factor for the primary graft dysfunction as well as the development of acute and chronic rejection. Neutrophils, along macrophages, are pivotal in the innate immune-driven liver IRI, whereas the effective neutrophil-targeting therapies remain to be established. In this review, we summarize progress in our appreciation of the neutrophil biology and discuss neutrophil-based therapeutic perspectives. RECENT FINDINGS: New technological advances enable to accurately track neutrophil movements and help to understand molecular mechanisms in neutrophil function, such as selective recruitment to IR-stressed tissue, formation of neutrophil extracellular traps, or reverse migration into circulation. In addition to pro-inflammatory and tissue-destructive functions, immune regulatory and tissue-repairing phenotype associated with distinct neutrophil subsets have been identified. SUMMARY: Newly recognized and therapeutically attractive neutrophil characteristics warrant comprehensive preclinical and clinical attention to target IRI in transplant recipients. url: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6786799/ doi: 10.1007/s40472-019-0230-4 id: cord-340576-dabcs3w5 author: Nishikawa, Hiroki title: Liver Cirrhosis and Sarcopenia from the Viewpoint of Dysbiosis date: 2020-07-24 words: 8153.0 sentences: 464.0 pages: flesch: 41.0 cache: ./cache/cord-340576-dabcs3w5.txt txt: ./txt/cord-340576-dabcs3w5.txt summary: In individuals with chronic liver diseases (CLDs), metabolic or nutritional dysfunctions including protein-energy malnutrition (PEM) or muscle abnormalities are frequently found, which can be related to disabilities, poor quality of life, or mortality [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] . LC-related complications themselves such as hepatocellular carcinoma (HCC), ascites, spontaneous bacterial peritonitis (SBP), varices, hepatic encephalopathy (HE), and acute or chronic liver failure (ACLF) can cause sarcopenia [22, 40] . LC-related complications themselves such as hepatocellular carcinoma (HCC), ascites, spontaneous bacterial peritonitis (SBP), varices, hepatic encephalopathy (HE), and acute or chronic liver failure (ACLF) can cause sarcopenia [22, 40] . Cumulative evidence has highlighted the relevance of increase in intestinal permeability (i.e., leaky gut syndrome) and consequent bacterial translocation in the development of CLDs. Particularly, in recent hypotheses regarding patients with non-alcoholic fatty liver disease (NAFLD), intestinal permeability impairment, dietary habits, and gut dysbiosis are considered to be the main pathogenic triggers [85] [86] [87] . abstract: Sarcopenia in patients with liver cirrhosis (LC) has been attracting much attention these days because of the close linkage to adverse outcomes. LC can be related to secondary sarcopenia due to protein metabolic disorders and energy metabolic disorders. LC is associated with profound alterations in gut microbiota and injuries at the different levels of defensive mechanisms of the intestinal barrier. Dysbiosis refers to a state in which the diversity of gut microbiota is decreased by decreasing the bacterial species and the number of bacteria that compose the gut microbiota. The severe disturbance of intestinal barrier in LC can result in dysbiosis, several bacterial infections, LC-related complications, and sarcopenia. Here in this review, we will summarize the current knowledge of the relationship between sarcopenia and dysbiosis in patients with LC. url: https://www.ncbi.nlm.nih.gov/pubmed/32722100/ doi: 10.3390/ijms21155254 id: cord-018801-amet0wx4 author: Park, Caroline title: Care of the Patient with Liver Failure Requiring Transplantation date: 2018-05-04 words: 4703.0 sentences: 237.0 pages: flesch: 30.0 cache: ./cache/cord-018801-amet0wx4.txt txt: ./txt/cord-018801-amet0wx4.txt summary: Depending on acuity, patients with decompensated chronic or acute fulminant liver failure generally require preoperative intensive care unit admission to manage organ dysfunction. Depending on acuity, patients with decompensated chronic or acute fulminant liver failure generally require preoperative intensive care unit (ICU) admission to manage organ dysfunction. In patients that develop AKI post-liver transplantation, treatment includes the prevention of hypotension and decreased use of unnecessary blood products. Early postoperative infections in liver transplant patients are typically bacterial and related to the donor''s status (previous infections from advanced cirrhosis), the surgical procedure itself, prolonged use of invasive catheters, and duration of mechanical ventilation. The resulting lack of blood flow and developing ischemia and necrosis from hepatic artery thrombosis present with signs and symptoms similar to fulminant liver failure patients with elevated liver serum tests, coagulopathy, and severe metabolic acidosis. abstract: Patients undergo liver transplantation to address chronic liver failure, acute fulminant liver failure, or primary liver cancer. Depending on acuity, patients with decompensated chronic or acute fulminant liver failure generally require preoperative intensive care unit admission to manage organ dysfunction. Those with chronic liver failure are allocated an organ based on waiting list position determined by their local organ procurement organization (OPO). This position is dependent upon blood type and Model for End- Stage Liver Disease (MELD) score. These patients thus are critically ill and require preoperative ICU monitoring and care. Patients with hepatocellular carcinoma (HCC) who require liver transplantation are given a MELD exception and rarely require preoperative ICU care. The patient’s ability to undergo liver transplant in the setting of HCC is determined by the Milan criteria or the University of California, San Francisco (UCSF) criteria. url: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7123773/ doi: 10.1007/978-3-319-71712-8_55 id: cord-303046-unksl7p4 author: Pawlotsky, Jean-Michel title: COVID-19 and the liver-related deaths to come date: 2020-06-11 words: 1899.0 sentences: 78.0 pages: flesch: 36.0 cache: ./cache/cord-303046-unksl7p4.txt txt: ./txt/cord-303046-unksl7p4.txt summary: As a result of lockdowns and suspension of usual clinical care activities for the benefit of patients with COVID-19, the SARS-CoV-2 pandemic is having a major effect on the management of patients with chronic liver diseases, in particular those with cirrhosis, hepatocellular carcinoma and in liver transplantation programmes. The COVID-19 pandemic will also negatively affect the care and management of patients with hepatocellular carcinoma, generating delayed diagnosis, deferred treatment (including medical and surgical, such as access to liver transplantation), loss to follow-up and, ultimately, increased mortality. Most COviD-19-induced liver-mortality will be delayed, resulting from deferred care for liver diseases, reduced funding for public health interventions and the global economic crisis, which will lead to increases in alcohol and drug use and in blood-borne virus transmissions, while access to care and funding are reduced. abstract: Coronavirus disease 2019 (COVID-19) itself and/or the use of hepatotoxic drugs might negatively affect the course and management of patients with pre-existing chronic liver diseases. However, the greatest effect of COVID-19 on liver diseases will be indirect and delayed, resulting from the impending global economic crisis. url: https://www.ncbi.nlm.nih.gov/pubmed/32528138/ doi: 10.1038/s41575-020-0328-2 id: cord-332827-gll4nqdd author: Peixe, Paula title: Hepatology in the COVID Era: Another C Virus, again Challenging the Liver date: 2020-04-30 words: 3989.0 sentences: 221.0 pages: flesch: 52.0 cache: ./cache/cord-332827-gll4nqdd.txt txt: ./txt/cord-332827-gll4nqdd.txt summary: In published series, liver disease was not identified as a risk factor for SARS-Cov2 infection [11] [12] [13] [14] [15] . The authors state that NAFLD patients also had a higher risk of progression to severe COVID-19 and present an increased viral clearance time. Immune-mediated liver diseases, particularly autoimmune hepatitis, have not been mentioned as risk factors for COVID-19, but the immunosuppressive treatment required has triggered fears about the risk of infection in patients. Extensive records and targeted studies are needed to explore multiple open-ended questions such as the severity and mortality of COVID-19 and episodes of acute-on-chronic or decompensation associated with the presence of this disease (ascites, hepatic encephalopathy, digestive bleeding, kidney dysfunction, and the risk of infection) or the response to treatment [25, 26] . However, it is not yet possible to say whether transplantation-associated immunosuppression can alter the predisposition for the acquisition of SARS-Cov2 infection or how COVID-19 evolves in these patients. abstract: nan url: https://www.ncbi.nlm.nih.gov/pubmed/32775544/ doi: 10.1159/000508116 id: cord-030369-4dn02a35 author: Peng, Liang title: Clinical Manifestations and Laboratory Tests of AECHB and Severe Hepatitis (Liver Failure) date: 2019-05-21 words: 35858.0 sentences: 1603.0 pages: flesch: 38.0 cache: ./cache/cord-030369-4dn02a35.txt txt: ./txt/cord-030369-4dn02a35.txt summary: Once pulmonary infection is present, the disease condition will likely deteriorate, directly causing death; (3) a majority of infections are nosocomial infection, and pathogens are usually resistant to common antibiotics, making therapy challenging; (4) the pathogens causing infection are diverse but mainly Gram-negative bacteria, although the incidence of Gram-positive and fungal infections is increasing; (5) infection is closely related to the prognosis for liver failure patients. Although their clinical manifestation differ significantly, the "coexistence of acute and chronic failures" is shared by failures of all those organs; (2) CLF classification has been generally recognized at home and abroad, and the necessity of classification are further proved by the difference between CLF and the other three types; (3) CLF cases are relatively large in proportion (nearly 30%), which is still increasing (since the proportion of ALF/SALF are lowering); (4) Complications of CLF are common and are found in various forms, with bad prognosis; (5) In CLF patients with correlation to HBV, virus replication are commonly found, which is closely related to decompensation. abstract: This chapter describes the clinical symptoms and signs of AECHB and HBV ACLF, classification, grading of HBV ACLF and their features, diagnostic principles and standards in liver pathology, biochemistry, and virology of HBV ACLF. 1. Liver failure is defined as serious damage to the liver cause by a variety of etiologies, leading to liver function disorder or even decompensation, and clinical syndromes with coagulopathy, jaundice, hepatic encephalopathy, and ascites. 2. Severe hepatitis B can be indicated pathologically by apparent hepatocellular necrosis, including extensive multifocal, confluent, bridging, sub-massive or massive necrosis. 3. Laboratory tests during the course of severe exacerbation of chronic hepatitis B can reflect pathological changes and liver function in a timely manner, providing objective and informative reference data for evaluation of disease severity and treatment efficacy. Among the most important laboratory tests are those for prothrombin activity, international normalized ratio, and increases in total bilirubin concentration. 4. Severe hepatitis B is associated with interactions between the virus and host factors. Detection of HBV DNA, HBV genotype, quasispecies and HBV mutation can provide important theoretical bases for the prevention, control or mitigation of the progress of severe hepatitis B. 5. Noninvasive imaging modalities can be used to visualize the entire liver and parts of it. Measuring liver volume to evaluate liver size and liver reserve capacity is regarded as important in diagnosis, surgical approach and prognostic evaluation of patients with severe exacerbation of chronic hepatitis B and liver failure. 6. Model for End-Stage Liver Disease (MELD) is the first quantitative method developed to assess whether a patient with liver failure requires a liver transplant. The predictive value of the MELD model has been improved by the MELD-Na, iMELD, and MESO models. Several other valuable prognostic models have been developed. For example, for patients with HBV-ACLF, the established TPPM scoring system was found to be more predictive than MELD score. url: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7418529/ doi: 10.1007/978-94-024-1603-9_1 id: cord-353633-a4pu6rlu author: Perakakis, Nikolaos title: The role of omics in the pathophysiology, diagnosis and treatment of non-alcoholic fatty liver disease date: 2020-07-23 words: 14722.0 sentences: 701.0 pages: flesch: 32.0 cache: ./cache/cord-353633-a4pu6rlu.txt txt: ./txt/cord-353633-a4pu6rlu.txt summary: Non-alcoholic fatty liver disease (NAFLD) is a multifaceted metabolic disorder, whose spectrum covers clinical, histological and pathophysiological developments ranging from simple steatosis to non-alcoholic steatohepatitis (NASH) and liver fibrosis, potentially evolving into cirrhosis, hepatocellular carcinoma and liver failure. The disease is characterized initially by hepatic lipid accumulation (nonalcoholic fatty liver; NAFL), that can often progress to non-alcoholic steatohepatitis (NASH), liver fibrosis or cirrhosis, as outlined in detail elsewhere in this special issue [1] . Several studies have assessed the impact of epigenetic modifications in the development and progress of NAFLD ( Figure 2 ) as well as in the association of NAFLD with other metabolic diseases by focusing on DNA methylation, histone modifications and miRNA expression profiles that can significantly affect transcriptional activity. Proteomic analysis to identify differentially expressed proteins between subjects with metabolic healthy obesity and non-alcoholic fatty liver disease abstract: Non-alcoholic fatty liver disease (NAFLD) is a multifaceted metabolic disorder, whose spectrum covers clinical, histological and pathophysiological developments ranging from simple steatosis to non-alcoholic steatohepatitis (NASH) and liver fibrosis, potentially evolving into cirrhosis, hepatocellular carcinoma and liver failure. Liver biopsy remains the gold standard for diagnosing NAFLD, while there are no specific treatments. An ever-increasing number of high-throughput Omics investigations on the molecular pathobiology of NAFLD at the cellular, tissue and system levels produce comprehensive biochemical patient snapshots. In the clinical setting, these applications are considerably enhancing our efforts toward obtaining a holistic insight on NAFLD pathophysiology. Omics are also generating non-invasive diagnostic modalities for the distinct stages of NAFLD, that remain though to be validated in multiple, large, heterogenous and independent cohorts, both cross-sectionally as well as prospectively. Finally, they aid in developing novel therapies. By tracing the flow of information from genomics to epigenomics, transcriptomics, proteomics, metabolomics, lipidomics and glycomics, the chief contributions of these techniques in understanding, diagnosing and treating NAFLD are summarized herein. url: https://doi.org/10.1016/j.metabol.2020.154320 doi: 10.1016/j.metabol.2020.154320 id: cord-342930-f7cw2ca6 author: Portincasa, Piero title: Hepatic consequences of COVID-19 infection. Lapping or biting? date: 2020-06-01 words: 3010.0 sentences: 160.0 pages: flesch: 44.0 cache: ./cache/cord-342930-f7cw2ca6.txt txt: ./txt/cord-342930-f7cw2ca6.txt summary: Although the most frequent and critical clinical 15 presentation is secondary to the involvement of the lung (fever, cough), the infection by SARS16 CoV-2 virus may lead to a systemic and multi-organ disease [10] , also involving the gastrointestinal 17 tract (nausea/vomiting, or diarrhea) [11, 12] . Although the level of serum transaminases could be already elevated before the onset of COVID-14 19, results from clinical reports and autopsy studies [26, 49, 50] suggest that liver dysfunction can 15 be an expression of a worse disease evolution, and that an isolated elevation of transaminases alone 16 is likely to be the indirect expression of a systemic inflammation. In one study, patients 17 developing abnormal liver tests had higher risks of progressing to severe disease [51] , and the 18 finding is associated with longer hospital stay [62] . Non-alcoholic fatty liver diseases in patients with 19 COVID-19: A retrospective study abstract: The outbreak of coronavirus disease 2019 (COVID-19) starting last December in China placed emphasis on liver involvement during infection. This review discusses the underlying mechanisms linking COVID-19 to liver dysfunction, according to recent available information, while waiting further studies. The manifestations of liver damage are usually mild (moderately elevated serum aspartate aminotransferase activities), and generally asymptomatic. Few patients can still develop severe liver problems, and therapeutic options can be limited. Liver dysfunction may affect about one-third of the patients, with prevalence greater in men than women, and in elderly. Mechanisms of damage are complex and include direct cholangiocyte damage and other coexisting conditions such as the use of antiviral drugs, systemic inflammatory response, respiratory distress syndrome-induced hypoxia, sepsis, and multiple organ dysfunction. During new COVID-19 infections, liver injury may be observed. If liver involvement appears during COVID-19 infection, however, attention is required. This is particularly true if patients are older or have a pre-existing history of liver diseases. During COVID-19 infection, the onset of liver damage impairs the prognosis, and hospital stay is longer. url: https://doi.org/10.1016/j.ejim.2020.05.035 doi: 10.1016/j.ejim.2020.05.035 id: cord-275637-ea6w2kqv author: Roca-Fernandez, A. title: HIGH LIVER FAT ASSOCIATES WITH HIGHER RISK OF DEVELOPING SYMPTOMATIC COVID-19 INFECTION - INITIAL UK BIOBANK OBSERVATIONS date: 2020-06-05 words: 2912.0 sentences: 160.0 pages: flesch: 47.0 cache: ./cache/cord-275637-ea6w2kqv.txt txt: ./txt/cord-275637-ea6w2kqv.txt summary: Conclusions UK Biobank data demonstrated an association between pre-existing liver disease and obesity with severe COVID-19, with higher proportions of liver fat in obese individuals a likely risk factor for symptomatic disease and severity. The aim of this study was to test the hypothesis that liver disease, and specifically liver fat accumulation, is a risk factor for developing symptomatic COVID-19. . https://doi.org/10.1101/2020.06.04.20122457 doi: medRxiv preprint Furthermore, the 32.7% of obese patients with liver fat ≥10% had a higher likelihood of being symptomatic and testing positive for COVID-19 (OR: 2.96, p=0.02). Our study demonstrates that in addition to the previouslyreported risk factors of male gender, non-white-British ethnicity, and obesity (1-3), liver fat is also a significant risk factor for having symptomatic COVID-19, with a person testing positive for COVID-19 being 1.85 times more likely to have pre-existing severe fatty liver disease. abstract: Background A high proportion of COVID-19 patients develop acute liver dysfunction. Early research has suggested that pre-existing fatty liver disease may be a significant risk factor for hospitalisation. Liver fat, in particular, is a modifiable parameter and can be a target for public health policy and individual patient plans. In this study we aimed to assess pre-existing liver disease as a risk factor for developing symptomatic COVID-19. Methods From 502,506 participants from the UK Biobank, 42,146 underwent MRI (aged 45-82), and had measures of liver fat, liver fibroinflammatory disease and liver iron. Patients were censored on May 28th to determine how many had tested for COVID-19 with symptomatic disease. UK testing was restricted to those with symptoms in hospital. COVID-19 symptoms included fever, dry cough, sore throat, diarrhoea and fatigue. Univariate analysis was performed on liver phenotypic biomarkers to determine if these variables increased risk of symptomatic COVID-19, and compared to previously described risk factors associated with severe COVID-19, including to age, ethnicity, gender and obesity, Findings Increased liver fat was associated with a higher risk for symptomatic confirmed COVID-19 in this population in univariate analysis(OR:1.85, p=0.03). In obese participants, only those with concomitant fatty liver([≥]10%) were at increased risk(OR:2.96, p=0.02), with those having normal liver fat (<5%) showing no increased risk(OR:0.36, p=0.09). Conclusions UK Biobank data demonstrated an association between pre-existing liver disease and obesity with severe COVID-19, with higher proportions of liver fat in obese individuals a likely risk factor for symptomatic disease and severity. Public policy measures to protect patients with liver disease who may have almost double the risk of the general population should be considered, especially as dietary and pharmacological strategies to reduce body weight and liver fat already exist. Funding University of Oxford, Innovate UK, UK Biobank. Authors are employees of Perspectum Ltd. url: http://medrxiv.org/cgi/content/short/2020.06.04.20122457v1?rss=1 doi: 10.1101/2020.06.04.20122457 id: cord-279667-ikfduu2k author: Ronnje, Louise title: Complicated COVID-19 in pregnancy: a case report with severe liver and coagulation dysfunction promptly improved by delivery date: 2020-09-04 words: 3361.0 sentences: 207.0 pages: flesch: 50.0 cache: ./cache/cord-279667-ikfduu2k.txt txt: ./txt/cord-279667-ikfduu2k.txt summary: title: Complicated COVID-19 in pregnancy: a case report with severe liver and coagulation dysfunction promptly improved by delivery Severe COVID-19 promptly improved by the termination of the pregnancy or atypical HELLP (Hemolysis, Elevated Liver Enzymes and Low Platelet Count) exacerbated by concomitant COVID-19 infection could not be ruled out. CONCLUSIONS: This case adds to the growing body of evidence which raises concerns about the possible negative maternal outcomes of COVID-19 infection during pregnancy and advocates for pregnant women to be recognized as a vulnerable group during the current pandemic. We report a case of severe COVID-19 during in third trimester pregnancy, which led to an emergency Caesarean section and preterm delivery at 32 + 6 weeks of gestational age. Atypical presentation of HELLP could not be ruled out and the importance of a multidisciplinary team in the treatment and management of severe COVID-19 during pregnancy is critical for positive patient outcome. abstract: BACKGROUND: It has been proposed that pregnant women and their fetuses may be particularly at risk for poor outcomes due to the coronavirus (COVID-19) pandemic. From the few case series that are available in the literature, women with high risk pregnancies have been associated with higher morbidity. It has been suggested that pregnancy induced immune responses and cardio-vascular changes can exaggerate the course of the COVID-19 infection. CASE PRESENTATION: A 26-year old Somalian woman (G2P1) presented with a nine-day history of shortness of breath, dry cough, myalgia, nausea, abdominal pain and fever. A nasopharyngeal swab returned positive for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. Her condition rapidly worsened leading to severe liver and coagulation impairment. An emergency Caesarean section was performed at gestational week 32 + 6 after which the patient made a rapid recovery. Severe COVID-19 promptly improved by the termination of the pregnancy or atypical HELLP (Hemolysis, Elevated Liver Enzymes and Low Platelet Count) exacerbated by concomitant COVID-19 infection could not be ruled out. There was no evidence of vertical transmission. CONCLUSIONS: This case adds to the growing body of evidence which raises concerns about the possible negative maternal outcomes of COVID-19 infection during pregnancy and advocates for pregnant women to be recognized as a vulnerable group during the current pandemic. url: https://doi.org/10.1186/s12884-020-03172-8 doi: 10.1186/s12884-020-03172-8 id: cord-018620-3kqx8arn author: Rueda, Mario title: Hepatic Failure date: 2016-10-09 words: nan sentences: nan pages: flesch: nan cache: txt: summary: abstract: The progression of liver disease can cause several physiologic derangements that may precipitate hepatic failure and require admission to an intensive care unit. The underlying pathology may be acute, acute-on chronic, or chronic in nature. Liver failure may manifest with a variety of clinical signs and symptoms that need prompt attention. The compromised synthetic and metabolic activity of the failing liver affects all organ systems, from neurologic to integumentary. Supportive care and specific therapies should be instituted in order to improve outcome and minimize time of recovery. In this chapter we will discuss the definition, clinical manifestations, workup, and management of acute and chronic liver failure and the general principles of treatment of these patients. Management of liver failure secondary to certain common etiologies will also be presented. Finally, liver transplantation and alternative therapies will also be discussed. url: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7123541/ doi: 10.1007/978-3-319-33341-0_18 id: cord-025168-be7zube4 author: Saleh, Mahshid title: Perspective of placenta derived mesenchymal stem cells in acute liver failure date: 2020-05-24 words: 6533.0 sentences: 361.0 pages: flesch: 41.0 cache: ./cache/cord-025168-be7zube4.txt txt: ./txt/cord-025168-be7zube4.txt summary: Adipose tissue-derived mesenchymal stem cells (AD-MSCs) are isolated from adipose tissue by liposuction, are capable of differentiation to hepatocytelike cells in the presence of HGF, FGF-1, and FGF-4 factors and participate in the regeneration of hepatocytes and vasculogenesis [61] . Several studies have shown that MSCs secrete tropic factors and can be effective in reducing inflammation, fibrosis and apoptosis of liver cells as well as repairing damaged tissue by stimulating angiogenesis [74] . It can be argued that the beneficial effects of MSCs in liver diseases (including ALF) are not limited to hepatocyte repair, but rather the tropical factors released by Fig. 1 Mesenchymal stem cells and its effects on acute liver failure them modulate the deleterious effects of the immune response [142] . Bone marrow-derived mesenchymal stem cells inhibits hepatocyte apoptosis after acute liver injury In vivo hepatic differentiation potential of human umbilical cord-derived mesenchymal stem cells: therapeutic effect on liver fibrosis/cirrhosis abstract: Acute Liver failure (ALF) is a life-threatening disease and is determined by coagulopathy (with INR ≥ 1.5) and hepatic encephalopathy as a result of severe liver injury in patients without preexisting liver disease. Since there are problems with liver transplantation including lack of donors, use of immunosuppressive drugs, and high costs of this process, new therapeutic approaches alongside current treatments are needed. The placenta is a tissue that is normally discarded after childbirth. On the other hand, human placenta is a rich source of mesenchymal stem cells (MSCs), which is easily available, without moral problems, and its derived cells are less affected by age and environmental factors. Therefore, placenta-derived mesenchymal stem cells (PD-MSCs) can be considered as an allogeneic source for liver disease. Considering the studies on MSCs and their effects on various diseases, it can be stated that MSCs are among the most important agents to be used for novel future therapies of liver diseases. In this paper, we will investigate the effects of mesenchymal stem cells through migration and immigration to the site of injury, cell-to-cell contact, immunomodulatory effects, and secretory factors in ALF. url: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7245988/ doi: 10.1186/s13578-020-00433-z id: cord-002272-c7f1l13s author: Sauter, Kristin A. title: Macrophage colony-stimulating factor (CSF1) controls monocyte production and maturation and the steady-state size of the liver in pigs date: 2016-07-21 words: 6589.0 sentences: 374.0 pages: flesch: 52.0 cache: ./cache/cord-002272-c7f1l13s.txt txt: ./txt/cord-002272-c7f1l13s.txt summary: title: Macrophage colony-stimulating factor (CSF1) controls monocyte production and maturation and the steady-state size of the liver in pigs Combined with earlier data from the mouse, this study supports the existence of a CSF1-dependent feedback loop, linking macrophages of the liver with bone marrow and blood monocytes, to mediate homeostatic control of the size of the liver. The expected increase in half-life was confirmed, and CSF1-Fc administration to mice produced substantial increases in circulating monocyte and tissue macrophage numbers, at much lower doses than the native protein. Cluster 2 (Fig. 9B) , the set of genes reduced in the CSF1-Fc-treated pigs, most likely reflects the functional zonation of the liver between periportal and perivenous regions of liver lobules (8, 19, 48) and the selective proliferation of cells derived from portal progenitors that has been observed in regenerating liver (15, 34, 36) . abstract: Macrophage colony-stimulating factor (CSF1) is an essential growth and differentiation factor for cells of the macrophage lineage. To explore the role of CSF1 in steady-state control of monocyte production and differentiation and tissue repair, we previously developed a bioactive protein with a longer half-life in circulation by fusing pig CSF1 with the Fc region of pig IgG1a. CSF1-Fc administration to pigs expanded progenitor pools in the marrow and selectively increased monocyte numbers and their expression of the maturation marker CD163. There was a rapid increase in the size of the liver, and extensive proliferation of hepatocytes associated with increased macrophage infiltration. Despite the large influx of macrophages, there was no evidence of liver injury and no increase in circulating liver enzymes. Microarray expression profiling of livers identified increased expression of macrophage markers, i.e., cytokines such as TNF, IL1, and IL6 known to influence hepatocyte proliferation, alongside cell cycle genes. The analysis also revealed selective enrichment of genes associated with portal, as opposed to centrilobular regions, as seen in hepatic regeneration. Combined with earlier data from the mouse, this study supports the existence of a CSF1-dependent feedback loop, linking macrophages of the liver with bone marrow and blood monocytes, to mediate homeostatic control of the size of the liver. The results also provide evidence of safety and efficacy for possible clinical applications of CSF1-Fc. url: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5076001/ doi: 10.1152/ajpgi.00116.2016 id: cord-288721-3bv3aak6 author: Schneider, Annika title: Single organelle analysis to characterize mitochondrial function and crosstalk during viral infection date: 2019-06-11 words: 5604.0 sentences: 309.0 pages: flesch: 39.0 cache: ./cache/cord-288721-3bv3aak6.txt txt: ./txt/cord-288721-3bv3aak6.txt summary: Thus, single-organelle and multi-parameter resolution allows to explore altered energy metabolism and antiviral defence by tagged mitochondria selectively in virus-infected cells and will be instrumental to identify viral immune escape and to develop and monitor novel mitochondrial-targeted therapies. When challenged with high concentrations of calcium (100 µM), mitochondria isolated from virus-infected livers are much more fragile shown by time-dependent loss of membrane potential and change of their morphology indicated by decrease in side-scatter (Fig. 2F ). Number of viable mitochondria detected per second by flow-cytometry declined after calcium challenge, consistent with loss of mitochondrial integrity, and did so much faster in samples from virus-infected livers (Fig. 2F ). In order to further evaluate mitochondrial functionality, we challenged mitochondria with Ca 2+ as stress test and performed time kinetic measurements of DilC 1 (5) fluorescence and side-scatter of mito-DsRed + and mito-DsRed − mitochondria isolated from Ad-CMV-mitoRL infected livers. abstract: Mitochondria are key for cellular metabolism and signalling processes during viral infection. We report a methodology to analyse mitochondrial properties at the single-organelle level during viral infection using a recombinant adenovirus coding for a mitochondrial tracer protein for tagging and detection by multispectral flow cytometry. Resolution at the level of tagged individual mitochondria revealed changes in mitochondrial size, membrane potential and displayed a fragile phenotype during viral infection of cells. Thus, single-organelle and multi-parameter resolution allows to explore altered energy metabolism and antiviral defence by tagged mitochondria selectively in virus-infected cells and will be instrumental to identify viral immune escape and to develop and monitor novel mitochondrial-targeted therapies. url: https://www.ncbi.nlm.nih.gov/pubmed/31186476/ doi: 10.1038/s41598-019-44922-9 id: cord-017603-wq4cgqs2 author: Shanmugam, Naresh title: Acute Liver Failure in Children date: 2018-10-16 words: 4424.0 sentences: 248.0 pages: flesch: 40.0 cache: ./cache/cord-017603-wq4cgqs2.txt txt: ./txt/cord-017603-wq4cgqs2.txt summary: Trying to address this issue, Bhaduri and Vergani defined ALF in children as "a rare multisystem disorder in which severe impairment of liver function, with or without encephalopathy, occurs in association with hepatocellular necrosis in a patient with no recognized underlying chronic liver disease" [2] . They used the following criteria to define acute liver failure (ALF) in children: (1) hepatic-based coagulopathy defined as a prothrombin time (PT) ≥ 15 s or international normalized ratio (INR) ≥ 1.5 not corrected by vitamin K in the presence of clinical hepatic encephalopathy (HE) or a PT ≥ 20 s or INR ≥ 2.0 regardless of the presence or absence of clinical hepatic encephalopathy (HE), (2) biochemical evidence of acute liver injury and (3) no known evidence of chronic liver disease [3] . A similar study in children failed to show any benefit, and Paediatric Acute Liver Failure study group does not recommend routine use of in non-acetaminophen-induced ALF in children [33] . abstract: “Acute liver failure” (ALF) and “fulminant liver failure” are terms used interchangeably to describe severe and sudden onset of liver cell dysfunction leading on to synthetic and detoxification failure across all age groups. Considerable variations exist between ALF in children and adults, in terms of aetiology and prognosis. Encephalopathy is not essential to make a diagnosis of ALF in children but when present has a bad prognosis. Early recognition of ALF and initiation of supportive management improve the outcome. Liver transplantation remains the only definitive treatment when supportive medical management fails. url: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7122201/ doi: 10.1007/978-3-319-96400-3_8 id: cord-283120-hyzk59qv author: Sharma, Ashish title: Liver disease and outcomes among COVID-19 hospitalized patients- a systematic review and meta-analysis date: 2020-10-16 words: 2630.0 sentences: 157.0 pages: flesch: 48.0 cache: ./cache/cord-283120-hyzk59qv.txt txt: ./txt/cord-283120-hyzk59qv.txt summary: In this meta-analysis, we aim to study the occurrence and association of liver injury, comorbid liver disease and elevated liver enzymes in COVID-19 confirmed hospitalizations with outcomes. MATERIALS AND METHODS: Data from observational studies describing comorbid chronic liver disease, acute liver injury, elevated aspartate aminotransferase (AST), alanine aminotransferase (ALT) levels and outcomes of COVID-19 hospitalized patients from December 1, 2019, to June 30, 2020 was extracted following PRISMA guidelines. The aim of the study is to evaluate the role of the comorbid chronic liver disease (CM-CLD), elevated liver enzymes and COVID-19 associated acute liver injury (COVID-19 ALI) in predicting the outcomes in confirmed COVID-19 hospitalized patients. The Maentel-Haenszel formula was used to calculate dichotomous variables to obtain odds ratios (ORs) along with its 95% confidence intervals to describe the association of comorbid liver disease, elevated liver enzymes, acute liver injury and outcomes of COVID-19 patients in each study. abstract: INTRODUCTION AND OBJECTIVES: The coronavirus disease 2019 (COVID-19) pandemic has been a challenge globally. In severe acute respiratory syndrome (SARS) epidemic 60% of patients had hepatic injury, due to phylogenetic similarities of the viruses it is assumed that COVID-19 is associated with acute liver injury. In this meta-analysis, we aim to study the occurrence and association of liver injury, comorbid liver disease and elevated liver enzymes in COVID-19 confirmed hospitalizations with outcomes. MATERIALS AND METHODS: Data from observational studies describing comorbid chronic liver disease, acute liver injury, elevated aspartate aminotransferase (AST), alanine aminotransferase (ALT) levels and outcomes of COVID-19 hospitalized patients from December 1, 2019, to June 30, 2020 was extracted following PRISMA guidelines. Adverse outcomes were defined as admission to intensive care unit (ICU), oxygen saturation <90%, invasive mechanical ventilation (IMV), severe disease and in-hospital mortality. Odds ratio (OR) and 95% confidence interval (95%CI) were obtained. RESULTS: 24 studies with 12882 confirmed COVID-19 patients were included. Overall prevalence of CM-CLD was 2.6%, COVID-19-ALI was 26.5%, elevated AST was 41.1% and elevated ALT was 29.1%. CM-CLD had no significant association with poor outcomes (pooledOR:0.96;95%CI:0.71–1.29; p = 0.78). COVID-19-ALI (1.68;1.04–2.70; p = 0.03), elevated AST (2.98;2.35–3.77; p < 0.00001) and elevated ALT (1.85;1.49–2.29; p < 0.00001) were significantly associated with higher odds of poor outcomes. CONCLUSION: Our meta-analysis suggests that acute liver injury and elevated liver enzymes were significantly associated with COVID-19 severity. Future studies should evaluate changing levels of biomarkers amongst liver disease patients to predict poor outcomes of COVID-19 and causes of liver injury during COVID-19 infection. url: https://www.ncbi.nlm.nih.gov/pubmed/33075578/ doi: 10.1016/j.aohep.2020.10.001 id: cord-032181-gmcugd8h author: Song, Jian-Xin title: Main Complications of AECHB and Severe Hepatitis B (Liver Failure) date: 2019-05-21 words: 51165.0 sentences: 2516.0 pages: flesch: 37.0 cache: ./cache/cord-032181-gmcugd8h.txt txt: ./txt/cord-032181-gmcugd8h.txt summary: 3. Hepatorenal syndrome, which is characterized by renal failure, hemodynamic changes in arterial circulation and abnormalities in the endogenous vascular system, is a common clinical complication of end-stage liver disease, and one of the important indicators for the prognosis of patients with severe hepatitis. The latest report indicated that basic laboratory examinations for coagulation function testing in common use at present, such as PT, APTT, international normalized ratio (INR) etc., have little correlation with occurrence of gastrointestinal bleeding in these patients, thereby revealing the importance to search and pay close attention to those complicating disease upregulating bleeding risk, such as bacterial infection, renal failure, hemodynamic change after portal hypertension, dysfunction of endotheliocyte as well as macrophagocyte and so on [107] . abstract: This chapter describes the clinical features, and diagnosis of complications in AECHB including secondary bacterial infections, coagulation disorder, water electrolyte disorder, hepatorenal syndrome, hepatic encephalopathy, hepatopulmonary syndrome and endotoxemia: 1. Patients with severe hepatitis have impaired immunity and are therefore vulnerable to all kinds of infections. After infection, these patients may experience shock, DIC and multiple organ failure, all of which seriously affect their prognosis and are major causes of death. Concurrent infections consist primarily of infections of the lungs, intestines, biliary tract, and urinary tract, as well as spontaneous bacterial peritonitis and sepsis. 2. Severe hepatitis may reduce the synthesis of coagulation factors and enhance their dysfunction and increase anticoagulants and platelet abnormalities, leading to coagulopathy. Infection, hepatorenal syndrome and complications can further aggravate coagulopathy, resulting in DIC and seriously affecting patient prognosis. 3. Hepatorenal syndrome, which is characterized by renal failure, hemodynamic changes in arterial circulation and abnormalities in the endogenous vascular system, is a common clinical complication of end-stage liver disease, and one of the important indicators for the prognosis of patients with severe hepatitis. 4. Water electrolyte disorder (water retention, hyponatremia, hypokalemia, hyperkalaemia) and acid-base imbalance are common in patients with severe hepatitis. These internal environment disorders can lead to exacerbation and complication of the illness. 5. Hepatic encephalopathy is a neurological and psychiatric anomaly syndrome based on metabolic disorder, and an important prognostic indicator for patients with severe hepatitis. 6. The hepatopulmonary syndrome is an important vascular complication in lungs due to systemic hypoxemia in patients with cirrhosis and portal hypertension. The majority of patients with HPS are asymptomatic. Long-term oxygen therapy remains the most frequently recommended therapy for symptoms in patients with severe hypoxemia. 7. Endotoxemia, an important complication of severe hepatitis, is not only a second hit to the liver, but also leads to other complications including SIRS and MODS. url: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7498917/ doi: 10.1007/978-94-024-1603-9_2 id: cord-005949-8po9xe5g author: Streetz, K.L. title: Akutes Leberversagen: Übersicht zur aktuellen Diagnostik und Therapie date: 2013-11-06 words: 1378.0 sentences: 150.0 pages: flesch: 45.0 cache: ./cache/cord-005949-8po9xe5g.txt txt: ./txt/cord-005949-8po9xe5g.txt summary: Die amerikanische "acute liver failure study group" unterscheidet in Bezug auf die Zeit zwischen dem Auftreten von Koagulopathie und beginnender hepatischer Enzephalopathie weiterhin zwischen dem hyperakuten (<7 Tage), dem akuten (7-28 Tage) und dem subakuten (28 Tage -6 Monate) Leberversagen [9] . Die etablierte Therapie des häufigen paracetamolinduzierten ALV besteht in der intravenösen Gabe von N-Acetylcystein (NAC) in Form eines 72-stündigen Reduktionsschemas (NAC: 150 mg/kg/h für 1 h, dann 12,5 mg/kg/h für 4 h und 6,25 mg/kg/h für 67 h). Interessanterweise wurde in einer prospektiven multizentrischen Studie gezeigt, dass es beim nicht durch Paracetamol bedingtem ALV unter Gabe von NAC zumindest bei Patienten mit niedriggradiger hepatischer Enzephalopathie (°I-II) ebenfalls zu einer Verbesserung des transplantatfreien Überlebens kommt [10] . Hier wurde gezeigt, dass 84% der Patienten mit ALV nach Erhalt einer frühen Transplantation überlebten, während die Überlebensrate ohne Lebertransplantation bei nur 34% lag. abstract: Although acute liver failure is a rare disease with a prevalence of 5 per 1 million people, it has a considerablely high mortality rate of 34 %. The main causes in western civilizations are drug overdose (acetaminophen) and viral hepatitis. Patients are affected by the loss of liver synthesis function and are at risk of developing hepatic encephalopathy and possible multiorgan failure. Specific therapies consisting of the administration of N-acetylcysteine (acetaminophen) or of nucleotide/nucleoside analogs (hepatitis B) are possible, but are often not adequate. Orthotopic liver transplantation is, therefore, frequently the only remaining effective therapy for severe acute liver failure. Due to organ shortage, new prognostic tools, e.g., the Acute Liver Failure Study Group (ALFSG) score, have been developed to improve patient selection using sufficiently stringent selection criteria. url: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7096005/ doi: 10.1007/s00063-013-0285-4 id: cord-355395-rckzi8vz author: Tian, Dandan title: Hepatic complications of COVID‐19 and its treatment date: 2020-05-21 words: nan sentences: nan pages: flesch: nan cache: txt: summary: abstract: COVID‐19 is highly contagious and has a variety of clinical manifestations, it can affect a number of other organs in addition to the lungs, and liver injury may occur. SARS‐CoV‐2 can cause liver injury through systemic inflammatory response syndrome (SIRS), cytokine storms, ischemia‐reperfusion injury, side effects of treatment drugs, and underlying liver disease and can attack liver cells directly via ACE2. Clinical studies have found that liver injury in COVID‐19 patients mainly manifests as abnormal liver biochemical indicators, but there have been no reports of liver failure caused by this disease. The number of COVID‐19 patients with liver injury is increasing, and the incidence of liver injury in COVID‐19 patients with severe disease are higher than in patients with mild disease. Liver injury may be a risk factor for progresses and worsens in patients with COVID‐19, and it is necessary to pay attention to the occurrence of liver injury in the diagnosis and treatment of COVID‐19. This article is protected by copyright. All rights reserved. url: https://www.ncbi.nlm.nih.gov/pubmed/32437004/ doi: 10.1002/jmv.26036 id: cord-261608-4sjlg0p0 author: Trejo-Paredes, Camila title: COVID-19-INDUCED LIVER INJURY: A CLINICAL DISTRACTION? date: 2020-10-31 words: 455.0 sentences: 42.0 pages: flesch: 45.0 cache: ./cache/cord-261608-4sjlg0p0.txt txt: ./txt/cord-261608-4sjlg0p0.txt summary: title: COVID-19-INDUCED LIVER INJURY: A CLINICAL DISTRACTION? His hospital course was also complicated by acute renal failure requiring renal replacement therapy, coagulopathy, and encephalopathy which coincided with liver injury trailing behind the peak of inflammatory markers. Emerging data support the hypothesis that liver injury in COVID-19 is often the result of SARS-CoV-2 directly binding to ACE2+ cholangiocytes, leading to cholangiohepatitis. In addition, cytokine storm may further exacerbate the hepatic injury in COVID-19 (2). Hepatic congestion in ventilated patients, shock liver and particularly, drug-induced liver injury (DILI) remains an important consideration in COVID-19 patients. CONCLUSIONS: COVID-19 induced viral hepatitis is now being increasingly identified as a self-resolving complication and the physician should be mindful of it and in the right setting, it may only be a clinical distraction. We should be cognizant of other potential causes of liver injury in COVID-19 patients like concurrent infection, sepsis-induced and DILI. Liver injury in COVID-19: The current evidence COVID-19 and the liver: little cause for concern. abstract: nan url: https://www.sciencedirect.com/science/article/pii/S0012369220330877 doi: 10.1016/j.chest.2020.08.901 id: cord-277535-u283k70i author: Vaja, Rakesh title: Drugs and the liver date: 2020-09-22 words: 4012.0 sentences: 239.0 pages: flesch: 49.0 cache: ./cache/cord-277535-u283k70i.txt txt: ./txt/cord-277535-u283k70i.txt summary: Additionally, drugs can also modify how the liver functions and cause dysfunction or even failure of the organ both by a direct effect on the liver or by alteration in liver blood flow. Furthermore, once a patient has been recognized to be suffering with liver dysfunction or failure drug choice and dosing regime will need to be rationalized. After reading this article you should: C understand the mechanisms of drug metabolism by the liver C have an appreciation of alterations to drug choice and dosing regimens in patients with liver disease due to their altered pharmacokinetics C know the management of a patient with paracetamol overdose There are many different isoforms of CYP450, classified according to their amino acid sequencing into families, subfamilies and individual genes. NSAIDS are contraindicated for systemic use in most liver disease patients, because of increased bioavalibilty, the high risk of precipitating gastrointestinal bleeding and renal failure. abstract: The liver is a major organ with multiple functions. A number of drugs are metabolized by the liver during phase 1 and 2 reactions which include complex processes involving cytochrome P450 enzymes. Genetic and acquired variability in cytochrome P450 activity may have profound effects on pharmacokinetics. Additionally, drugs can also modify how the liver functions and cause dysfunction or even failure of the organ both by a direct effect on the liver or by alteration in liver blood flow. It is important to recognize the signs and symptoms of liver failure in patients and identify possible causes including drug interactions. Furthermore, once a patient has been recognized to be suffering with liver dysfunction or failure drug choice and dosing regime will need to be rationalized. Paracetamol overdose can have severe and life threatening consequences for patients due to its effect on liver function. It is the leading cause of acute liver failure in the UK, 1 Correct and early management is crucial and will be discussed within this article. url: https://api.elsevier.com/content/article/pii/S1472029920301399 doi: 10.1016/j.mpaic.2020.07.001 id: cord-324529-xbrdtxnz author: Wang, Ming title: Clinical characteristics and risk factors of liver injury in COVID-19: a retrospective cohort study from Wuhan, China date: 2020-10-07 words: 4045.0 sentences: 223.0 pages: flesch: 49.0 cache: ./cache/cord-324529-xbrdtxnz.txt txt: ./txt/cord-324529-xbrdtxnz.txt summary: title: Clinical characteristics and risk factors of liver injury in COVID-19: a retrospective cohort study from Wuhan, China This study was designed to evaluate the clinical characteristics and risk factors of COVID-19-associated liver injury. extracted the currently largest cohort regarding 1099 mainly moderate SARS-CoV-2 infected patients and showed 39.4% with severe disease had elevated AST and 28.1% had elevated ALT, and the proportion was 18.2% and 19.8% in patients with non-severe disease [6] .Given that the number of patients in these studies is relatively small, information about the clinical characteristics of liver injury in these patients is scarce. The present study showed that liver injury was more prevalent in male, severe or critically ill patients with percutaneous oxygen saturation ≤ 93% or peak temperature ≥ 38.5 °C on admission, and comprehensively delineated the risk factors for COVID-19-associated liver injury. abstract: BACKGROUND: Coronavirus disease 2019 (COVID-19) has rapidly become a major international public health concern. This study was designed to evaluate the clinical characteristics and risk factors of COVID-19-associated liver injury. METHODS: A fraction of 657 COVID-19 patients were retrospectively analyzed. Clinical and laboratory data were derived from electronic medical records and compared between patients with or without liver injury. Multivariate logistic regression method was used to analyze the risk factors for liver injury. RESULTS: Among 657 patients, 303 (46.1%) patients had liver injury with higher rate in severe/critically ill patients [148/257 (57.6%)] than those in moderate cases [155/400 (38.8%)]. The incidence of liver injury was much higher in male [192/303 (63.4%)] than female [111/303 (36.6%)], and in severe/critical patients [148/303 (48.8%)] with percutaneous oxygen saturation ≤ 93% [89/279 (31.9%)] or peak body temperature ≥ 38.5 °C [185/301 (61.5%)] on admission. Liver injury-related inflammations included increased white blood cells, neutrophils and decreased lymphocytes. More patients with liver injury than without had increased serum IL-2R, TNFα, ferritin, hsCRP, PCT, ESR, γ-GT, and LDH. Multivariate regression analysis revealed that increasing odds of liver injury were related to male, higher serum hsCRP (≥ 10 mg/L), and neutrophil-to-lymphocyte ratio (NLR) (≥ 5). Moreover, more deceased patients (14/82 (17%)) had significantly elevated serum TBIL than discharged patients [25/532 (4.7%)]. CONCLUSION: Liver injury is a common complication in COVID-19 patients. The potential risk factors of liver injury include male, hsCRP and NLR score. A close monitor of liver function should be warned in COVID-19 patients, especially in severe/critical individuals. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1007/s12072-020-10075-5) contains supplementary material, which is available to authorized users. url: https://doi.org/10.1007/s12072-020-10075-5 doi: 10.1007/s12072-020-10075-5 id: cord-340325-0oh40b6r author: Witzigmann, Dominik title: Lipid nanoparticle technology for therapeutic gene regulation in the liver date: 2020-07-02 words: nan sentences: nan pages: flesch: nan cache: txt: summary: abstract: Hereditary genetic disorders, cancer, and infectious diseases of the liver affect millions of people around the globe and are a major public health burden. Most contemporary treatments offer limited relief as they generally aim to alleviate disease symptoms. Targeting the root cause of diseases originating in the liver by regulating malfunctioning genes with nucleic acid-based drugs s holds great promise as a therapeutic approach. However, employing nucleic acid therapeutics in vivo is challenging due to their unfavorable characteristics. Lipid nanoparticle (LNP) delivery technology is a revolutionary development that has enabled clinical translation of gene (editing) therapies. LNPs can deliver siRNA, mRNA, DNA, or gene-editing complexes, providing opportunities to treat hepatic diseases by silencing pathogenic genes, expressing therapeutic proteins, or correcting genetic defects. Here we discuss the state-of-the-art LNP technology for hepatic gene therapy including formulation design parameters, production methods, preclinical development and clinical translation. url: https://www.sciencedirect.com/science/article/pii/S0169409X20300727?v=s5 doi: 10.1016/j.addr.2020.06.026 id: cord-291851-xesef17i author: Wong, Yu-Jun title: A systematic review and meta-analysis of the COVID-19 associated liver injury date: 2020-08-31 words: 4382.0 sentences: 275.0 pages: flesch: 52.0 cache: ./cache/cord-291851-xesef17i.txt txt: ./txt/cord-291851-xesef17i.txt summary: Our meta-analysis aims to compare the risks and clinical outcomes of COVID-19 associated liver injury among adults with severe and non-severe COVID-19. The objective of this meta-analysis is to compare the risk and clinical outcome of COVID-19 associated liver injury between COVID-19 patients with severe and non-severe COVID-19. In this meta-analysis, we included all studies that met the following inclusion criteria: (1) population: adult patients infected with the COVID-19, (2) reported outcome data on liver enzymes derangement (3) reported outcome data on the risk or severity of liver injury between severe and non-severe COVID-19. We extracted data on the demographic of study populations (age, gender, sample size, the proportion of subjects with baseline chronic liver disease and the use of Lopinavir/ritonavir) as well as the pattern of COVID-19 associated liver injury (ALT, AST, bilirubin, albumin and GGT) from all included studies. and performed a meta-analysis on the severity and risk of COVID-19 associated liver injury in these patients. abstract: INTRODUCTION AND OBJECTIVES: The novel coronavirus disease 2019 (COVID-19) has affected more than 5 million people globally. Data on the prevalence and degree of COVID-19 associated liver injury among patients with COVID-19 remain limited. We conducted a systematic review and meta-analysis to assess the prevalence and degree of liver injury between patients with severe and non-severe COVID-19. METHODS: We performed a systematic search of three electronic databases (PubMed/MEDLINE, EMBASE and Cochrane Library), from inception to 24(th) April 2020. We included all adult human studies (>20 subjects) regardless of language, region or publication date or status. We assessed the pooled odds ratio (OR), mean difference (MD) and 95% confidence interval (95%CI) using the random-effects model. RESULTS: Among 1543 citations, there were 24 studies (5961 subjects) which fulfilled our inclusion criteria. The pooled odds ratio for elevated ALT (OR = 2.5, 95%CI: 1.6-3.7, I(2) = 57%), AST (OR = 3.4, 95%CI: 2.3-5.0, I(2) = 56%), hyperbilirubinemia (OR = 1.7, 95%CI: 1.2-2.5, I(2) = 0%) and hypoalbuminemia (OR = 7.1, 95%CI: 2.1-24.1, I(2) = 71%) were higher subjects in critical COVID-19. CONCLUSION: COVID-19 associated liver injury is more common in severe COVID-19 than non-severe COVID-19. Physicians should be aware of possible progression to severe disease in subjects with COVID-19-associated liver injury. url: https://api.elsevier.com/content/article/pii/S1665268120301617 doi: 10.1016/j.aohep.2020.08.064 id: cord-290412-m6fesoyb author: Zhao, Chang-qing title: Traditional Chinese medicine for treatment of liver diseases: progress, challenges and opportunities date: 2014-09-30 words: 4271.0 sentences: 211.0 pages: flesch: 43.0 cache: ./cache/cord-290412-m6fesoyb.txt txt: ./txt/cord-290412-m6fesoyb.txt summary: In this article, we introduce TCM herbal preparations from the Chinese materia medica (such as Fuzheng Huayu) that are typically used for the treatment of liver diseases. TCM is widely applied in the treatment of liver diseases in China by both Chinese medicine doctors and Western medicine doctors because its ability to protect hepatocytes, inhibit hepatic inflammation and reduce fibrosis in the liver. Several patent drugs (Chinese herbal formulas) for treatment Clinical observations showed that FZHYC can effectively improve liver function and decrease the expression of fibrosis biomarkers such as serum hyaluronic acid, collagen type IV, procollagen type III and laminin, in chronic liver disease patients with fibrosis or cirrhosis [43, 44] . Randomized controlled multicenter clinical trial for integrated treatment of community-acquired pneumonia based on traditional Chinese medicine syndrome differentiation Optimized project of traditional Chinese medicine in treating chronic kidney disease stage 3: a multicenter double-blinded randomized controlled trial abstract: Abstract Traditional Chinese medicine (TCM) is commonly used in treating liver diseases worldwide, especially in China. The advantages of using TCM for treatment of liver diseases include: protecting hepatocytes, inhibiting hepatic inflammation and antifibrosis in the liver. In this article, we introduce TCM herbal preparations from the Chinese materia medica (such as Fuzheng Huayu) that are typically used for the treatment of liver diseases. Literature surrounding the mechanisms of TCM therapy for treatment of liver diseases is presented and discussed. We propose that side effects of herbal compounds are often under-appreciated, and that more care should be taken in the prescription of potentially hepatotoxic medicines. Further, to deepen the understanding of TCM mechanisms, new techniques and methodologies must be developed. Future studies will lead to the enhancement of clinical outcomes of TCM. As complementary and alternative therapies, TCMs will play an expanding role in the future of liver disease treatment. url: https://www.sciencedirect.com/science/article/pii/S209549641460039X doi: 10.1016/s2095-4964(14)60039-x id: cord-000083-3p81yr4n author: nan title: Poster Exhibition date: 2009-01-31 words: 112815.0 sentences: 7542.0 pages: flesch: 56.0 cache: ./cache/cord-000083-3p81yr4n.txt txt: ./txt/cord-000083-3p81yr4n.txt summary: R. China Background: The objective of this study was to evaluate the early virologic response for prediction of achievement of HBeAg seroconversion and hepatitis B virus (HBV) DNA negativity after two years of lamivudine treatment in chronic hepatitis B (CHB) patients. Methods: A total of 620 patients who tested positive for hepatitis B surface antigen and were referred to Chiba University Hospital between February 1985 and March 2008 were included in the study, and their following characteristics were analyzed: age, gender, the status of HBeAg, ALT, HBV-DNA level, and PLT. Methods: A total of 60 patients with chronic hepatitis B, 32 (53.3%) were HBeAg positive (group A) while 28(46.7%) were HBeAg negative (group B) were included in this study after meeting the following criteria: age 18 to 60 years, HBsAg positive for more than 6 months, serum HBV-DNA was >5 log(10) copies/mL and ALT more than two times the upper normal limit. abstract: nan url: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2712310/ doi: 10.1007/s12072-009-9123-4 id: cord-006391-esnsa4u5 author: nan title: Abstracts 5(th) Tripartite Meeting Salzburg/Austria, September 9–11,1982 date: 1982 words: 44844.0 sentences: 2433.0 pages: flesch: 50.0 cache: ./cache/cord-006391-esnsa4u5.txt txt: ./txt/cord-006391-esnsa4u5.txt summary: In our parallel tests using an excision-sample technique [2] which is considerably more sensitive than the DGHM procedure, we have observed the following mean reductions in the counts of accessible bacteria: iodine in ethanol, 96%; povidone-iodine, 89%; chlorhexidine in ethanol, 88%; iso-propanol, The purpose of this study was to compare radiation injury in Guinea Pig small bowel (1) devoid of contents (2) containing bile (3) containing pancreatic juice. Studies in vitro employing isolated perfused rat pancreas and stomach revealed following results: Mean basal pancreatic somatostatin release in normal, diabetic and transplanted rats were 12___3, 24-t-7, and 17__+4 pg/ml, respectively. As these changes appear closely correlated to the blood glucose levels which show a 30 % decrease at 4 h and progressive restoration towards normal values up to 24 h, attempts have been made to alter the insulin/glucagon ratio by glucose infusion after PH and study its relation to liver regeneration. abstract: nan url: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7101735/ doi: 10.1007/bf01279099 id: cord-016757-3d320c0a author: nan title: Acute and chronic liver insufficiency date: 2008 words: 9786.0 sentences: 705.0 pages: flesch: 46.0 cache: ./cache/cord-016757-3d320c0a.txt txt: ./txt/cord-016757-3d320c0a.txt summary: Hepatic coma can be subdivided according to its aetiology as follows: (1.) hepatocyte disintegration coma (ϭ endogenous coma due to the loss of parenchyma), (2 ( ( .) liver cell failure coma (ϭ exogenous coma due to metabolic disorders, almost always in the presence of cirrhosis), (3.) electrolyte coma (ϭ so-called "false" coma due to dyselectrolytaemia, almost always iatrogenic), and (4.) mixed forms of coma. Acute liver failure (ALF) is defined as an acute clinical picture with jaundice due to a most severe disorder in the liver function and/or massive liver cell necrosis which, without any pre-existing liver disease, culminates in hepatic coma (ϭ endogenous coma) within 8 weeks. 11) Consequently, severe damage to liver cells and widespread necrosis are usually the result of a network of altered cellular and humoral reactions, which for their part are often the initial cause of acute liver failure due to their synergistic and interactive effects (H. Fulminant hepatic failure caused by acute fatty liver of pregnancy treated by orthotopic liver transplantation abstract: The term “liver insufficiency” denotes a break down in the functions of the liver. The syndrome of functional liver failure covers a wide spectrum of clinical, biochemical and neurophysiological changes. In principle, liver insufficiency can occur without previous liver damage as well as with already existing liver disease. It is characterized by a deterioration in the synthesizing, regulatory and detoxifying function of the liver. This final stage of liver disease terminates in hepatic coma. url: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7121136/ doi: 10.1007/978-3-540-76839-5_20 id: cord-022483-hdmwv540 author: nan title: Gastrointestinal Disease date: 2009-06-05 words: 19315.0 sentences: 1127.0 pages: flesch: 44.0 cache: ./cache/cord-022483-hdmwv540.txt txt: ./txt/cord-022483-hdmwv540.txt summary: In the neonatal period, commonly reported causes of abdominal pain are meconium impaction, small-intestinal volvulus, enteritis or colitis, uroperitoneum, intussusception, gastric ulcers, and ileus secondary to prematurity, septicemia, or neonatal encephalopathy. Lower-intestinal contrast studies (i.e., barium enema) have been reported to have 100% sensitivity and 100% specificity for identifying mechanical obstruction (meconium impaction, atresia coli) of the transverse colon or small colon in foals less than 30 days of age ( Figure 11-14) . The only published study on 20 foals less than two weeks of age with acute abdominal pain reported that an exploratory celiotomy revealed functional ileus (45%), meconium impaction (25%), large-colon displacement (15%), small intestine displaced around the base of the cecum (10%), ruptured gastric ulcer, and small colon obstructed by the ovarian ligament. 8 These reports underscore the difficulty in definitively identifying the cause of abdominal pain prior to exploratory celiotomy in neonatal foals, as clearly some of these cases, such as enteritis and functional ileus, would not be considered to be predominantly surgical diseases. abstract: nan url: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7156017/ doi: 10.1016/b978-1-4160-2353-1.50016-8 id: cord-022555-a7ie82fs author: nan title: Digestive System, Liver, and Abdominal Cavity date: 2011-12-05 words: 66452.0 sentences: 3846.0 pages: flesch: 48.0 cache: ./cache/cord-022555-a7ie82fs.txt txt: ./txt/cord-022555-a7ie82fs.txt summary: One study found that, of cats investigated for gastrointestinal disease, 9 of 33 cats (27%) had no pathology recognized proximal to the jejunum (i.e., the effective length of diagnostic endoscopes would have precluded diagnosis), and other organs were affected in 9 of 10 cats with inflammatory bowel diseases and 7 of 8 cats with intestinal small cell lymphoma. 60, 64 Quantification of serum cobalamin levels is recommended in cats with clinical signs of small bowel diarrhea, ones suspected to have an infiltrative disease of the small intestine (inflammatory bowel disease or gastrointestinal lymphoma), or ones with pancreatic dysfunction. Survey radiographs may be normal in cats with esophagitis and strictures, but are useful to rule out other causes for the clinical signs, such as a foreign body, or to detect related problems, such as aspiration pneumonia. 8, 29 Other non-neoplastic causes reported for gastric or gastroduodenal ulceration in cats include parasites (e.g., Ollulanus tricuspis, Toxocara cati, Aonchotheca putorii, Gnathostoma spp.), bacterial infections, toxins, inflammatory bowel disease, and foreign bodies. abstract: nan url: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7158306/ doi: 10.1016/b978-1-4377-0660-4.00023-5 id: cord-022754-ehq9qnoo author: nan title: Liver date: 2012-07-25 words: 87886.0 sentences: 5297.0 pages: flesch: 39.0 cache: ./cache/cord-022754-ehq9qnoo.txt txt: ./txt/cord-022754-ehq9qnoo.txt summary: Conversely, in cases of chronic end-stage liver disease, such as cirrhosis, serum hepatic enzyme activities may not be markedly increased, or may even be within the reference interval as a result of the replacement of hepatocytes with fibrous tissue. World Small Animal Veterinary Association (WSAVA) Standards for the Clinical and Histological Diagnosis of Canine and Feline Liver Disease suggest that the cytologic evaluation of bile forms part of the minimum diagnostic requirement for cats with extrahepatic cholestasis and for dogs guidance. 32 Hyperglobulinemia can be seen in dogs with cirrhosis, but it remains to be determined whether this corresponds with increased autoantibodies as occurs in humans with autoimmune hepatitis, or whether it reflects nonspecific systemic antibody production in response to antigens from the portal blood which bypass the liver through acquired PSSs. 83 Mild nonregenerative anemia may be a reflection of chronic disease. abstract: nan url: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7161409/ doi: 10.1016/b978-1-4160-3661-6.00061-4 id: cord-023017-k6edtg58 author: nan title: AASLD Abstracts (pp. 282A–382A) date: 2006-02-10 words: 65796.0 sentences: 3553.0 pages: flesch: 51.0 cache: ./cache/cord-023017-k6edtg58.txt txt: ./txt/cord-023017-k6edtg58.txt summary: 14/55 (25%) patients in AC who did not discontinue by week 24 received ribavirin dose reduction in comparison to 31/108 ( The clinical outcome in response to combination therapy for treatment of chronic hepatitis C virus (HCV) infection appears to be different for Caucasian versus African American patients. Over the period of combination therapy, most patients in which serum virus titers were reduced to non detectable levels had significant increases in T cell responses to HCV proteins. CHRONIC Background: Recent large prospective trials demonstrated that the combination therapy of interferon (1FN)-alphalribavirin significantly increased the ratio of a sustained virological response in patients with chronic hepatitis C in comparison with IFN monotherapy, especially in patients with high HCV-RNA titer and genotype lb. Results: Patients with chronic HCV infection showed higher MxA gene expression levels than healthy controls, indicating that hepatitis C virus induces IFN production. abstract: nan url: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7165819/ doi: 10.1002/hep.1840380505 id: cord-023033-tgt69ir6 author: nan title: Poster Session (pp. 78A–178A) date: 2006-02-10 words: 16102.0 sentences: 855.0 pages: flesch: 45.0 cache: ./cache/cord-023033-tgt69ir6.txt txt: ./txt/cord-023033-tgt69ir6.txt summary: Methods: We performed a retrospective analysis comparing outcomes, and the incidence, timing, and severity of histologic recurrence of HCV following transplantation in patients who underwent living donor liver transplant compared to recipients of cadaveric organs. Local liver immune responses are thought to play a major role in chronic autoimmune diseases directed at biliary epithelium.Using the apical sodium dependent bile acid transporter (ASBT) promoter to drive biliary epithelial cell -specific expression of a membrane form of ovalbumin (OVA), we have previously developed OVA-BIL transgenic mice. Thus, our AIM was to ascertain whether Kupffer cells express death ligands and contribute to hepatocyte apoptosis and liver fibrosis in the bile duct ligated mouse, an animal model of cholestasis. Control experiments confirmed that Y2 protein inhibited IFNa-induced ISRE-mediated signaling in Huh-T7 cells; relative luciferase activity was reduced from 653 (pH771 IFNP nAb increased HCV core Ag replication by 42% and 23% compared to no treatment (p=O.O1). abstract: nan url: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7165951/ doi: 10.1002/hep.1840380503 id: cord-016880-q44623s8 author: van Hoek, B. title: 22 Levertransplantatie date: 2015-01-02 words: 6891.0 sentences: 636.0 pages: flesch: 60.0 cache: ./cache/cord-016880-q44623s8.txt txt: ./txt/cord-016880-q44623s8.txt summary: Uit analyse van patiënten die getransplanteerd zijn terwijl ze buiten de Milaan-criteria vielen, blijkt dat met name micro-angio-invasie een slechte prognostische marker is en dat de overleving bij grotere of meer dan drie tumoren nog goed kan zijn als er geen micro-angio-invasie is. [29] Bij een hemodynamisch instabiele patiënt kan OLT -of auxiliaire levertransplantatie met een grote resectie van de natieve lever [30] -beter zijn omdat resectie van de necrotische lever het toxic liver-syndroom -door cytokines -kan tegengaan. [48] Het Epstein-Barr-virus (EBV) kan (bij 1% van de levertransplantaties) leiden tot posttransplantatielymfomen (PTLD); die zijn tegenwoordig vaak curatief te behandelen en voor een deel mogelijk te voorkomen door EBV-DNA-metingen in het eerste jaar, met zonodig aanpassen van de immuunsuppressie. Bij de levende donor wordt een resectie verricht van de linkslaterale segmenten van de lever, die vervolgens gebruikt worden voor transplantatie bij het kind. abstract: In 1963 verrichtte Thomas Starzl in Denver de eerste levertransplantatie bij de mens. In 1966 werden in Nederland de eerste twee (auxiliaire, zie par. 22.3.6) levertransplantaties verricht in Leiden en Arnhem, in 1968 startte Cambridge. Helaas resulteerden de eerste levertransplantaties niet in langetermijnoverleving als gevolg van niet-optimale operatietechniek, matige immuunsuppressie en onbekendheid met complicaties. url: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7121307/ doi: 10.1007/978-90-313-7437-3_22 ==== make-pages.sh questions [ERIC WAS HERE] ==== make-pages.sh search /data-disk/reader-compute/reader-cord/bin/make-pages.sh: line 77: /data-disk/reader-compute/reader-cord/tmp/search.htm: No such file or directory Traceback (most recent call last): File "/data-disk/reader-compute/reader-cord/bin/tsv2htm-search.py", line 51, in with open( TEMPLATE, 'r' ) as handle : htm = handle.read() FileNotFoundError: [Errno 2] No such file or directory: '/data-disk/reader-compute/reader-cord/tmp/search.htm' ==== make-pages.sh topic modeling corpus Zipping study carrel